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In the search for effective methods to mitigate the increasing rates of abuse and addiction of 
illicit substances, a variety of neurological pathways have been explored. Towards this goal of 
reducing drug abuse and ultimately overdose-related deaths, two avenues of research have 
emerged: 1) a preventative approach, the development of pain-relieving medications without the 
abuse and addiction liabilities associated with current therapies, and 2) a responsive approach, the 
development of medications for people suffering from drug abuse and addiction. The natural 
product salvinorin A can be manipulated towards both of these research avenues through the 
development of opioid receptor (MOR) agonists for treating pain with reduced abuse liabilities 
as well as through the development of  opioid receptor (KOR) agonists with improved 
pharmacokinetic properties towards the development of therapies that attenuate relapse and 
withdrawal.  
Previous structure-activity relationship (SAR) studies of salvinorin A identified that replacing 
the C2-acetate with a C2-benzoate resulabstracts in a compound that is 4-fold selective for MORs 
over KORs. In an effort to increase this selectivity, to allow for probing the physiological effects 
induced upon activation of MORs with this non-morphine scaffold, a potent and selective MOR 
agonist kurkinorin (MOR EC50 = 1.2 ± 0.2 nM, and KOR > 10,000nM) was identified. Upon in 
vivo evaluation, kurkinorin was determined to elicit centrally-mediated antinociception with 
similar potency to morphine and a reduced tolerance, sedation, and reward profile in comparison 
to morphine. Through a SAR campaign, a variety of kurkinorin analogues were synthesized and 
evaluated in vitro for their ability to activate G-proteins and recruit β-arrestin-2 upon MOR 
activation. Through these studies, compounds that are more potent than kurkinorin at MORs, 
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compounds that are biased towards β-arrestin-2 recruitment, and compounds that are biased 
towards G-protein activation have been identified.  
Salvinorin A suffers from poor pharmacokinetic properties, including low water solubility and 
rapid metabolism. In an effort to address this issue of water solubility, we sought to identify a point 
on the molecule through which its water solubility could be modified without sacrificing KOR 
activity.  Previous studies indicated that salvinorin A’s lactone functionality was not necessary for 
KOR activity; therefore, the lactone was modified to further explore its necessity and tolerance to 
modification. Analogues that varied in chain length, stereochemistry, and polarity at the lactone 
position were synthesized and evaluated for their ability to activate KORs. Overall, small linear 
moieties were well-tolerated, while bulkier groups were not. Salvinorin A analogues that are potent 
KOR agonists with polar, ionizable moieties in the C17-position have been identified, and the 
lactone position has been validated as a position on the molecule through which the 
pharmacokinetic properties can be manipulated without significant loss of KOR activity.  
Salvinorin A has a very short half-life in humans (<15 minutes upon inhalation). SAR work in 
the past has focused on developing analogues with reduced metabolic liabilities, specifically 
through replacement of the acetate moiety, while maintaining KOR activity. However, the 
metabolism of many of these compounds had not been directly compared, to one another or to 
salvinorin A. Therefore, we developed a method to analyze the metabolic profiles of salvinorin A 
and its analogues in liver microsomes. Through screening salvinorin A and its analogues, several 
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Drug Addiction and Pain 
The epidemic in America 
The United States is currently experiencing an opioid and drug abuse epidemic.1 Between 2014 
and 2015, the number of deaths attributed to drug overdose rose significantly, from 47,055 to 
52,404.2 In fact, 2015 saw the highest number of overdose deaths of any year recorded (Figure 
1.1).3 From 2010 to 2014, the same drug classes were being abused and causing overdoses: opioids, 
including oxycodone, heroin, morphine, hydrocodone, fentanyl, and methadone; stimulants, 
cocaine and methamphetamine; and benzodiazepines, including alprazolam and diazepam. While 
the top ten drugs causing overdose did not vary over the five year period, the order of those drugs 
did. Notably, recent years have seen an increase in heroin overdose which more than tripled 
between 2010 and 2014, as well as overdoses attributed to fentanyl which doubled in a single year 
(2013-2014).4  
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With over half of these overdose deaths attributed to opioids, 60.9% in 2014 to 63.1% in 2015,2 
the public response has been to equip law enforcement personnel with the opioid antagonist 
naloxone (Narcan®). The goal of this endeavor is that these first responders can administer 
naloxone and reverse the overdose effects, thereby preventing death.5 As of April 2016, thirty-
three states have already implemented training and arming of the police force with naloxone, and 
this number continues to rise.5 
A discussion of the opioid epidemic is incomplete without discussing the prevalence of pain 
and prescription opioids, as nearly half of the opioid-related deaths in 2015 involved prescription 
opioids.3 Pain affects about 100 million American adults, which is more than cancer, heart disease 
and diabetes combined.6 The estimated costs in the US are over $600 billion, including healthcare, 
disability compensation and lost workdays; however, the personal costs in terms of suffering and 
quality of life cannot be measured.7 Opioid analgesics are the gold-standard for pain treatment and 
have been so for many years, despite their many adverse effects, including tolerance, dependence, 
and respiratory depression.8 The long-term use of opioids often leads to analgesic tolerance, 
requiring higher doses to achieve pain relief.9 As the opioid doses is increased, the patient is at 
higher risk for developing dependence and ultimately becoming addicted to the opioid therapy.10 
Even so, opioids are still the most prescribed drug class for pain.11 Conversely, patients who are 
suffering from chronic pain are often hesitant to use opioids due to the associated risks and social 
and legal issues associated with using opioids, which results in frequently undertreated and 
inadequately treated pain.12 Therefore, the development of pain relievers without these stigmas 
and side effects is a critical medical need. 
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Addiction and the reward pathway 
Overdoses are often the result of a drug addiction, the most severe form of substance abuse.1 
Drug addiction was once perceived as a character flaw or moral inadequacy, but scientific 
advances have now more clearly defined it as a chronic illness, with characteristics similar to other 
widely accepted chronic illnesses such as type 2 diabetes mellitus, asthma, and hypertension.13 All 
of these diseases, including addiction, are chronic, have no known cure, are prone to relapse, and 
are affected by a variety of factors including genetic, environmental, social, and behavioral. 
Additionally, all of these diseases have treatments with which patients often find it difficult to 
comply.1, 13  
 Addictive drugs act in different ways, but their overall effect is the same—a euphoric or 
pleasurable experience that is the result of activation of the reward regions in the brain.14 As misuse 
of addictive substances continues into abuse, progressive neuroadaptations, or structural and 
functional changes, occur in the brain of the individual. Addiction is commonly broken down into 
three stages: 1) Binge and intoxication; 2) Withdrawal and negative affect; 3) Preoccupation and 









anticipation (Figure 1.2).14 Each of these stages can be traced to specific neuroadaptations in the 
brain that result from substance abuse.  
During the first stage of addiction, binge and intoxication, consumption of the intoxicating 
substance occurs, and the user experiences euphoria from its activation of the reward pathways. 
The effects of this stage are commonly attributed to actions in the basal ganglia, more specifically 
activations of dopamine and opioid signaling through the nucleus accumbens.15 All addictive 
substances activate the reward pathway, increasing dopamine levels to produce their euphoric 
effects, and this response is mediated through the nucleus accumbens.16 This rewarding response 
to the drug motivates individuals to use the drug again. Chronic substance abuse can cause neurons 
to fire at the anticipation of the substance rather than the substance itself, which results in 
associated triggers, or cues, that promote seeking and usage of the substance.14 Ultimately, these 
addictive substances “hijack” the reward system of the brain, as acute administration decreases 
reward thresholds, increasing reward, but chronic administration increases these reward thresholds 
resulting in decreased reward.17 
The second stage of the addiction cycle, withdrawal and negative effects, occurs after the 
euphoric effects of taking the substance subside and the individual feels less energetic and excited 
and more depressed and anxious. Addicted individuals no longer have the same motivation to 
pursue natural rewards because their reward systems have been conditioned to focus on the more 
potent dopamine release that occurs with the drug or the drug cues. Their reward pathways also 
become less sensitive to both drug and non-drug stimulation, so that the same amount of the 
substance results in a lessened degree of euphoria after long-term use. This dampened reward 
pathway also explains why addicted individuals are no longer motivated to pursue natural stimuli 
by which they had previously been motivated and found rewarding.14  
5 
 
These withdrawal and negative effects are modulated by the extended amygdala. 
Neuroadaptations in the amygdala result in increased stress reactivity and negative emotions. In 
non-addicted individuals, this “antireward” system helps to maintain homeostasis, but the pathway 
is overactive in addicted brains and results in withdrawal symptoms upon drug removal from the 
system.18 These withdrawal effects can present as a negative emotional state or dysphoria and 
increase in severity to physical illness that can be fatal in the most severe cases.17a Several 
neurotransmitters have been shown to be under- or over-activated and together contribute to the 
motivational effects of withdrawal. Notably, dopamine and serotonin levels are decreased while 
dynorphin (the  opioid receptor endogenous agonist) is increased which all contribute to the 
dysphoric effects felt during withdrawals.18 Also, the anxiolytic and stress effects of withdrawal 
are attributed to the decreases in GABA and neuropeptide Y and the increases in corticotropin-
releasing factor and norepinephrine.18 Eventually, the brain becomes reliant on the drug to 
stimulate the reward pathway, and adapts in such a way that the addicted individual requires the 
drug to maintain relief from the negative effects experienced in the drug’s absence.1  
The final stage of the addiction cycle, preoccupation and anticipation, involves the actions of 
the prefrontal cortex. Neuroimaging studies have correlated prefrontal cortex dysfunction in 
addicted individuals to higher rates of relapse and impaired executive processes.19 The prefrontal 
cortex is responsible for executive function, which includes decision making, organizing thoughts, 
regulating social behavior (i.e. impulses, emotions, and actions), differentiating between 
conflicting thoughts, and selecting and initiating action. Executive processes are vital in making 
decisions regarding taking or stopping the drug, including the social and personal implications 
involved with each decision.1 All of these processes are impaired in addicted individuals due to 
the down-regulated dopamine signaling. These neuroadaptations in the prefrontal cortex lower the 
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addicted individuals’ ability to resist strong urges, such as taking the drug, as well as prevent them 
from following through on decisions, such as to stop taking the drug. Together, these prefrontal 
cortex neuroadaptations help explain how addicted individuals who genuinely desire to be free of 
their addiction have such difficulty resisting the impulse to take the drug.14 As these 
neuroadaptations remain even after the individual is able to attain abstinence, they also explain 
some of the difficulty that recovering drug users have to maintain their sobriety.19-20      
The three stages of addiction are a viscous cycle, with each stage increasing the addicted 
individual’s compulsivity and decreasing their control of their addiction. The initial use of the drug 
activates the reward system and gives the user a “high” that they want to continue, often leading 
to binge intoxication. Repeated use of the drug can dampen the brain’s reward system, causing the 
user to become tolerant to the drug which requires more of the substance to get the same euphoric 
effect. Similarly, this reduced sensitivity affects non-drug related rewards so that the addicted 
individual does not feel the same pleasure out of naturally rewarding activities as they once did. 
Thus the individual is more motivated to seek the “high” they get from taking drugs rather than 
non-drug related rewards. Upon withdrawal of the drug, an addicted individual experiences 
negative physical effects and dysphoric emotions, both of which lead the individual to take more 
drug. After long-term substance abuse, individuals become dependent upon the substance in that 
their bodies require the substance to relieve the dysphoria and physical withdrawal symptoms. The 
cycle of addiction is difficult for the user to escape, as the physical effects of withdrawal are painful 
and additional changes in the brain reduce the addicted individual’s ability to resist the urge and 
impulse to use the drug. Deficits in executive function often prevent addicted individuals from 
accomplishing their goal to stop taking the drug, which leads to drug seeking and relapse.14   
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Of the 29 million American adults who will partake in using an illicit or nonmedical drug during 
their lifetimes, less than 20% of them (5.4 million) will progress to substance abuse and 
addiction.17a This discrepancy between use and abuse indicates that there are risk factors for 
addiction and that some people are more prone than others to transition from substance use to 
abuse. Genetic, social, developmental, and environmental factors all play a role in determining 
susceptibility for drug use, abuse, and addiction. Family history of drug abuse increases the risks 
for developing drug addiction, possibly through genetic heritability and/or learned parenting 
practices.1, 21 Adolescence is a vulnerable point in life for the development of drug use and misuse 
behaviors. Individuals who are raised in environments that expose them to drug use or in high 
stress environments, such as being subject to physical, sexual, or emotional abuse, parental 
instability, neglect, or poverty, have an increased risk of developing addiction.1, 14 Individuals who 
suffer from mental illnesses are also at higher risks for misusing and abusing drugs.22 The transition 
from drug use to abuse to addiction requires long-term exposure to the drug and does not occur in 
every person who uses these addictive substances. 
The Opioid System 
Opioid receptors 
Many drugs of abuse, particularly prescription pain killers such as morphine and oxycodone, 
target the opioid system. Therefore, modulation of opioid receptors carries therapeutic potential 
for treating pain and addiction. Opioid receptors are divided into three types, µ (MOR), κ (KOR), 
and δ (DOR),23 and are expressed by neurons in the central and peripheral nervous systems (CNS 
and PNS), neuroendocrine cells, and immune cells.7 All three opioid receptors are class A G-
protein coupled receptors (GPCRs) with seven transmembrane spanning helices and 50-70% 
genetic homology between them. The sigma and epsilon receptors were once proposed to be in the 
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opioid family, but DNA and sequence analysis concluded that they do not belong in the same 
family as the “classical” opioid receptors.9 However, the nociceptin receptor (NOR), is considered 
to be a fourth opioid receptor, of a non-opioid branch of the family. This distinction is made 
because the NOR does not bind, and its effects are not reversed by, the classic opioid antagonist 
naloxone, but it is structurally similar to the classical opioid receptors as a GPCR with a similar 
amino acid primary sequence.24 
The opioid receptors have endogenous peptides that activate them,25 and just like their receptor 
targets, these opioid peptides are also expressed throughout the CNS and PNS.9 These peptides all 
share a common Tyr-Gly-Gly-Phe-Met/Leu sequence, which is known as the opioid sequence. The 
enkephalins (Met- and Leu-enkephalin) are derived from proenkephalin, -endorphin is derived 
from proopiomelanocrtin, and all three are potent antinociceptives that activate both MORs and 
DORs.  The dynorphins are derived from prodynorphin and can be both pronociceptive, acting at 
N-methyl-D-aspartate (NMDA) receptors, or antinociceptive, acting at KORs.7 A fourth type of 
opioid peptide, the endomorphins, act selectively at MORs, but their precursor protein is unknown 
and they are unique in that they do not contain the opioid sequence.9 The NOR receptors also have 
an endogenous peptide that activates it, nociceptin/orphanin FQ, that is similarly derived from a 
precursor polypeptide pre-pro-nociceptin.24 
In 2012, the structures of all three opioid receptors were published in the inactive, antagonist-
bound state: MOR bound to the morphinan antagonist -FNA;26 KOR bound to the antagonist 
JDTic;27 and DOR bound to naltrindole28 and a bifunctional DOR antagonist/MOR agonist 
peptide.29 More recently, the crystal structure of the MOR bound to the agonist BU72 was 
published30 as well as a NMR-based structure of the KOR bound to its endogenous peptide agonist 
dynorphin,31 but to date no active crystal structures of KOR or DOR have been solved.  
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Each of the three opioid receptor subtypes modulates nocicpetion, but they all have differing 
roles in addiction.32 Activation of MORs not only causes analgesia, but also results in euphoria, or 
a feeling of well-being that can be a contributing factor towards abuse of MOR agonists. Several 
side effects of clinically-used opioids are the direct result of activation of MORs, such as sedation, 
constipation, and respiratory depression.9, 33 The MOR is responsible for mediation of the 
rewarding and addictive properties of many abused drugs, primarily due to the increases of 
dopamine transmission and euphoria produced upon MOR activation.32, 34 The rewarding effects 
of MOR activation are antagonized by the KOR through its suppression of dopamine release and 
dysphoric effects.35 KOR activation also results in analgesia, but it does not mediate respiratory 
depression or constipation.9 DOR activation provides analgesia and reduces anxiety but has also 
been attributed to convulsions and constipation.9  The role of the DOR in the reward pathway and 
addiction is not as well defined as for MOR and KOR, but its role in anxiety reduction and 
attenuation of depressive-like states is well recognized. The DOR receptor does appear to be 
implicated in emotional processes associated with addiction.32  
The opioid receptors are inhibitory GPCRs, and as such, activation through agonist binding 
induces a conformational change that allows for binding of heterotrimeric Gi/o proteins to the 
receptor C terminus (Figure 1.3). Upon displacement of GDP with GTP, the trimeric G protein 
dissociates into G and G subunits. The Gsubunit is responsible for the inhibition of adenylyl 
cyclases that results in a decrease in cAMP accumulation within the cell and thus decreased cAMP-
dependent Ca2+ influx. Prevention of action potential propagation and neuronal excitation is also 
acheived by the G subunit as it opens the G protein-coupled inwardly rectifying K
+ (GIRK) 




Attenuation of neuron excitability is achieved through the modulation of Ca2+ concentrations, and 
the G subunit suppresses Ca
2+ influx and modulates both pre- and post-synaptic Ca2+ channels. 
All of these G-protein-mediated pathways ultimately decrease nociceptive stimulus transmission 
and significantly reduce pain perception.9  
A single activated receptor can couple multiple G proteins and each, in turn, dissociate and 
activate downstream second messengers, ultimately resulting in signal amplification. The receptor 
must be desensitized in order to turn off the signal transduction process. This desensitization 
process is two-fold. The GPCR is first phosphorylated by a second-messenger protein kinase (i.e. 
protein kinase A or C) or by a GPCR kinase (GRK). Phosphorylation of intracellular regions of 
the receptors promotes the binding of -arrestins.37 Once -arrestins are bound to the opioid 
receptor, G protein coupling can no longer occur and receptor internalization is promoted by 
endocytosis in clathrin-coated pits. Upon internalization, the receptor can be recycled, via 
 
Figure 1.3: Opioid receptor signaling. 
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dephosphorylation and reintegration into the membrane which restores signal transduction, or it 
can be targeted to the lysosome where it is degraded. The phosphorylation and degradation 
pathways of opioid receptors are thought to contribute to the development of tolerance to opioid 
drugs.9, 36 
The opioid receptor--arrestin complexes have also been shown to activate signaling cascades, 
specifically activation of members of the mitogen-activated protein kinase (MAPK) family. These 
proteins include ERK 1 and 2, JNK, and p38. The mechanisms of MAPK activation for each of 
the specific opioid receptors have not been fully delineated, but multiple mechanisms appear to be 
at work, including -arrestin-independent Gand -arrestin-dependent mechanisms.36 
Recent research has indicated that, in addition to intracellular signaling and phosphorylation, 
opioid receptors interact with nearby proteins directly. Homo- and heterodimers of opioid 
receptors have been identified, where the receptors are oligomerized with another receptor of the 
same or different type, respectively.38 Additional subtypes of receptors have also been postulated 
to exist from alternative splicing and posttranslational modifications.39 While much work has been 
done to prove the existence of both the oligomerized and splice variant opioid receptors, their 
existence is still a debated topic among experts in the field.9, 40  
Functional selectivity  
The idea of functional selectivity (or biased agonism) has recently been of interest in the field 
of GPCR research. GPCRs are dynamic systems with many structural conformations, and these 
different conformations activate the signaling pathways to varying extents. Functional selectivity 
refers to the ability of ligands to stabilize different conformations of a single receptor subtype and 
thus differentially regulate the downstream signaling cascades. Oftentimes the pathways being 
differentiated through functional selectivity are activation of G protein pathways versus -arrestin 
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recruitment.37 While the exact mechanisms by which functional selectivity is modulated have not 
been fully elucidated, studies have demonstrated that GPCRs bound to ligands biased for one 
pathway adopt different conformations than when they are bound to ligands biased for another 
pathway.41 Furthermore, biased ligands have been shown to stabilize the -arrestin as well as the 
receptor in distinct conformations from unbiased ligands.42  
Recent work in the area of targeting GPCRs has focused on developing ligands that are 
functionally selective, or biased, for one pathway over another in an effort to decouple the various 
downstream effects of each pathway.37 Identification of these biased ligands requires evaluating 
compounds for different pathways coupled to a single receptor and comparing the activities from 
those assays to a standard, unbiased or neutral compound.43 This comparison is often expressed as 
a bias factor, or a quantitative value of the bias for one pathway over another. 43-44    
Opioid receptors have been at the forefront of the functional selectivity field. Early studies 
dosing mice lacking -arrestin-2 with morphine demonstrated that the animals did not develop 
tolerance or other side effects associated with morphine.45 These studies were the first to give 
insight into the possibility that the analgesic effects at MOR could be dissociated from the side 
effects through the development of functionally selective compounds.37 Other studies have 
similarly shown that functionally selective KOR activation can dissociate some of the negative 
side effects from the beneficial physiological effects.46  
Opioids as Drugs 
Structural classifications of current opioids 
Arguably the world’s oldest drug, morphine was self-administered by drinking the milk of the 
opium poppy dating back as early as 3400 B.C.33 Friedrich Sertuerner identified the alkaloid 
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morphine as the active ingredient in opium in 1803.47 Since the characterization of morphine’s 
structure in 1925,48 hundreds of derivatives of the structure have been made, and many of these 
derivatives have been FDA-approved for pain treatment.47 However, most of these new opioid 
compounds have been unable to diverge from the morphinan or a structurally similar core. In fact, 
most opioids on the market can be divided into four main structural classes, all of which heavily 
rely on morphine’s structure. These include epoxymorphinans (the most similar to morphine and 
most common class), benzomorphans, phenylpiperidines, and diphenylheptanes (Figure 1.4). 
Morphine itself is an epoxymorphinan, as are the commonly used drugs codeine, hydrocodone, 
hydromorphone, oxycodone, oxymorphone, buprenorphine, nalbuphine, butorphanol, and 
levorphanol.33 The second most-prominent structural class are the phenylpiperidines. These drugs 
are synthetic but were inspired by the phenylpiperidine found in morphine. Drugs in this class 
include meperidine, fentanyl, remifentanil, sufentanil, and alfentanil, and are very potent MOR 
agonists.33 To date, only one benzomorphan, pentazocine, is FDA-approved, but others are used 
in opioid research. These benzomorphans have mixed activities at the MORs and KORs.33 The 
diphenylheptanes include propoxyphene and methadone, both of which are MOR agonists.33 
Figure 1.4: Common opioid structural classes. 
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Recently, two other drugs have been developed, tramadol and tapentadol, which both have MOR 
activity, but also mediate pain relief through other pathways, mainly the inhibition of 
norepinephrine reuptake.47 These compounds are the most structurally unique in comparison to 
morphine, but they do still resemble the morphine core due to their phenolic or methoxyphenyl 
moiety, three-carbon spacers, and tertiary basic amines.47 
Research throughout the years has helped to develop strong structure-activity relationships 
(SARs) between the morphinan backbone and activity at the opioid receptors. Modification of the 
N-substituent (R3 in Figure 1.4) affects the activity significantly. Creating a quaternary nitrogen 
restricts the compound to the periphery, while conversion of the methyl group to a 
cyclopropylmethyl or allyl group switches the activity from a MOR agonist to an antagonist. The 
phenolic hydroxyl group at C3 is required for activation of MORs. Drugs such as codeine have the 
phenol masked as a methoxy group (R1 = Me), but it is demethylated in vivo by the cytochrome 
P450 enzyme 2D6 (CYP2D6) to the more active phenol. The 14-substituent (R2) can either be a 
hydrogen or a hydroxyl group. The non-natural 14-OH compounds have slower penetration 
across the blood-brain barrier, but their slower penetration is compensated for by much higher 
potency at MORs. The naturally occurring allylic 6-OH-substituent can be oxidized to the ketone 
and the 7,8-alkene reduced with activity at MORs maintained. This modification does reduce the 
effectiveness of these compounds as cough suppressants, so the oxidized compounds are not used 
for this indication.49 
Targeting the opioid system: Pain therapies 
Opium has been used for thousands of years for the treatment of pain.47 The primary active 
ingredient in opium is morphine, which exerts its analgesic and euphoric effects through the MOR. 
Most current, clinically-used opioids also function through activation of the MOR, either 
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selectively or nonselectively. While the analgesic effects of these drugs are mediated through 
MOR activation, so too are the side effects most commonly associated with them, including 
sedation, nausea, respiratory depression, and constipation.9  
Compounds with dual mechanisms of action have also been investigated. Partial agonists for 
MOR and compounds that have mixed MOR/KOR activity have also been targeted for pain 
treatments, but these compounds generally have analgesic ceilings (a dose that elicits the 
maximum response, and increasing the dose does not increase analgesic efficacy) and can 
precipitate withdrawals if given with pure MOR agonists.7 The dual-acting analgesic tramadol is 
a weak activator of the MOR, causes the release of serotonin, and inhibits the reuptake of 
norepinephrine. Together, these mechanisms contribute to tramadol’s overall analgesic efficacy. 
Further, the open-chain tramadol analogue tapentadol has similar in vivo efficacy to oxycodone, 
with a reduced risk of gastrointestinal issues.47 Additionally, recent work has shown that dual 
MOR/DOR agonism elicits analgesia without conditioned place preference development; however 
the animals did self-administer the compound, indicating that it does have abuse liabilities.50 
Although MOR activation is associated with opioid-related side effects, the MOR is still of 
interest in the search for better pain therapies. Decoupling the analgesic effects from the negative 
side effects is currently being investigated through the development of functionally selective 
ligands. TRV130 is G protein biased, with reduced -arrestin-2 recruitment relative to  traditional 




opioids, and is currently undergoing clinical trials (Figure 1.5). Thus far, TRV130 has shown 
reduced respiratory depression and gastrointestinal side effects.51 Other functionally selective 
MOR agonists have been described recently, including mitragynine52 and herkinorin,53 among 
others.54  
In addition to the MOR, the DORs and KORs have been implicated as effective targets for 
treating nociception. Unlike the MOR, activation of the DOR does not have any reinforcing or 
addictive properties. DOR agonists have successfully treated chronic inflammatory nociception 
and bone cancer-associated nociception in animal models.55 Co-administration of a MOR agonist 
with a DOR antagonist has been shown to enhance analgesia in comparison to the MOR agonist 
alone without an increased risk of side effects.8 The analgesic effects of KOR activation are limited 
by the KOR-induced dysphoria. However, as dysphoria only occurs upon activation of KORs in 
the CNS, peripheral targeting of KORs is a possible treatment option for pain therapies. 
Peripherally restricted KOR agonists have demonstrated analgesic efficacy in animal models of 
visceral and inflammatory nociception without the common MOR-associated side effects.47 
Peripheral restriction of MOR agonists has also been demonstrated to reduce the centrally-
mediated side effects while maintaining analgesic efficacy in animal models of nerve damage, 
visceral, inflammatory, and cancer nociception.7   
Clinically used addiction therapies 
All of the few approved therapeutic options for treating drug abuse and addiction target opioid 
receptors. Methadone was the first approved therapeutic for long-term management of addictions 
to opioids.56 It is a safer, longer-acting MOR agonist than many abused opioids, and as such, 
methadone therapy replaces the illicit use of opioids for a safer opioid that is administered in 
controlled settings. As a full MOR agonist, methadone itself is an addictive drug, but because of 
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its improved safety profile and longer course of action, methadone therapy is still an effective 
treatment for drug addiction.57 Buprenorphine is also approved for the treatment of opioid abuse, 
but unlike methadone, it is a partial MOR agonist with KOR antagonism. Because of its high 
affinity for the MOR, buprenorphine can block the effects of the abused MOR agonists. Similarly, 
the MOR antagonist naltrexone is effective in treating opioid addiction, as well as alcohol 
dependence, but as an antagonist (lacking any agonism for MOR), it is considered safer and lacks 
the possibility of addiction. Therefore, naltrexone treatment is not the substitution of one addiction 
for another but the prevention of the rewarding properties of the abused substance. However, due 
to the antagonism of the MOR receptor and its lack of euphoric effects, patient compliance and 
retention on naltrexone treatment are reduced compared to buprenorphine and methadone.34 
Additionally, it is important to note that antagonism of the MOR can precipitate withdrawal 
symptoms if given to someone who has developed dependence to MOR agonists, and these 
withdrawal symptoms must be monitored, as they can be life-threatening.7 
These currently approved addiction therapies for opioid abuse have many drawbacks. None of 
these substances are able to combat the neurobiological changes that have occurred in the brain 
due to addiction. In fact, methadone and buprenorphine are both considered maintenance therapies, 
as the individual is still addicted to the substance, and naltrexone simply blocks the “high” from 
taking the addictive drugs. Although these drawbacks may seem considerable, no other alternatives 
currently exist. Additionally, no medications have been approved for the treatments of other 
addictions, such as marijuana, cocaine, and amphetamine abuse.1  
Targeting the opioid system: Addiction therapies 
The above therapeutics approved for treating opioid addiction are also being tested for their 
18 
 
efficacy in treating other addictions, specifically stimulant abuse. Patients on either methadone or 
buprenorphine maintenance treatment use less cocaine.58 Similarly, patients treated with 
naltrexone have reduced amphetamine use.59 In animal models, a combination therapy of 
buprenorphine and naltrexone decrease cocaine-seeking and cocaine-induced conditioned place 
preference without having a high abuse potential,60 and methadone successfully prevents cocaine-
induced conditioned place preference.61   
While many abused substances are MOR agonists, some studies have shown promise that 
modulation of the MOR receptor may be a useful treatment for abuse and addiction. Some, but not 
all, MOR antagonists have shown success in attenuating cocaine- and heroin-seeking, cocaine-
induced conditioned place preference, and cocaine self-administration.62 This blocking of heroin’s 
rewarding effect can be explained simply in that heroin is a MOR agonist and blockade of the 
MOR prevents the rewarding properties. However, the interplay between cocaine and the MOR is 
more complex, as the data thus far suggest that cocaine activates MORs by increasing expression 
of endogenous opioid peptides.62b Because MOR activation has a high potential to lead to abuse, 
the development of functionally selective MOR ligands may provide a way to modulate the MOR 
system and affect drug abuse actions without the treatment itself being addictive. Recent advances 
in the field of functionally selective opioid ligands have led to the identification of several biased 
MOR agonists, including herkinorin and mitragynine, among others (Figure 1.5).52, 54, 63  
While the MOR system has historically received the most research attention, recent research 
interests have shifted toward the use of DOR and KOR ligands for addiction therapies due to their 
lessened chance of abuse development. The DOR system’s role in drug addiction is still being 
defined, but several studies indicate that it is a viable drug target. DOR antagonists decrease 
morphine-, cocaine-, and amphetamine-induced conditioned place preference,64 and DOR agonists 
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increase morphine-induced conditioned place preference.65 DOR antagonists suffer from the same 
depressant effects as KOR agonists. An early study evaluating the DOR antagonists in cocaine 
self-administration models showed that no effect was seen below the threshold where the 
depressant effects were seen.66  
The KOR system appears to be an attractive way to treat stimulant and other drug addictions 
without the high potential for abuse seen with MOR agonists. Several studies have shown that 
KOR agonists decrease self-administration of both cocaine and morphine while KOR antagonists 
do not affect the self-administration of either drug.67 KOR activation causes dysphoria, which can 
result in conditioned place aversion at high enough doses. Therefore, animal studies where 
locomotor activity could affect the readout of the assay must confirm that the doses of KOR agonist 
are not causing dysphoria and affecting the animal’s activity.68 However, many of the KOR 
agonists have been shown to successfully prevent cocaine- and morphine-induced conditioned 
place preference at doses below the threshold that results in conditioned place aversion.69 The 
KOR system also appears to have a role in the withdrawal mechanism, as the naloxone-induced 
morphine withdrawal was attenuated with KOR agonists and potentiated with KOR antagonists.70 
Additionally, cocaine reinstatement has been shown to be attenuated by both KOR agonists and 
antagonists.71 Of note, as these results appear to be contradictory with agonists and antagonists 
both eliciting the same physiological effect, it has been said that the results from the KOR 
antagonist studies “remain highly controversial.”62b  
Targeting multiple opioid receptors has also shown success in animal models of drug abuse. 
Ligands that are dual MOR/KOR agonists attenuate self-administration of cocaine and heroin 
without as many side effects as highly selective KOR agonists.72 Similarly, dual KOR/DOR 
20 
 
agonism blocked cocaine-induced conditioned place preference without causing conditioned place 
preference or conditioned place aversion on its own.73  
A recent strategy for targeting drug addiction has been to prevent the diversion of prescription 
pain killers, thereby restricting the source of many of the drugs being used recreationally through 
the development of abuse-deterrent prescription opioid formulations. These tamper-resistant and 
longer-acting formulations not only help prevent abuse but also ensure patient compliance.74  
Patient compliance issues have led to the development of longer-acting treatments for addiction 
therapies. Depot formulations that only have to be administered once a month have been developed 
for both naltrexone and buprenorphine. Currently, only the depot formulation of naltrexone 
(Vivitrol®) is on the market, but the depot formulation of buprenorphine recently received fast-
track designation by the FDA after a successful clinical trial.75  
Several approaches to tamper-resistant formulations have also been developed; 1) The 
prescribed opioid is contained in a pill along with a sequestered MOR antagonist that is only 
released if the pill is crushed; 2) The prescribed opioid is in a gel that is too viscous or insoluble 
to inject by syringe; and 3) The pill itself is resistant to crushing or solvating in common solvents.76 
Another method of abuse treatment, Suboxone®, combines the use of the partial MOR agonist 
buprenorphine and the MOR antagonist naloxone in a 4:1 mixture. Due to naloxone’s low oral 
bioavailability, if Suboxone® is taken sublingually as prescribed, no significant antagonism by 
naloxone will be seen and only the partial agonism by buprenorphine will have an effect. 
Suboxone® is dosed in a film that is nearly impossible to crush into a powder and snort, but if it is 
dissolved, the naloxone will antagonize any effect that the buprenorphine would have.76-77 
Extended-release oxycodone (OxyContin) was a heavily abused prescription drug before it was 
reformulated. In fact, over half of people admitted to drug treatment centers admitted to snorting 
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or orally taking oxycodone (53% and 55%, respectively). The reformulated pill is tamper-resistant 
in that it cannot be easily crushed or dissolved. As of August 9, 2010, the only form of OxyContin 
available is the reformulated version. The change was made with FDA approval but without 
notification of the general public or the prescribing physicians. In the first three years after this 
change was made, the rates of OxyContin-related abuse and overdoses reduced dramatically (48% 
and 65%, respectively). While these numbers seem like positive outcomes, some have argued that 
the inability to abuse prescription oxycodone has led addicted individuals to seek other drugs for 
their “high.” During this time when OxyContin statistics were improving, abuse of extended-
release oxymorphone increased 236%.78  Similarly, heroin overdose rates nearly tripled during 
those three years and are still continuing to rise.4 Therefore, while abuse-deterrent opioid 
formulations seem to have a beneficial effect of preventing the abuse of that specific drug, larger, 
more broadly effective solutions to the drug addiction problem are required.  
Salvinorin A as a Novel Opioid 
Issues with current opioids as therapies for pain and addiction 
In the development of both pain and addiction therapies, a striking need for improvement over 
the current options is evident. Current standards of care for both pain and opioid addiction involve 
MORs, and the side effects from their use cannot be overlooked. Most, if not all, of these 
compounds are structurally similar to morphine, and although they have different pharmacological 
effects (full agonist, partial agonist, antagonist), they all act at the MOR in a similar fashion and 
result in the same side effects as morphine (Figure 1.6).47 For this reason, research over the last 
decade has focused on identifying non-morphine-derived opioids.  
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Historical use and identification 
The Mexican mint plant Salvia divinorum has been used for many years by the indigenous 
Mazatec people of Oaxaca, Mexico.79 They used the plant in spiritual divination rituals for its 
hallucinogenic effects, elicited with a similar potency to that of LSD. They also realized its healing 
properties and used small doses to treat sicknesses such as diarrhea, anemia, headaches, 
rheumatism, and the “semimagical” disease panzón de borrego, which was thought to be a 
sorcerer’s curse of a swollen belly.80 To elicit these effects, S. divinorum can be consumed by 
chewing or smoking the leaves, which creates the most potent hallucinogenic effects, or by 
crushing the leaves and extracting the juice to drink, which does not produce significant 
hallucinations.81 
The biological effects of S. divinorum prompted exploration into its active components. In the 
early 1980s, the active compound in S. divinorum was identified simultaneously by two separate 
groups to be the neoclerodane diterpene salvinorin A (Figure 1.7).79, 82 Although salvinorin A is 
responsible for the hallucinogenic effects of S. divinorum, it did not act at any receptor sites that 
Figure 1.6: Structures of morphine and analogues.  
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were known to mediate hallucinations.81 In 2002, Roth and colleagues determined that salvinorin 
A’s biological activity might be due to its potent and selective activation of KORs.83 This makes 
salvinorin A the first non-nitrogenous opioid ever discovered. In fact, prior to its discovery, a basic 
amine was considered to be a requirement for binding and activation of any opioid receptor.80 
Metabolism 
The in vivo half-life (t1/2) of salvinorin A is very short across all species studied. In rats, i.p. 
administration of salvinorin A resulted in a maximum concentration (Cmax) in the plasma seen 
within 10-15 minutes of dosing.84 A similar trend was seen for intravenous injection of salvinorin 
A in monkeys, with a t1/2 of less than an hour.
85 In a human study involving smoked salvinorin A, 
the Cmax in plasma was seen within 2 minutes post inhalation, and within 90 minutes, no salvinorin 
A was detected. This study also observed strong correlations between the subjective drug effect 
felt by the person and their plasma concentration of salvinorin A.86  
The short t1/2 of salvinorin A is attributed to its rapid metabolism. The primary metabolite of 
salvinorin A is salvinorin B, which is formed by cleavage of the C2-acetate (Figure 1.8).87 
Carboxylesterases have been determined to be responsible for the salvinorin A to B conversion.88 
Additional metabolizing enzymes have been implicated in salvinorin A’s metabolism, notably the 
cytochrome P450 enzymes (CYPs) CYP2D6, CYP1A1, CYP2C18, and CYP2E1 and the UDP-
glucuronosyltransferase (UGT) UGT2B7,84 although the specific products of these metabolic 
 
Figure 1.7: Structure of salvinorin A. 
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reactions have not been conclusively determined. Another specific product of metabolism has been 
determined to be the hydrolysis of the lactone ring  by calcium-dependent lactonases to form the 
ring-opened products of both salvinorin A and B.88  
Structure-activity relationships 
The structural complexity of salvinorin A has made the development of analogues via total 
synthesis challenging, although there are now several routes towards the total synthesis of 
salvinorin A itself.89 All analogues of salvinorin A to date have been developed through 
semisynthetic methods, and although effective, the types of analogues that can be accessed via 
semisynthesis is limited due to the many reactive moieties within the molecule that do not tolerate 
harsh conditions.67b, 80 
Overall, most salvinorin A analogues to date have focused on modifications to the C2-acetate 
moiety and the furan ring. There are also a few analogues with modifications to the A-ring, C-ring, 
and C4-carbomethoxy moiety, although accessing these regions is generally more synthetically 
strenuous than the acetate and furan.  
The C2 position tolerates a variety of substituents, while still maintaining KOR activity. Alkyl 
esters and ethers, carbamates, and sulfonates are generally well-tolerated, with the ethoxymethyl, 
methoxymethyl, and mesylate derivatives being more potent than or equipotent to salvinorin A 
Figure 1.8: Primary metabolism of salvinorin A. 
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itself (Figure 1.9). The general C2-SAR trend for KOR activity is that steric bulk is not tolerated 
but small, alkyl groups are.80 While aromatic groups at the C2 position are not well-tolerated for 
KOR activity, substituting the acetate for a benzoate results in a MOR-selective rather than KOR-
selective compound, herkinorin (Figure 1.9). Herkinorin was not only the first non-nitrogenous 
MOR agonist ever described,90 it was also the first G-protein biased MOR agonist.63 The SAR 
about the phenyl ring of herkinorin has been extensively explored and has been shown to tolerate 
meta- and para- substituted derivatives and a variety of heterocyclic substitutions. Epimerization 
of C2 is not well-tolerated in either the KOR agonists or the MOR agonists.80 
Furanyl derivatives of salvinorin A have also been explored, although the exploration of this 
position has been limited by the reaction conditions that the salvinorin A core will tolerate. 
Substitutions at the C16 position are possible, and generally small, linear substituents are tolerated 
with the 16-Br- and 16-ethynyl- derivatives being equipotent with salvinorin A (Figure 1.10).67b 
Figure 1.10: Salvinorin A furanyl-derivatives. 
Figure 1.9: Salvinorin A derivatives at the C2 position. 
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Modifications to the furan itself have also been accomplished, such as the 2-furanyl derivative, 
C12-carboxylic acid and esters, and homologated furans; however, none of these derivatives have 
been nearly as potent as salvinorin A.80 
In addition to these changes at the furan and acetate moieties, several other analogues of 
salvinorin A have been synthesized, but very few of these modifications have resulted in activity 
at the KORs or MORs (Figure 1.11). Several notable exceptions include the reduction of the C1-
ketone to the deoxy compound or the reduction of the C17-lactone to either the lactol or the 
corresponding pyran ring, indicating that these carbonyls are not necessary parts of the decalin 
core for activating KORs. Additionally, limited modifications to the C4-carbomethoxy group have 
been accomplished, with activity maintained in the ethyl ester derivative.80 
Proposed mode of binding 
Because of salvinorin A’s structural uniqueness as an opioid agonist, its binding at the KOR 
has been debated and proposed for many years. The iconic salt bridge found between the basic 
amines of other opioids and the aspartate residue conserved among the opioid receptors cannot be 
made due to the lack of basic amine in salvinorin A. Many proposed binding poses have been 
suggested for how salvinorin A binds at the KOR,91 but because no crystal structure exists of the 
active KOR, these proposed structures are simply suggestions that need to be validated with 
experimental evidence. Mutagenesis studies have also been conducted to selectively mutate an 
Figure 1.11: Derivatives of salvinorin A with KOR activity. 
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amino acid in the binding pocket and evaluate salvinorin A’s ability to activate the mutated 
receptor.27, 91 While these studies offer some insight into which amino acids are interacting directly 
with the ligands at the binding site, the data can be difficult to interpret as perturbing a single 
amino acid can destabilize the active conformation of the structurally complex KOR. This 
complication is highlighted by the fact that mutating amino acids outside of or on the edge of the 
binding site has detrimental effects on the activity of salvinorin A at the KOR.91b  
In 2012, the KOR crystal structure bound to JDTic was published,27 which gave insight into the 
binding pocket of the KOR but in an inactive state (Figure 1.12). However, as this is the best 
picture of the receptor to date, it has been used to study salvinorin A’s interaction at the receptor 
binding pocket. The original report proposed a binding pose of a salvinorin A derivative, RB-64, 
which has a thiocyanate moiety that has been shown to bind covalently to cysteines in the KOR 
binding pocket.27, 91e The proposed interactions of salvinorin A and the KOR do align, for the most 
part, with experimental SAR data generated through the evaluation of salvinorin A analogues at 
the KOR in vitro.  
Needs for improvement 
Salvinorin A has proven to be a structurally unique opioid scaffold that is useful in probing the 
effects of MORs and KORs, both in vitro and in vivo. However, the evaluation of salvinorin A and 
its derivatives in vivo has often presented with conflicting results, depending on the compound and 
the route of administration. Often, these discrepancies can be attributed to salvinorin A’s structural 
 
Figure 1.12: Structure of JDTic, KOR antagonist. 
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issues that prevent its further development as a drug candidate, including its rapid metabolism and 
low oral bioavailability.80 
In vitro evaluation indicates that the compounds are acting at KORs with similar potency, but 
upon administration to animals, the effects vary widely. For instance, salvinorin A showed low 
and inconsistent antinociceptive effects, while the 2-methoxymethyl-salvinorin B derivative 
showed potent antinociception in mouse models.92 These two compounds behave similarly in vitro, 
but the mechanisms for their significant in vivo differences cannot be fully delineated. In this assay, 
salvinorin A could be metabolized before reaching the site of action, whereas 2-methoxymethyl-
salvinorin B is presumably more metabolically stable and may be able to reach the site of action 
to elicit the antinociceptive effects. Conversely, the two compounds could be activating the KORs 
in functionally selective ways that results in antinociception for the methoxymethyl-salvinorin B 
derivative but not for salvinorin B.80  
Salvinorin A and all of the analogues reported to date are very water insoluble.93 This lack of 
solubility limits the doses that can be given to the animals as well as the routes of administration. 
In most cases, the compounds were dissolved in DMSO or other organic solvents and buffer 
mixtures and given via intraperitoneal (i.p.) injection.93 This administration complicated the 
interpretation of the studies because different solvent solutions are often required to solubilize 
different compounds, and as organic solvents can have pharmacological effects of their own,94  
vehicle-treated animals must be treated with the specific, corresponding solvent mixtures used 
with each drug in order to compare the two results. The low solubility of these compounds require 
large volumes for delivery of the drug, which can limit the amount of dose that can be administered 
in animals, but the i.p. administration method is limited to low volume injections because of the 
small size of rodents’ peritoneal cavity. These factors can limit the amount of dose that can be 
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administered in animals.95 Furthermore, while i.p. administration is an effective method for 
research purposes, it does not correspond to any method of administration in humans, which is 
necessary for furthering a drug through pre-clinical trials.93 
Evaluation of salvinorin A and its derivatives in animals is also complicated by the potential 
for aversive and dysphoric effects resulting from KOR activation. Salvinorin A has been shown to 
attenuate cocaine-induced reinstatement of cocaine self-administration, but it has also been shown 
to reduce locomotor activity and elicit an aversive response in a conditioned place aversion test. 
Activation of the KOR and the associated decreases in dopamine release could be the cause of the 
positive results seen in the cocaine reinstatement models, but the KOR-related side effects must 
be evaluated at the specific doses in order to determine if, for example, the reduction in locomotor 
activity is what is actually keeping the animals from self-administering cocaine.80  
Overall, salvinorin A has proven to be a promising lead compound in the development of both 
pain and addiction therapies. However, improvements to the pharmacokinetic and metabolic 
profiles of salvinorin A derivatives as well as improved selectivity of the MOR-active compound 
herkinorin are still needed to further advance the therapeutic use of these compounds.  
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2. Project Rationale and Specific Aims 
Overall Rationale 
In the search for effective methods to mitigate the increasing rates of abuse and addiction of 
elicit substances, a variety of neurological pathways have been explored. Towards this goal of 
reducing drug abuse and ultimately overdose-related deaths, two avenues of research have 
emerged: 1) a preventative approach, the development of pain relieving medications without the 
abuse and addiction liabilities associated with current therapies, and 2) a responsive approach, the 
development of medications for people suffering from drug abuse and addiction.1 
The opioid system in particular has been validated as a pathway through which both pain and 
reward are mediated.2 Activation of the  opioid receptor (MOR) results in the pain-relieving and 
rewarding effects of all currently-used opioid drugs, but a growing body of evidence suggests that 
these two effects can be dissociated, resulting in pain relief without abuse liability.3 The  opioid 
receptor (KOR) is a target of interest in the development of therapeutics for a variety of diseases, 
including inflammation,4 drug addiction,5 pain,6 and depression.7  
Current MOR agonists on the market suffer from similar, though not identical, side effect 
profiles.8 As the side effect profiles are not identical among all MOR agonists, the possibility for 
differentiating the beneficial pain-relieving effects from the MOR-induced side effects exists. In 
exploring this phenomenon, the concept of functional selectivity has emerged. Recent advances in 
the area of functional selectivity have indicated that multiple pathways can be activated upon 
agonist binding to the MOR, including G-protein activation, phosphorylation by multiple kinases, 
and recruitment of -arrestins. Each of these pathways mediates a variety of downstream effects, 
and much work has been done to understand the physiological results of specific pathway 
47 
 
activation and the downstream effectors associated with each pathway.3c Although tolerance, 
dependence, and addiction are highly complex biological responses, recent advances have been 
made in understanding some of the molecular pathways that contribute to their development. The 
fact that -arrestin-2 contributes to MOR-mediated tolerance was demonstrated in -arrestin-2-
knock out mice treated with morphine. The antinociceptive effects were enhanced and prolonged, 
and morphine-induced tolerance was inhibited.3a, 3b Additional studies have indicated that protein 
kinase C also contributes to morphine tolerance, as a protein kinase C inhibitor reversed tolerance 
development to morphine and other MOR agonists.9 Due to the high structural similarities of 
current MOR agonists, the development of functionally selective MOR agonists with reduced 
abuse liability may be realized through the exploration of different structural scaffolds.  
Compounds that act at the KOR are of interest towards the development of both a preventative 
and a responsive approach for combating the current drug abuse and addiction epidemic. KOR 
activation has been shown to have both an antinociceptive effect6 and an antirewarding effect.10 
The rewarding effects of drugs of abuse are attenuated by KOR agonists, which helps to prevent 
the binge and intoxication stage of the addiction cycle. This attenuation is the result of modulation 
of dopamine levels in the CNS.11  In animal models of drug abuse, KOR agonists have shown 
success in reducing drug self-administration, attenuating withdrawal symptoms, and preventing 
relapse.11-12 However, many classical KOR agonists, such as U50,488 and U69,593, suffer from 
detrimental side effects, including sedation, aversion, dysphoria, emesis, and depression.11 
Salvinorin A and its analogues have been explored towards the development of a pain and drug 
abuse therapy targeting either the MORs or KORs, but their use has been limited by poor drug-
like properties. While salvinorin A is an attractive lead in drug discovery campaigns because of its 
high selectivity for the KOR and its structural uniqueness in comparison to other opioids,13 its low 
48 
 
water solubility and rapid metabolism must be overcome for further development.14 Additionally, 
study of the antinociceptive effects of herkinorin at the MOR are complicated by its activity at the 
KOR.15 Thus, strategies to improve herkinorin’s MOR selectivity towards the development of a 
pain therapy with reduced side effects as well as improvements to salvinorin A’s pharmacokinetic 
and metabolic profiles are needed. 
Aim 1: Development of Pain Therapies with Reduced Side Effects 
Replacement of salvinorin A’s C2-acetate moiety with a benzoate, as seen in herkinorin, shifts 
the activity from a KOR agonist to a MOR agonist (Figure 2.1).15 However the utility of herkinorin 
is limited by its low selectivity for the MOR, being only 4-fold selective for the MOR over KOR,16 
as well as the fact that it is peripherally restricted,17 and thus cannot be used to probe centrally 
mediated processes. SAR campaigns to explore this interesting activity profile identified that 
replacing the ester linkage of herkinorin with an amide, named herkamide, eliminates KOR activity 
and increases the potency at the MOR.18 However, this compound was not further explored due to 
the complex and low-yielding synthesis required for the introduction of the amide.18  
Salvinorin A analogues with activity at the MOR such as herkinorin and herkamide are 
interesting research probes, as they are structurally dissimilar from all other MOR agonists. The 
 
Figure 2.1: Structures of salvinorin A and herkinorin. 
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lack of basic nitrogen and the unique structural motif was hypothesized to be able to activate the 
MOR in a unique fashion that resulted in antinociception with the potential for fewer adverse 
effects. Therefore, the development of a potent salvinorin A-based MOR agonist that allows for 
further SAR exploration was a research goal. 
Design and evaluation of kurkinorin in vitro and in vivo 
As herkamide showed over 3,000-fold selectivity for the MOR over the KOR, the structures of 
herkinorin and herkamide were compared to determine what structural feature could be imparting 
the large selectivity differences between these structurally similar compounds. The X-ray crystal 
structures of these two compounds indicates that the amide and the ester adopt different 
orientations.16 The ester linkage holds the phenyl ring in a position that eclipses the decalin ring 
system while the amide linkage holds the phenyl ring planar to the decalin core. While these are 
not necessarily the bioactive conformations of these compounds, these X-ray structures did 
indicate a possible reason for the selectivity changes.  
Because access to herkamide analogues is synthetically challenging, we sought to design a 
compound that held the phenyl ring in a similarly planar conformation to the decalin core as seen 
in herkamide. To accomplish this task, we envisioned the installation of a double bond between 
C2 and C3 would affect this planar conformation. Synthetic p49strategies were developed to 
oxidize salvinorin B to install this unsaturation, and after coupling with benzoic acid, the 
unsaturated analogue of herkinorin, named kurkinorin, is generated (Figure 2.2).16  
 
Figure 2.2: Chemical structure of kurkinorin 
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Initial evaluation of kurkinorin in vitro indicated that it was a potent and selective MOR agonist 
(EC50 = 1.2 nM, >8,000 / selectivity). Kurkinorin was further evaluated in vivo for its 
effectiveness to elicit antinociception followed by a comparison of its side effect profile to 
morphine. To evaluate antinociception, male B6-SJL mice were injected with either drug or 
vehicle, and their tails were dropped into a hot water bath (50 °C), with a 10 s time cutoff to prevent 
tissue injury. The withdrawal latency was measured, and a higher withdrawal latency corresponds 
to a higher antinociceptive effect.19 The development of tolerance was also evaluated in this assay 
by generating a dose-response curve on day 1 of treatment, followed by consecutive, daily dosing, 
and then regenerating the dose-response curve at the end of the test. Compounds that generate 
tolerance result in a right-shifted dose-response curve following repeated treatments.3a Sedation is 
an issue associated with MOR agonists and was thus of interest in this study. To evaluate sedation, 
animals were placed on a rotating rod and the time that they were able to stay on the rod was 
measured. Animals not experiencing sedation should be able to stay on the rod for the full time 
evaluated, 300 s, but sedated animals fall off the rod before the end point.20 Lastly, the rewarding 
effects of MOR agonists is of concern, as they can contribute to the development of abuse and 
addiction. Conditioned place preference assays were used to determine rewarding effects, and in 
this paradigm, animals repeatedly received a dose of either vehicle or drug in one side of a two-
sided chamber. On the test day, the amount of time the animal spent on the drug side versus the 
vehicle side was measured, and if the two are significantly different, the drug was said to be 
rewarding (or aversive, if the animal spent more time in the unpaired chamber).21 
Study 1: Evaluation of kurkinorin analogues with substitutions to the phenyl ring 
The effects of kurkinorin both in vitro and in vivo warranted further exploration. The developed 
synthetic methodology allowed for a robust SAR campaign, and analogues of herkinorin and 
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kurkinorin with substitutions to the 2-, 3-, and 4-positions of the phenyl ring were synthesized and 
evaluated for their ability to activate MORs. This was accomplished through a functional assay 
that measures forskolin-induced cAMP accumulation in CHO cells stably expressing MORs.22 
This assay is a measurement of G-protein activation, as agonist binding to the receptor activates 
the Gi-protein and initiates the inhibition of adenylyl cyclase, which results in a reduction of cAMP 
accumulation. Forskolin is used in this assay to stimulate adenylyl cyclase and increase the signal-
to-noise readout.  
Study 2: SAR-guided design and synthesis of kurkinorin analogues  
To further probe the MOR binding pocket, kurkinorin substituents were synthesized and 
evaluated based upon the results from the phenyl-substituted analogues. Although this initial SAR 
campaign did not yield any compounds with more favorable activity profiles at the MOR than the 
unsubstituted kurkinorin, we did identify trends that we were able to use to guide the next set of 
analogues in the search for MOR agonists with reduced side effect profiles. Notably, although no 
substituted phenyl compounds were more potent than the original, the substitutions at the 4- and 
3-positions were generally more potent than the 2-position, and the most potent of the substituted 
analogues were methoxy and fluoro substituted derivatives. Using these results to guide our 
analogue design, we explored 1) heterocyclic derivatives in comparison to phenyl derivatives and 
2) hydrogen bond possibilities off the aromatic ring. The salvinorin A core of kurkinorin and 
derivatives is not amenable to common deprotection methods, and thus the optimization of both 
protecting groups and deprotection methods was accomplished in order to synthesize several of 
the desired analogues.  
Study 3: Evaluation of SAR-driven kurkinorin analogues  
These SAR-driven analogues were evaluated in vitro for their ability to activate the MOR G-
52 
 
protein associated pathway through inhibition of forskolin-induced cAMP accumulation. 
Compounds that displayed potent activation of MOR-associated G-proteins were further evaluated 
for their ability to recruit β-arrestin-2 through MOR activation. The DiscoverX (Fremont, CA) β-
arrestin PathHunterTM technology was used for this analysis, which utilizes enzyme fragment 
complementation (EFC). Both the receptor and β-arrestin-2 are tagged with a fragment of β-
galactosidase that is only activated upon complementation. The recruitment of β-arrestin-2 to the 
receptor results in the activated enzyme, and the addition of substrate that is converted into a 
luminescent product allows for a dose-dependent increase in luminescence. This luminescence is 
then used to determine the extent of β-arrestin-2 recruitment. DAMGO ([D-Ala2, N-MePhe4, Gly-
ol]-enkephalin, a potent and selective MOR peptidic probe) had previously been shown to highly 
recruit β-arrestin-2 through MOR activation,23 and was thus used as the positive control to which 
all data were normalized. 
Much work has been done to develop models for quantifying the degree of functional 
selectivity, or bias, that accounts for the differences between the assays and pathways,24 and we 
employed a bias calculation equation25 (Equation 2.1) that normalizes data to the activity of 
DAMGO in both assays, similar to previous work.24c, 24e This equation allows for the normalization 
of the effective concentration eliciting 50% of maximum response (EC50) and the maximum 
efficacy (Emax) of each compound to the unbiased ligand DAMGO in both the G-protein-mediated 
cAMP pathway as well as the β-arrestin-2 recruitment pathway. Being unbiased, DAMGO has a 
bias factor of 1, and bias factor values less than 1 indicate bias towards the G-protein activation 
pathway and those greater than 1 indicate bias towards β-arrestin-2 recruitment.  
Equation 2.1. Bias factor equation. 
𝒍𝒐𝒈 𝑩𝒊𝒂𝒔 𝑭𝒂𝒄𝒕𝒐𝒓 =  log  
𝐸𝑚𝑎𝑥𝑡𝑒𝑠𝑡 ×  𝐸𝐶50𝐷𝐴𝑀𝐺𝑂
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Aim 2: Development of New Synthetic Approaches toward Refinement of Salvinorin 
A’s Pharmaceutical Properties 
While classical KOR agonists suffer from common side effects, salvinorin A has been shown 
to differ in its binding at the KOR as well as in its cellular and behavioral effects.11 These results 
further highlight salvinorin A’s potential as a structural lead towards the development of therapies 
for pain and drug abuse with a reduced side effect profile compared to classic opioids. The potency 
and selectivity of salvinorin A at the KOR does not need improvement, as is often the case in drug 
discovery efforts, because it activates the KOR with an EC50 value in the picomolar range. 
However, efforts to develop salvinorin A analogues with more favorable pharmacokinetic 
properties had not been attempted. Early into the SAR studies of salvinorin A, it was recognized 
that the carbonyl of the lactone moiety was not essential for KOR activity.26 Additionally, the 
original report of the KOR crystal structure bound to JDTic modeled salvinorin A into the binding 
pocket and found that salvinorin A likely binds with the lactone facing the pocket opening, without 
any meaningful receptor interactions (Figure 2.3).27 We hypothesized that substituting at the C17 
   
Figure 2.3: Docked structure of RB-64 (salvinorin A analogue) at the KOR.  Figure adapted from Wu, H., et. 
al. Structure of the human kappa-opioid receptor in complex with JDTic. Nature 2012, 485, 327-332. Used with 
permission. 
Lactone pointing out of 




position would be tolerated at the KOR and that this position could allow for the inclusion of water-
solubilizing moieties without sacrificing KOR activity.  
Study 1: Development of chemical methodology to selectively functionalize the C17 position 
The initial report detailing the modification of the lactone moiety describes the synthesis of 
three derivatives: Salvinorin A lactol, 17-Deoxysalvinroin A, and 8,17-Didehydro-17-
deoxysalvinorin A (Figure 2.4).26 The lactol was formed through reduction of salvinorin A with 
diisobutylaluminum hydride; however, the reproduction of this reaction in a selective manner was 
not accomplished and required further optimization. The deoxygenation of the C17 position to 
form the two other analogues was straightforward following the published method. As no other 
substitutions at this position had been done, reaction conditions allowing C17 substitution also 
required exploration and optimization. 
Reduction and substitution of the C17 carbonyl results in an additional stereogenic center on 
the salvinorin A core. For most compounds with C17-substitions, these epimeric compounds were 
separated via simple flash column chromatography; however, some derivatives did require 
preparative HPLC purification to separate the epimers. Determination of the stereochemistry at the 
C17 position required 2D-NMR techniques, and most compounds were unambiguously identified 
via NOESY correlations. 
Figure 2.4: Structures of C17-modified salvinorin A analogues. 
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Study 2: Evaluation of compounds with C17 modifications 
The analogues were evaluated for their ability to inhibit forskolin-induced cAMP accumulation 
through KOR activation. Evaluation of a variety of analogues, including when possible both - 
and -substituted derivatives, allowed for the generation of SAR at the C17 position. The activity 
values of the compounds were useful in designing further analogues.  
Study 3: Design, synthesis, and evaluation of analogues with C2 and C17 modifications 
Although SAR studies on the different pieces of salvinorin A have been done, no study has 
demonstrated that known SAR of different points can be combined to better optimize the molecule. 
In order to determine if changes in the structure result in corresponding activity changes, the C17 
modifications were incorporated into C2-modified compounds that had previously been generated 
in the lab and had shown activity at KORs and MORs. These compounds would also provide 
insight into the binding poses at the receptor. When structural changes are made to salvinorin A, 
it is generally thought that the molecule maintains the same binding pose; however, as we do not 
have crystal structures, this assumption cannot be confirmed. By making these dual-modified 
compounds, the activity shifts between salvinorin A and the mono-modified compounds can be 
compared to those of the dual-modified compounds. If the structural modifications still allow the 
compounds to bind in similar poses, then the activity trends should be similar between the mono- 
and dual-modified compounds. Additionally, by modifying the C17 position of the MOR agonist 
herkinorin, the necessity of the lactone for MOR activation can be evaluated to determine if the 
similarities between the KOR and MOR pockets allows for the similar structural modifications.  
Aim 3: Understanding the Metabolism of Neoclerodane Diterpenes 
The metabolism of salvinorin A has been attributed to activity of CYP450 enzymes, UGTs, and 
carboxylesterases, with the most rapid effects attributed to the C2-acetate cleavage by 
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carboxylesterases.14b, 28 Due to the short t1/2 of salvinorin A because of this rapid acetate cleavage, 
many salvinorin A analogues have been synthesized with modifications to the acetate in order to 
prevent metabolism while maintaining biological activity.29 Many of these compounds have been 
presumed to be more metabolically stable because of these C2-modifications, but the interpretation 
of their in vivo activities is speculative without also evaluating their metabolic stability.30 
Study 1: Development of a robust system for determining the metabolic stability of 
neoclerodane diterpenes 
Several previous studies have determined the metabolic stability of salvinorin A both in vitro 
and in vivo,31 but very few have evaluated the metabolism of salvinorin A analogues in comparison 
to salvinorin A itself.29a, 32 Of the studies that did include this comparison, one required the use of 
isotopically-labeled salvinorin A and derivatives,32 and the other was not reproducible in our lab 
due to the omission of key methodological details.29a Therefore, we sought to develop a robust 
method that allowed for the evaluation of in vitro metabolic stability of a wide variety of 
neoclerodane diterpene analogues without requiring the use of radiolabeled compounds.  
A method was developed using rat liver microsomes and varying the time, concentrations of 
compounds and proteins, buffer conditions, and quenching methods to optimize conditions for 
quantitative LCMS analysis. Incubation of compounds with rat liver microsomes in either the 
presence or absence of nicotinamide adenine dinucleotide phosphate (NADPH) followed by 
LCMS analysis at varying time points allowed for the evaluation of their metabolic profiles. 
CYP450 enzymes require NADPH for activity, and thus the metabolism seen in the presence of 
NADPH can be attributed to CYPs. However, in the absence of NADPH, CYP450 enzymes are 
inactive, and thus the metabolism observed without NADPH can be attributed to other 
metabolizing enzymes.  
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Study 2: Evaluation of the metabolic stability of salvinorin A and selected analogues 
With a robust method for evaluating salvinorin A and derivatives in hand, the CYP450 enzyme-
mediated and non-CYP450 enzyme-mediated metabolic stabilities were determined, allowing for 
direct comparison of how specific chemical modifications modulate the metabolic liabilities of 
salvinorin A. In the case of salvinorin A, previous reports have demonstrated that salvinorin A is 
a substrate for carboxylesterases.14b, 28 In our assay, we compared the metabolic profile of 
salvinorin A with its derivatives under the same conditions to determine how the change in 
chemical structure affects the metabolic stability of the compound. Thus using conditions without 
NADPH (inactive CYP450 enzymes), we monitor if esterase activity has been modulated through 
the chemical modifications.  
These data are useful in interpreting in vivo results, specifically regarding a compound’s 
duration of action and whether its ability to activate the receptor or its metabolic stability are 
resulting in specific changes in comparison to other compounds. Several salvinorin A analogues 
have been developed over the last decade that were thought to have increased stability profiles,15, 
29c, 33 and the development of this method allows us the opportunity to directly compare the 
metabolic stability of salvinorin A and these analogues. This method also allows for the direct 
comparison of the C2-C17 modified analogues described in Aim 2. These analogues have 
modifications to the acetate and lactone moieties which have both been confirmed to be sites of 
metabolism in salvinorin A,14b and so metabolic comparison allowed for further analysis of the 
role of each moiety in the metabolic stability of the compounds. The use of this method in 
conjunction with the ongoing synthetic and pharmacologic initiatives in the lab also led to the 
identification of a spirobutyrolactone moiety as a more metabolically stable bioisosteric 
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3. Development of Pain Therapies with Reduced Side Effects 
Background: Design and evaluation of kurkinorin in vitro and in vivo 
The design of kurkinorin was based upon the comparison of the X-ray crystal structures of 
herkinorin and herkamide (Figure 3.1).1 Specifically, the conformations of the phenyl rings of the 
two compounds differ significantly. In herkinorin, the phenyl ring is eclipsed relative to the decalin 
core; whereas the phenyl ring of herkamide sits planar to the decalin core. Although these X-ray 
crystal structures represent only two possible conformations of the molecules, and not necessarily 
the conformations bound to the receptor, they suggested that modifying the configuration of the 
C2 position of herkinorin might result in improved selectivity and potency for MORs.  
Therefore, we hypothesized that locking the conformation of the C2 substituent would impart 
selectivity between the MOR and KORs. The selectivity of herkamide could be attributed to one 
of two different interactions occurring due to its apparent conformational restriction: 1) the 
 
 
Figure 3.1: X-ray crystal structures of herkinorin and herkamide. 
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coplanarity of the phenyl and decalin ring systems or 2) an upward movement of the C2 substituent 
from the - to the -face of the decalin core. The inversion about C2 on salvinorin A had 
previously been reported to result in activity loss at KORs.2 Thus, inversion of the C2 stereocenter 
was expected to reduce KOR activity and therefore increase MOR selectivity, and locking the C2 
substituent planar to the decalin core, as seen in the crystal structure of herkamide, was anticipated 
to result in increased MOR activity. Accordingly, we hypothesized that a compound with this 
planar conformation could be generated by installing a double bond in the A-ring, as seen in 
kurkinorin, and in order to determine if further movement towards the -face was tolerated, or 
even preferred, we inverted the C2 stereochemistry to form 2-epi-herkinorin.  
In order to evaluate our hypothesis that the planarity of the ring would impart MOR selectivity, 
synthetic methods were required to install that unsaturation. After evaluation of a variety of 
methods to accomplish this transformation, it was determined that oxidation of salvinorin B with 
Cu(OAc)2 was able to produce this transformation in acceptable yields (Scheme 3.1).
3 Of note, 
  
Reagents and conditions: a) Cu(OAc)2, MeOH/CH2Cl2 (1:1), 67% yield; b) PhCOOH, DMAP, EDCI, CH2Cl2, 
52% yield. 
Scheme 3.1: Synthetic route to kurkinorin. 
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the product of this isolation process is a mixture of two isomeric enols 3.1 and 3.2 that rapidly 
equilibrate between one another through the presumed -diketone. Following chromatography, 
immediate characterization of 3.1 by NMR spectroscopy revealed a 3:1 mixture of 3.1 and 3.2 
However upon standing, solutions containing 3.1 slowly equilibrated to thermodynamically stable 
enol 3.2.  
Acylation of either the mixture of 3.1 and 3.2 or pure 3.2 with benzoic acid provided a single 
regioisomer (Scheme 3.1), presumably due to less steric hindrance upon addition at the preferred 
position over the regioisomer. The structure was confirmed to be the desired kurkinorin by 2D 
NMR studies. Briefly, the C3 proton correlated via COSY to the C4 proton and via HMBC to C1, 
C2, C4, and C5. The proton of C10 lacked any observable COSY correlations. Additionally, HSQC 
confirmed that carbons C3 and C10 each bear a single proton, further validating the regiochemistry 
of kurkinorin (Figure 3.2).1 
 
Figure 3.2: Unambiguous determination of the kurkinorin structure.  
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To determine how the configuration of the C2 position in herkinorin affects potency and 
selectivity at MORs, the 2-epi-herkinorin2b and the unsaturated analogue kurkinorin were 
evaluated for activity at MORs, KORs, and DORs. In the forskolin-induced cAMP accumulation 
functional assay, the epimerization of herkinorin at the C2 position resulted in a complete loss of 
activity at both MOR and KORs, while kurkinorin, differing only in a degree of unsaturation from 
herkinorin, was determined to be a potent MOR agonist with an EC50 value of 1.2 ± 0.2 nM (Table 
3.1). Additionally, kurkinorin was extremely selective for MORs, possessing no activity at KORs 
at 10 M. This impressive >8,000-fold selectivity for MORs was greater than that of both 
herkinorin (4.25-fold selective over KOR) and morphine (66-fold selective over KOR). 
Furthermore, kurkinorin is of similar potency to DAMGO, a peptidic MOR ligand commonly 
employed for its high potency and selectivity for MORs, as well as fentanyl, one of the most potent 
MOR agonists used clinically.4 In the same functional assay evaluating activity at DORs, 
kurkinorin was active with an EC50 values of 74 ± 10 nM, which was unanticipated as few 
salvinorin-like compounds have DOR activity. Even so, kurkinorin’s MOR selectivity is still 
greater than 60-fold. However, this result opens the possibility of identifying DOR-selective 
neoclerodanes in the future.  
Table 3.1: MOR, KOR, and DOR Pharmacology: Inhibition of forskolin-induced cAMP accumulation. 
 EC50 ± SEM a, b (nM) Selectivity 
Compound      
DAMGO 0.6 ± 0.1 >10 000 c ND f >16 000 -- 
Morphine 3.7 ± 0.3 140 ± 10 780 ± 150e 66 150 
Fentanyl 0.3 ± 0.1 ND f ND f  -- 
Herkinorin 39 ± 4 170 ± 20 d >10 000 c 4.25 250 
Herkamide 3.0 ± 0.4 >10 000 c 690 ± 50  >3 000 210 
2-epi-Herkinorin >10 000 c >10 000 c ND f -- -- 
Kurkinorin 1.2 ± 0.2 >10 000 c 74 ± 10 >8 000 63 
Salvinorin A >10 000 c 0.030 ± 0.004 >10 000 c < 4.0E-6 -- 
aMean  standard error of the mean; n  2 individual experiments run in triplicate. bEmax = 100% unless 
otherwise noted. cEmax = 0 % up to 10 µM. d Emax = 64 ± 18 %. eEmax = 90  ± 2%.  f ND = Not Determined.  
69 
 
With the overall goal of developing an analgesic with reduced abuse liability in mind, the in vivo 
effects of kurkinorin were explored (Figure 3.3). Using the hot water tail flick test in mice, which 
is a model of centrally mediated antinociceptive effects, herkinorin was inactive up to 10 mg/kg 
as it does not penetrate the CNS.5 Interestingly, kurkinorin did elicit significant antinociception in 
this same model at 5 and 10 mg/kg, and at the 10 mg/kg dose, the antinociceptive effects of 
kurkinorin were similar to those elicited by morphine at 30 min post-treatment. Naloxone (10 
mg/kg s.c. 45 min) blocked the antinociceptive effects of kurkinorin, confirming an opioid-
receptor mediated process. 1   
 
Figure 3.3: A) The antinociceptive effects of herkinorin (green), kurkinorin (dark blue), and morphine (red) 
as assessed in the hot-water tail-flick assay in mice at 10 mg/kg, i.p. Naloxone blocks antinociceptive effects of 
kurkinorin (light blue). (B) Antinociceptive effects in the hot water tail-flick assay in mice following cumulative 
dosing on day 1 (filled symbols) and again on day 9 (open symbols) following daily administration of 10 
mg/kg/s.c. morphine or kurkinorin (n=7). (C) In mice, using a rotarod set to accelerate from 4 to 40 rpm over 300 
s, morphine (10 mg/kg/i.p.) showed a significant decrease in motor coordination compared to kurkinorin (10 
mg/kg/i.p.) and vehicle (n=6). (D) In mice, a significant place preference is seen in the morphine paired chamber 
but not with the same dose of kurkinorin when compared to vehicle. **p<0.01 compared to vehicle; #p<0.05 
compared to morphine. ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05, drug compared to vehicle; 
####p<0.0001, ###p<0.001, ##p<0.01, #p<0.05, morphine compared to kurkinorin. Data shown as mean ± SEM. 
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The CNS-penetration of kurkinorin may pose some additional risks, such as the sedation and 
abuse potential which are centrally mediated in morphine and other clinically used MOR agonists.6 
Therefore, we sought to determine if kurkinorin would also produce similar negative side effects. 
The development of tolerance was evaluated by comparing the dose-response curves of both 
morphine and kurkinorin in the hot water tail flick assay. On the first day of dosing, the two 
compounds were equipotent, with no significant potency differences seen between morphine (ED50 
5.3 mg/kg) and kurkinorin (ED50 5.0 mg/kg) (Figure 3.3b). On day 9, following chronic, daily 
administration (10 mg/kg/s.c), both morphine and kurkinorin showed the development of 
tolerance, but morphine showed significantly more tolerance (ED50 11.6 mg/kg) compared to 
kurkinorin (7.9 mg/kg). The motor coordination or sedative effects of both kurkinorin and 
morphine were evaluated using the rotarod test at doses that elicited the maximum antinociceptive 
effects (10 mg/kg) in the tail flick assay (Figure 3.3c). As expected, morphine induced significant 
sedation up to two hours post administration, while kurkinorin demonstrated slight sedation only 
at the 15 min time point with significantly less effect upon motor coordination compared to 
morphine overall. 1   
The rewarding effects were assessed using the conditioned place preference assay. Rats were 
paired with either drug (morphine or kurkinorin) or vehicle in daily conditioning sessions for 7 
consecutive days, and the time they spent in the paired chamber was measured on the eighth day. 
Using this paradigm, kurkinorin resulted in a conditioned place preference score (expressed as % 
time spent in the drug paired chamber) similar to the vehicle control at both 5 mg/kg and 10 mg/kg 




Study 1: Evaluation of kurkinorin analogues with substitutions to the phenyl ring 
The improved potency, selectivity, and in vivo activity of kurkinorin in comparison to 
herkinorin clearly warranted additional studies to establish SAR for compounds containing this 
modified core. Thus, analogues of herkinorin and kurkinorin were synthesized from salvinorin B 
or a mixture of 3.1 and 3.2, respectively, following the general method in Scheme 3.1 and were 
evaluated for their activity at MORs (Table 3.2).1 Initial analogues were designed to provide 
information on the steric and electronic properties allowed in the MOR binding site as well as to 
 
Table 3.2: MOR pharmacology: Inhibition of forskolin-induced cAMP accumulation, and scatter plot 
comparison of the pEC50 values of herkinorin analogues vs. kurkinorin analogues (inset). 
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Compound R= EC50 ± SEM
a,b (nM) EC50 ± SEM
a,b (nM) 
3.3 2-F-C6H5 400 ± 100 5 ± 1 
3.4 3-F-C6H5 460 ± 80 4.7 ± 0.4 
3.5 4-F-C6H5 800 ± 200 15 ± 2 
3.6 2-Cl-C6H5 3400 ± 200 290 ± 20 
3.7 3-Cl-C6H5 2400 ± 100 250 ± 30 
3.8 4-Cl-C6H5 660 ± 100 29 ± 8 
3.9 2-CH3-C6H5 1600 ± 400 240 ± 40 
3.10 3-CH3-C6H5 1800 ± 300 160 ± 30 
3.11 4-CH3-C6H5 430 ± 10 21.8 ± 0.3 
3.12 2-NO2-C6H5 2000 ± 1000 1910 ± 550 
3.13 3-NO2-C6H5 3500 ± 200 320 ± 10 
3.14 4-NO2-C6H5 1000 ± 100 31 ± 2 
3.15 2-CH3O-C6H5 3300 ± 300 2000 ± 1000 
3.16 3-CH3O-C6H5 330 ± 20 11 ± 2 
3.17 4-CH3O-C6H5 190 ± 60 8 ± 3 





provide a direct comparison between the herkinorin and kurkinorin scaffolds. These analogues 
consisted of electron donating (methyl, methoxy) and electron withdrawing (halogens, nitro) 
substitutions in the 2-, 3-, and 4-positions of the phenyl rings.  
All of these analogues retained full efficacy at MORs. In all cases, the unsaturated variants were 
more potent than their saturated analogues, by a factor of 1.3 to 97-fold. A scatter plot comparison 
of the pEC50 of the two libraries shows a correlation of activity between the two series, indicating 
that parallel changes in structure correspond to parallel changes in activity (Table 3.2, inset). This 
correlation suggests that both the herkinorin and kurkinorin series of analogues are potentially 
binding at a similar location in the MORs. Generally, substitutions at the 4-position were well 
tolerated, with 3-substituted analogues being slightly less active, and 2-substituted analogues being 
considerably less active than the 4-substituted analogues. Of these substituted phenyl analogues, 
the chloro- and nitro-substituted analogues were the least potent, indicating that electron-poor 
aromatic rings may be detrimental to activity.  
Study 2: SAR-guided design and synthesis of kurkinorin analogues 
In an effort to further probe MOR binding and activation by the kurkinorin scaffold, several 
heterocycles (3.18 – 3.30) were introduced as bioisosteres in place of the phenyl ring in kurkinorin 
(Table 3.3). Analogues with varied linkers between the ester and phenyl moieties were also 
explored (3.31 – 3.33) to probe the depth and shape of the binding pocket. Additionally, due to the 
activity of the methoxy-substituted kurkinorin derivatives, free and protected phenols (3.34 – 3.45) 
as well as benzylic alcohols and derivatives thereof (3.46 – 3.52) were sought in order to probe the 
H-bond characteristics in the MOR binding site and to manipulate the pKa of the ligands. The 
structural and activity differences between morphine and codeine highlight the role that H-bonding 
plays at the MOR, as the only structural difference between the two is a free phenol in morphine 
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and a methylated phenol in codeine, with codeine being significantly less active at the MOR than 
morphine.7 
The synthesis of these kurkinorin derivatives generally followed the previously reported method 
for the synthesis of kurkinorin (Scheme 3.1).1 However, the installation of free alcohols required 
protection methodology, which is not a straightforward task considering the complexity and 
lability of the salvinorin A core. Therefore, optimization of both protecting groups and 
deprotection methods was accomplished in order to synthesize a variety of the desired analogues.  
Initially, tert-butyldimethylsilyl (TBS)-protected phenolic acids were coupled to 3.1/3.2 and then 
deprotected using common tetra-n-butylammonium fluoride (TBAF) cleavage conditions 
(Scheme 3.2). While this method was generally successful for the phenolic substrates that had 
a Reagents and conditions: a) RCO2H, DMAP, EDCI, CH2Cl2; b)TBAF c) KHSO4; H2O, MeOH, Acetone 
(1:1:1). b Alternative reaction conditions: Prepared from corresponding MOM-protected compounds, 3.36 - 
3.39, CBr4, PPh3, DCE, 40 °C, overnight. 




only a single substitution on the phenyl ring, it was low yielding and resulted in side products of 
similar retention times during the preparative HPLC separation process. This issue was more 
evident in subsequent derivatives with halogen moieties installed ortho to the TBS-phenol, 
possibly due to the manipulation of the phenol’s pKa. In fact, multiple preparative HPLC 
purifications were not successful in purifying these compounds to greater than 90% purity. 
Therefore, other protection and deprotection methods were explored that would allow for such 
compounds to be synthesized and purified. Ultimately, using a methoxymethyl ether protecting 
group and the mild triphenylphosphine and carbon tetrabromide conditions reported by Peng, et. 
al. was successful.8 These conditions resulted in better resolution of the HPLC peaks and 
ultimately allowed for a better purification process. Similar purification issues were seen in the 
synthesis of the benzylic alcohol substituents. The TBS-protected hydroxymethyl benzoic acids 
were coupled to 3.1/3.2, but TBAF deprotection again yielded low amounts of product, with side 
products that complicated the purification process. This deprotection was successfully 
accomplished using previously reported mild deprotection conditions with slight modifications to 
accommodate the insolubility of the kurkinorin derivatives in water.9 A mixture of 1:1:1 
water/MeOH/Acetone, 0.5 eq. KHSO4, and the TBS-protected benzyl alcohol kurkinorin 
derivative stirring overnight resulted in the desired, free benzyl alcohol derivative. Using these 
methods and/or the EDCI/DMAP coupling conditions described previously,1 analogues 3.18 – 
3.52 were prepared. 
Study 3: Evaluation of SAR-driven kurkinorin analogues 
Previous SAR studies focused on herkinorin indicated that heterocyclic substitutions were well 
tolerated and resulted in potent MOR agonists.10 Replacement of the phenyl ring of kurkinorin 
with pyridines results in similar activity trends as seen for the phenyl ring substitutions with the 3- 
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and 4- pyridines being more potent than the 2-pyridine (3.18 - 3.20, Table 3.3). Increasing the 
number of nitrogen atoms in the ring, as seen in the pyrimidine analogue 3.21, maintains potency 
that is equipotent to that of the 4-pyridine analogue. Additionally,  modifying the pyridine ring 
with a methoxy group, which was previously shown to maintain activity, does not substantially 
increase the potency of the pyridine derivative (3.19 EC50 = 3.2 ± 0.8, 3.22 EC50 = 2.5 ± 0.3 nM).  
In addition to the nitrogen-containing heterocyclic analogues, heterocycles containing oxygen 
and sulfur atoms were also explored. The benzofuroyl-derivative of herkinorin was previously 
demonstrated to have modest MOR activity (EC50 = 1050 ± 80 nM);
10b thus, the corresponding 2-
benzofuroyl kurkinorin analogue 3.23 was evaluated and found to have a potency of 31 ± 9 nM. 
Modification of this moiety by substituting a sulfur atom for the oxygen atom, as seen in 3.24, 
results in an increase in potency (EC50 = 9 ± 2 nM). Because this compound was more potent than 
the benzofuran derivative, thiophene analogues were explored to determine if the fused benzene 
rings were crucial for activity or if they represented unnecessary steric bulk. The resulting 2- and 
3-thiophene derivatives, 3.25 and 3.26 respectively, were the most potent heterocyclic analogues 
evaluated and had activities similar to kurkinorin. To probe the directionality of the possible H-
bond acceptor capabilities of the sulfur and oxygen atoms of these analogues, the corresponding 
oxazole and thiazole derivatives were also synthesized. The 5-oxazole 3.27 and 5-thiazole 3.28 
were active, with EC50 values nearly identical to their larger benzofuran and thianapthene 
counterparts. However, both the 4-oxazole 3.29 and the 4-thiazole 3.30 were completely inactive 
up to the highest dose tested, 10 M. These results indicate that while steric bulk off the 5-
membered heterocyclic ring is tolerated, modifications to the directionality of the heteroatom’s H-
bond accepting abilities are not. 
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Analogues with differing linkers between the ester and phenyl moieties were also explored to 
further probe the depth of the binding pocket (3.31 - 3.33). The herkinorin analogues of these 
compounds, with methyl, ethyl, and ethylene linkers, have previously been evaluated for their 
affinity at MORs and KORs, and, interestingly, all displayed higher affinity for KORs than 
Table 3.3: MOR pharmacology of SAR-driven analogues: Inhibition of forskolin-induced cAMP 
accumulation. 
   
 
 R= EC50 ± SEM
a,b (nM) 
3.18 2-Pyridinyl 410 ± 50 
3.19 3-Pyridinyl 3.2 ± 0.8 
3.20 4- Pyridinyl 6 ± 1 
3.21 5-Pyrimidinyl 6 ± 1 
3.22 6-CH3O-3-Pyridinyl 2.5 ± 0.3 
3.23 2-Benzofuranyl 30 ± 9 
3.24 2-Thianapthenyl 9 ± 2 
3.25 2-Thiophenyl 1.4 ± 0.8 
3.26 3-Thiophenyl 1.3 ± 0.9 
3.27 5-Oxazolyl 30 ± 2 
3.28 5-Thiazolyl 5 ± 2 
3.29 4-Oxazolyl >10 000c 
3.30 4-Thiazolyl >10 000c 
3.31 CH2C6H5 130 ± 50 
3.32 CH2CH2C6H5 400 ± 100 
3.33 CHCHC6H5 30 ± 10 
3.34 3-OH-C6H4 1.3 ± 0.3 
 3.35 4-OH-C6H4 0.83 ± 0.04 
 3.36 3-F-4-OCH2OCH3-C6H3 3.4 ± 0.6 
 3.38 3-Br-4-OCH2OCH3-C6H3 1300 ± 200 
 3.39 3-Me-4-OCH2OCH3-C6H3 170 ± 20 
 3.40 3-F-4-OH-C6H3 0.6 ± 0.2 
 3.41 3-Cl-4-OH-C6H3 4 ± 1 
 3.42 3-Br-4-OH-C6H3 17 ± 7 
 3.43 3-Me-4-OH-C6H3 60 ± 10 
 3.44 6-Benzofuranyl 1.5 ± 0.6 
 3.45 5-Benzofuranyl 9 ± 2 
 3.46 4-CH2OH-C6H4 0.03 ± 0.01 
 3.47 3-CH2OH-C6H4 2.42 ± 0.07 
 3.48 4-CH2OCH3-C6H4 13 ± 3 
 3.49 4-CONH2-C6H4 0.19 ± 0.03 
 3.50 3-CONH2-C6H4 >10 000
c 
 3.51 3-oxoisoindolinyl 2.2 ± 0.2 
 3.52 1-oxoisoindolinyl 3.2 ± 0.7 
a Mean  standard deviation; n  2 individual experiments run in triplicate. b Emax = 100%, unless noted 
otherwise. c Emax = 0 % up to 10 µM. 
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MORs.11 The kurkinorin derivatives evaluated herein are active at MORs, but the extended linker 
does result in decreased MOR activity in comparison to kurkinorin. The alkyl linkers, 3.31 and 
3.32, allow for additional conformation mobility of the phenyl ring and result in over 100-fold 
decrease in MOR activity. The ethylene linker in 3.33 results in 25-fold loss in activity in 
comparison to kurkinorin, with an EC50 value of 30 ± 10 nM. These results indicate that the MOR 
binding pocket does allow for this extension of the phenyl ring, but these analogues did not add 
any beneficial interactions with the receptor to achieve potent MOR activation. 
Some of the most active compounds that we initially evaluated were phenyl derivatives 
substituted with methoxy- or fluoro-substituents (3.3b, 3.4b, 3.16b, and 3.17b, Table 3.2). 
Unfortunately, none of these compounds were more potent than kurkinorin itself, but their 
activities warranted further probing of the H-bond characteristics in the receptor binding pocket. 
To allow for both H-bond donating and accepting, we evaluated the 3’- and 4’-phenolic kurkinorin 
derivatives 3.34 and 3.35. This strategy was the first to identify a compound that showed a slight 
increase in potency in comparison to kurkinorin itself, with 3.34 and 3.35 having EC50 values of 
1.3 ± 0.3 nM and 0.83 ± 0.04 nM, respectively, vs. kurkinorin’s EC50 value of 1.2 ± 0.2 nM.  
With the potent 3.35 in hand, we sought to further modulate the pKa and H-bond donor 
capabilities of the compound by installing halogens adjacent to the phenol. Similarly to our initial 
results with the mono-substituted derivatives, the 3’F-4’OH-substitution of 3.40 was the most 
potent, at 0.6 ± 0.2 nM. The trend among these halogenated phenols follows the inverse of 
intramolecular halogen-hydrogen bond strength, with the 3’F-4’OH- being the strongest, followed 
by the 3’Cl-4’OH 3.41, and the 3’Br-4’OH 3.42 being the weakest of the three. This trend in 
activity potentially indicates that the phenolic hydrogens are either coordinating with the adjacent 
halogens12 or that the phenol is interacting with a weakly basic point on the receptor and the 
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halogens’ influence on lowering its pKa is strengthening that interaction, although the trend could 
also be explained by the increased bulk at the 3’-position. The installation of a methyl group ortho 
to the phenol, 3.43, allowed for the evaluation of this hypothesis, with a 3’-substitution of similar 
molecular size to the Br of 3.42 (Taft size parameters: CH3 = -1.24, Br = -1.16)
13 and no 
modification of the phenol’s pKa or H-bond donating capabilities. The decreased activity of 3.43 
compared to the halogenated phenol analogues indicates that the halogen-hydrogen bonding and 
pKa manipulation is be influencing the binding of 3.40 - 3.42 at the MOR more so than the steric 
factors. Further exploration of this interaction was accomplished by evaluating some of the MOM-
protected phenols. Interestingly, 3.36 and 3.39 are 4-6-fold less active than their phenolic 
counterparts, but 3.38 is significantly less active at MOR than 3.42. These results indicate that the 
binding site is able to accommodate the added mass of the MOM-protection and that sterically 
smaller 3’-substituents are preferred (3’F).  
Comparison of the activities of the free phenols 3.34 and 3.35 to the corresponding methoxy 
analogues 3.16 and 3.17 indicated that the H-bond donating properties of the phenolic derivatives 
were beneficial for MOR activity. In an effort to further probe the H-bond capabilities of the 
oxygen in this position, we evaluated benzofuran derivatives 3.44 and 3.45 as ring-locked 
derivatives of the methoxy analogues with locked conformations of H-bond acceptors. Although 
no preference was seen between the 3’- and 4’-methoxy derivatives, the 4’OH-derivative was more 
potent than the 3’OH-derivative and the opposite result was seen for their corresponding ring-
constrained derivatives. The benzofuran-6-carbonyl 3.44 was essentially equipotent to its 3’OH-
counterpart at 1.5 ± 0.6 nM, but the benzofuran-5-carbonyl 3.45 was 12-fold less potent at 9 ± 2 
nM than the 4’OH 3.35.  
79 
 
Based on the activity of the phenols, we decided to probe the depth of the binding pocket with 
benzyl alcohol derivatives. Not only was the methylene linker tolerated in the pocket, the 
4’CH2OH derivative 3.46 was over 25-fold more potent than the 4’OH-kurkinorin derivative with 
an EC50 value of 0.03 ± 0.01 nM. Due to this dramatic increase in potency, benzylic substitutions 
were further probed to determine what functionalities are tolerated in the pocket as well as what 
properties are mediating this increased potency. The 3’-benzylic alcohol 3.47 is not as potent as 
its 4’-counterpart 3.46 or the 3’phenolic compound 3.47, suggesting that the alcohol of the 
4’benzylic alcohol derivative is interacting with a residue in the back of the pocket and in space 
that the alcohol of the 3’derivative cannot reach. Additionally, methylating the benzylic alcohol to 
form 3.48 dramatically reduced potency to 13 ± 3 nM, a 433-fold potency decrease which indicates 
that either the H-bond donating ability of the benzyl alcohol is important or the additional methyl 
is not tolerated due to steric hindrance. Previously determined SAR about the phenyl ring of 
morphine demonstrated that replacement of morphine’s phenol with a carboxamido group 
maintained MOR activity.14 Given these previous findings and to further explore the H-bonding 
requirements on the kurkinorin scaffold, the benzyl alcohols were replaced with primary amides, 
which are capable of both H-bond donating and accepting. This replacement resulted in the potent 
4’CONH2 derivative 3.49 and the completely inactive 3’CONH2 derivative 3.50 (0.19 ± 0.03 nM 
and >10 000 nM, respectively). This dramatic difference in activity between a 3’- versus a 4’- 
substitution was intriguing, and warranted further exploration. We sought to determine if the 
directionality of the nitrogen’s H-bonding abilities were the reason for the activities by evaluating 
the ring-locked oxoisoindoline compounds. However, both the 3- and 4-oxoisoindoline 
compounds, 3.51 and 3.52 respectively, were of similar potencies, both to one another and to the 
3’CH2OH 3.47, with EC50 values of 2.2 ± 0.2 nM and 3.2 ± 0.7 nM, respectively. Both compounds 
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displayed greater than 10-fold drop in activity from 3.49, indicating that either the free 
carboxamido group in 3.49 is able to access a different site in the receptor that the ring-locked 
analogue cannot or that the added methylene unit is not tolerated sterically, but the ring locked 
analogue 3.52 rescued the activity from that of its inactive counterpart 3.50. 
Many of these kurkinorin analogues were further evaluated for their ability to recruit β-arrestin-
2 through MOR activation (Table 3.4). Analogues were chosen for β-arrestin-2 recruitment 
analysis based upon the SAR seen in the G-protein-mediated cAMP assay, and all analogues with 
potencies below 10 nM were evaluated. Additionally, compounds 3.30 and 3.50 were evaluated 
due to their complete inactivity in the cAMP assay despite high structural similarity to potent 
analogues 3.28 and 3.49, respectively, and compound 3.33 was evaluated to determine if the 
ethylene linker between the phenyl and ester moieties resulted in a significant conformational 
change in the receptor to induce signaling bias. DAMGO was previously determined to recruit β-
arrestin-2 through MOR activation and was used as the positive control of the β-arrestin-2 
recruitment assay.15 Morphine does not recruit to the same extent as DAMGO, and in the EFC 
assay utilized herein (described above, see p. 51), this trend holds true (Table 3.4). Herkinorin has 
previously been shown to activate the MOR without recruiting β-arrestin-2,10b, 16 however previous 
assays have employed fluorescent whole-cell imaging, and in this EFC assay, herkinorin does 
weakly recruit β-arrestin-2 with an EC50 > 3 µM and an efficacy of 72%. The previously published 
trend that herkamide recruits β-arrestin-2 to a higher extent than herkinorin holds true in this assay, 
and as would be expected from its conformational similarity to herkamide, kurkinorin recruits β-
arrestin-2 as well.  
The functional selectivity of these compounds was evaluated by determining their bias factors 
(see Equation 2.1).  As the standard to which all data are normalized, DAMGO has a bias factor 
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value of 1, indicating no signaling bias. The more sensitive β-arrestin-2 assay used here establishes 
that herkinorin does recruit β-arrestin-2, but is biased towards the G-protein coupled pathway, with 
a bias factor of 0.61. Compounds herkamide and kurkinorin have similar profiles, as originally 






DAMGO 42 ± 5 (97) 1.0 
Morphine 380 ± 40 (38) 0.36 
Fentanyl 38 ± 2 (70) 0.34 
Herkinorin 3400 ± 700 (72) 0.61 
Herkamide 560 ± 60 (85) 0.32 
Kurkinorin 140 ± 40 (96) 0.57 
3.3b 63 ± 4 (91) 5.0 
3.4b 41 ± 10 (79) 6.6 
3.17b 96 ± 30 (76) 4.6 
3.19 190 ± 20 (61) 0.76 
3.20 120 ± 30 (71) 2.71 
3.21 650 ± 90 (49) 0.32 
3.22 30 ± 10 (76) 4.42 
3.24 700 ± 100 (90) 0.90 
3.25 260 ± 30 (84) 0.33 
3.26 46.2 ± 0.1 (84) 1.69 
3.28 150 ± 10 (68) 1.64 
3.30 >25 000 (0) -- 
3.33 80 ± 10 (71) 22.5 
3.34 40 ± 10 (87) 1.98 
3.35 21 ± 4 (73) 2.13 
3.36 1300 ± 80 (80) 0.15 
3.38 >25 000 (0) 0.0 
3.39 >25 000 (0) 0.0 
3.40 24 ± 3 (79) 1.40 
3.41 180 ± 10 (69) 1.04 
3.42 1600 ± 300 (72) 0.57 
3.43 800 ± 100 (76) 4.34 
3.44 40 ± 10 (90) 2.62 
3.45 490 ± 80 (84) 1.21 
3.46 14 ± 1 (81) 0.14 
3.47 150 ± 30 (75) 0.87 
3.48 360 ± 80 (74) 1.98 
3.49 10 ± 3 (119) 1.57 
3.50 >25 000 (0) -- 
3.51 190 ± 60 (76) 0.65 
3.52 260 ± 60 (88) 0.81 
aMean  standard error of the mean; n  3 individual experiments run in triplicate. bMaximum efficacy 
values calculated based on DAMGO maximum stimulation. cBias factors were calculated using Eq. 2.1. Values 
<1 indicate bias towards the cAMP pathway and values >1 indicate bias towards the β-arrestin-2 pathway. 
DAMGO is the reference compound, with a bias = 1. 
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predicted in the project rationale, having bias factor values of 0.32 and 0.57, respectively, 
indicating a bias towards the G-protein coupled pathway.  
All of the analogues potent in the cAMP assay also recruited β-arrestin-2 to differing extents, 
while none of the analogues inactive in the cAMP assay (3.30 and 3.50) recruited β-arrestin-2. All 
phenyl substituted analogues were biased towards β-arrestin-2 recruitment. Interestingly, 3.21 is 
one of the most G-protein biased compounds, while the structurally similar 3.22 is one of the most 
β-arrestin-2 biased compounds, indicating that the 6-methoxy of 3.22 is able to engage in a point 
of contact with the receptor that favors β-arrestin-2 recruitment that 3.21 cannot. The phenolic 
compounds 3.40 and 3.41 are not biased, while 3.42 is slightly G-protein biased and 3.43 is β-
arrestin-2 biased, indicating that the size and properties of the 3’-substituent significantly affect 
the β-arrestin-2 recruitment of the analogues. The MOM-protected phenol 3.36 is only a weak 
recruiter of β-arrestin-2 and 3.39 does not recruit β-arrestin-2 at all, which indicates that the 
binding pocket of the receptor in the β-arrestin-2 recruitment conformation does not tolerate the 
steric bulk of both a 3’-substituent and the large 4’OMOM. Conversely, 3.33 with the ethylene-
linker has the highest bias factor of all analogues evaluated, at 22.5, suggesting that the spacer 
between the ester and phenyl moieties may allow the compound to adjust its orientation to allow 
for better accommodation by the different receptor conformation. The only other analogue with a 
similar bias factor to the MOM-protected phenols is 3.46, but due to its high potency in the cAMP 
assay, its bias factor is 0.14 despite its potent β-arrestin-2 recruitment of 14 ± 1 nM. Overall, the 
SAR trends between β-arrestin-2 recruitment and G-protein activation are different and indicate 
that compounds with larger 4’-substituents may have the potential to be biased activators of the 
MOR-associated G-protein pathway. 
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To determine the efficiency of the activity of these kurkinorin derivatives, their 
physicochemical properties were calculated and the metrics of ligand efficiency (LE) and 
lipophilic-adjusted ligand efficiency (LELP) were calculated based on their EC50 values in the G-
protein pathway (Supplemental Table 1). All analogues had total polar surface areas (tPSAs) over 
100 Å2 and sLogP values over the ideal 2.5,17 highlighting the need for further probing of the 
physicochemical properties of these analogues. Analogues 3.46 and 3.49 were the most efficient 
analogues, with LE values of 0.38 and 0.35, respectively, and LELP values of 9.49 and 8.26. 
Discussion 
Through SAR studies on the naturally-occurring KOR agonist salvinorin A, we have identified 
kurkinorin as a potent, selective, and centrally active probe for opioid receptors. Kurkinorin’s 
activation of MORs potently induces G-protein-mediated effects and, to a lesser extent, recruits β-
arrestin-2. Kurkinorin is the first non-nitrogenous opioid to show centrally-mediated 
antinociceptive activity. Also of importance, kurkinorin has reduced tolerance, sedation, and 
rewarding properties compared to morphine. 
Kurkinorin’s desirable in vivo effects led us to explore the SAR of this scaffold at the MORs. 
Through this campaign, we have identified structural trends required for activating MOR-
associated G-proteins, as well as for recruiting -arrestin-2 upon MOR activation. We have 
identified 3.46, a compound that is a potent and biased activator of the MOR-associated G-protein 
pathway with an EC50 value of 0.03 ± 0.01 nM and a bias factor of 0.14. We have also identified 
3.39, which is a selective activator of the G-protein pathway without any recruitment of -arrestin-
2. Although other analogues were more potent in activating the G-protein pathway, we believe that 
3.39 is an interesting starting point as a lead compound, which upon optimization, will allow for 
further probing of the requirements for activation of either MOR-associated pathway. 
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The molecular nature of kurkinorin’s reduced side effect profile in vivo is unclear, as it does 
recruit β-arrestin-2 to a greater extent than morphine, but given its distinctive properties and 
desirable in vivo effects, along with the SAR-guided analogues identified through its study, 
kurkinorin is an attractive probe for potentially differentiating analgesia from abuse liability. 
Furthermore, our findings provide additional evidence that moving away from morphine-based 
opioid ligands may serve as a viable strategy for dissociating central antinociception from common 
opioid induced side effects. 
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4. Development of New Synthetic Approaches toward Refinement of 
Salvinorin A’s Pharmaceutical Properties 
Results 
Salvinorin A’s potent KOR activity and unique structural composition contribute to its 
attractiveness as a lead compound in the search for KOR agonists to treat pain and addiction. 
However, in order for salvinorin A to be further developed as a potential drug candidate, its 
pharmaceutical properties, including its low bioavailability, rapid metabolism, and P-gp substrate 
activity, require optimization. In an effort to identify a point on the molecule through which its 
pharmaceutical properties could be modulated, the lactone position of salvinorin A was explored. 
The development of chemical methodology to functionalize this position and the evaluation of 
these C17-derivatives for their in vitro KOR activity allowed for the assessment of the lactone 
carbonyl’s necessity for KOR activity. 
Study 1: Development of chemical methodology to selectively functionalize the C17 position 
The original report describing the reduction of the salvinorin A lactone to the lactol 4.1 called 
for treatment with 13.6 eq. of diisobutylaluminum hydride (DIBALH) for 25 minutes.1 However, 
this reaction was done on a small scale (36.5 mol), and upon scale-up, this reaction was low 
yielding and required a large amount of DIBALH. Therefore, a full optimization of this reaction 
was undertaken to identify a method suitable to gram-scale reactions. Decreasing the DIBALH to 
3 equivalents and increasing the time of the reaction while maintaining the temperature at -78°C 
accomplished this goal. A significant side reaction was determined to be the deacetylation of the 
C2 position to form 4.2, but the DIBALH reduction was followed by an acetylation reaction which 
both acetylated the hemiacetal and re-acetylated any of the C2 position that had been deacetylated 
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from DIBALH (Scheme 4.1). This acetylated hemiacetal 4.3 was then used as the main 
intermediate for accessing substituents at the C17 position.  
Upon attaining a method to generate 4.3 in large quantities, methods for substituting at the 17-
position were explored (Scheme 4.2). Initially, masked nucleophiles, such as silyl-protected allyl 
or nitrile groups and silyl enol ethers, were added using BF3•Et2O (General Method A) to install a 
carbon-carbon bond at the 17-position (4.6 - 4.9).2 This Lewis acid catalyzed the formation of 
the oxocarbenium ion which allowed the masked nucleophile to add to the 17-position. However, 
the rest of the salvinorin A core does not tolerate the BF3•Et2O, particularly the furan, which 
decomposed readily, resulting in low-yielding reactions. This reaction method should produce both 
- and -substituted products, but because of the low yields, only -substituted products could be 
isolated in high enough quantities for further characterization and analysis. The only exception to 
this selectivity was in the case of 4.10 and 4.10 which was also the only non-silyl-protected 
 
Scheme 4.1: Synthetic route to access C17 position of salvinorin A 
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nucleophile added through this method. In an effort to overcome the issues with BF3•Et2O, a 
variety of Lewis acids were tested, but none were able to be used as a general method, as they 
either did not result in higher yields than the original BF3•Et2O or were not translatable across 
nucleophiles. The use of trimethylsilyl trifluoromethanesulfonate (TMSOTf) as the Lewis acid3 in 
the formation of 4.5 did result in an increased yield, but when this method was attempted with 
other nucleophiles, it did not result in an enhanced formation of any other analogues.  
By switching from a Lewis acid to a Brønsted-Lowry acid (hydrochloric acid, HCl) for reaction 
catalysis, the addition of alcohols to the 17-position was accomplished (Method B).4 This method 
aReagents and conditions: a) Nucleophile, BF3.Et2O, CH2Cl2,  -78°C; b) i. ROH (neat), HCl in dioxane, 0-5 °C, ii. 
Ac2O, DMAP, CH2Cl2; c) ROH, HCl in dioxane, THF, 0 °C; d) OXONE monopersulfate, DMF, 3h, r.t. 
bAlternative reaction conditions: Et3SiH, MeCN, TMSOTf, 0 °C;  cAlternative reaction conditions: prepared from 
corresponding 4.17, Dess-Martin Periodinane, CH2Cl2, overnight, rt. 




produced both - and -substituted products, which, depending on the substrate, were separable 
by either flash column chromatography or preparative HPLC. Initially these reactions were run 
with the alcohol as the solvent, but removing the excess alcohol proved challenging. Additionally, 
a major side product was determined to be the elimination product 4.4 (Scheme 4.1), which was 
predicted to be subdued if the reaction was kept at 0 °C, but due to the presence of the dioxane 
from the HCl solution, the reaction would freeze upon cooling to 0 °C and the side product 
generation could not be inhibited. Further improvement upon this method led to the optimized 
Method C, whereby 4.3 and the appropriate alcohol were dissolved in THF, cooled to 0 °C, HCl 
in dioxane was added dropwise, and the reaction was monitored until completion and immediately 
quenched. This method did produce some amounts of 4.4, but as both - and -substituted products 
were formed in high enough yields for isolation and characterization, the method was adopted.  
Determining the stereochemistry around the newly formed stereocenter at C17 was 
accomplished using NMR coupling constants and 2D NMR methods (Figure 4.1). Generally, 
protons with J-values higher than 6 are anti and lower than 5 are syn to one another.5 However, 
the C8 proton needed for this analysis is not easily identified because it is often buried under other 
 
Figure 4.1: Unambiguous determination of stereochemistry at the 17-position using NMR. 
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aliphatic protons. Although the epimers of 4.3 were not separated, this NMR analysis revealed that 
the product upon acetylation was predominantly the -epimer (C17 proton at 5.83 (d, J = 8.0 Hz), 
with NOESY correlations to the C12 proton 4.98 and the C20 methyl at 1.48). For the alcohol-
substituted compounds, determining the coupling constant of the C8 and C17 protons was 
straightforward, as the C17 proton was a doublet with only one J value. The coupling constant 
alone is enough to identify the stereochemistry, but NOESY studies were done to confirm that the 
C17 proton in the -substituted compounds correlated with the C8 proton, and the proton in the -
substituted compounds correlated with the C12 proton and the methyl group attached to C9. For 
the compounds without a C-O bond at C17 (4.6 - 4.9), the J-values for the C17 proton were in the 
ambiguous range between 5 and 6, and the J-value alone did not provide sufficient information 
with which to assign stereochemistry. In these cases, NOESY correlations were used to assign the 
stereochemistry.  
The HCl substitution conditions allowed for the installation of diols to the 17-position, and 
these substituted diols, 4.15 - 4.18, provided a valuable synthetic handle through which further 
modifications of the C17 substituent could be accessed. Oxidation of 4.17 andunder Dess-
Martin oxidation conditions resulted in the aldehydes 4.19 andSubsequent oxidation of these 
aldehydes using OXONE monopersulfate resulted in the carboxylic acids 4.20 and
With the development of the synthetic methodology to modify the lactone core of salvinorin A, 
analogues were designed to probe the SAR at the KOR in an effort to determine if polar, ionizable, 
or solubilizing groups would be tolerated at that position. Analogues 4.1 – 4.5 were designed to 
evaluate the necessity of the lactone carbonyl through its reduction and removal. The introduction 
of stepwise modifications to the polarity and steric bulk of the substitutions in analogues 4.6 – 4.14 
were used to assess the optimal substitution pattern to maintain KOR activity.  Finally, analogues 
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4.15 – 4.20 were designed based on the SAR of the previous analogues to determine the optimal 
chain length of the substitution as well as the tolerability of the polar alcohols, aldehydes, and 
carboxylic acids. 
Study 2: Evaluation of compounds with C17 modifications
The C17-analogues were evaluated for their ability to activate KORs in vitro. In CHO cells 
transfected with the KOR, the inhibition of forskolin-induced cAMP accumulation was measured. 
In this assay, salvinorin A is very potent with an EC50 value of 0.10 ± 0.03 nM (Table 4.1). 
Reducing the lactone to the lactol (4.1, tested as a mixture of epimers due to the rapid epimerization 
of the center) and eliminating the oxygen altogether (4.5) resulted in equipotent compounds with 
EC50 values of 1.2 nM. Although these compounds demonstrate a 12-fold reduction in activity, 
Table 4.1: KOR pharmacology: Inhibition of forskolin-induced cAMP accumulation 




0.10 ± 0.03 
4.1 
 
1.2 ± 0.3 
4.3 
 
2.4 ± 0.8 
4.4 
 
2.0 ± 0.5 
4.5 
 
1.2 ± 0.4 






they indicate that the carbonyl of salvinorin A is not absolutely critical for KOR binding. Similarly, 
introducing unsaturation at the C8-C17 bond, 4.4, reduces activity at KOR by 20-fold in 
comparison to salvinorin A with an EC50 value of 2.0 ± 0.5 nM. The differences in activity between 
4.4 and 4.5 can potentially be attributed to the change in 3-dimensional shape that results from 
modifying the diterpenoid core through the installation of the double bond. The kinked diterpenoid 
core of 4.4 is proposed to hold the C-ring in between the conformations of salvinorin A and its 
epimer, 8-epi-salvinorin A (Figure 4.2). 8-epi-salvinorin A is significantly less potent than both 
4.4 and salvinorin A at KOR (EC50 = 110 ± 30 nM),
6 indicating that some movement of the 
diterpenoid core is tolerated, but either the presence of the carbonyl in the epimerized analogue or 
the extension from the conformation of 4.4 to 8-epi-salvinroin A is not. Analogue 4.3 is the least 
active of this group, with a 24-fold reduction in activity and a potency of 2.4 ± 0.5 nM, potentially 
indicating that the acetylation introduces steric bulk that is not tolerated.  
 
Figure 4.2: Ligand-based alignment of salvinorin A (gray), 8-epi-salvinorin A (blue), and 4.4 (green) using 
substructure alignment in Forge (v 10.4.2; Cresset, Litlington, Cambridgeshire, UK; http://www.cresset-
group.com/forge/). Carbons 8 and 17 of salvinorin A numbered. See supplemental information for full method. 
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The activity of compounds with substitutions at the C17-position appears to be dictated more 
by the steric bulk of the moieties rather than the stereochemistry of the C17-position. In the carbon-
substituted analogues, activity decreases as the size of the moiety increases, from the small, linear 
nitrile (4.6), to the allyl (4.7), to the methyl and phenyl ketone derivatives (4.8 and 4.9), with 
EC50 values from 1.3 ± 0.7 nM to 165 ± 1 nM (Table 4.2). A similar trend was seen among the 
substituted alcohols. The isopropyl (4.11 and) and benzyl (4.10 and) substituents were 
much less potent than the allyl (4.12 and), propargyl (4.12 and), and propionitrile (4.13 
and) derivatives. The addition of diols allowed for the evaluation of polar alcohol moieties at the 
C17-poisiton, and various linkers between the C17 and the alcohol were explored. These alcohols 
Table 4.2: KOR activity of C17-derivatives: Inhibition of forskolin-induced cAMP accumulation 
 
Compound R= EC50 ± SEM
a,b (nM) EC50 ± SEM
a,b (nM) 
4.6 CN 1.3 ± 0.7 n.d. 
4.7 CH2CHCH2 45 ± 7 n.d. 
4.8 CH2COCH3 63 ± 3 n.d. 
4.9 CH2COC6H5 95 ± 5 n.d. 
4.10 OCH2C6H5 165 ± 1 90 ± 10 
4.11 OCH(CH3)2 120 ± 20 138 ± 5 
4.12 OCH2CHCH2 20 ± 5 14 ± 3 
4.13 OCH2CCH 7 ± 2 3.8 ± 0.4 
4.14 O(CH2)2CN 1.1 ± 0.5 5 ± 2 
4.15 OCH2(CH)2CH2OH (z) 1.1 ± 0.5 1.2 ± 0.6 
4.16 OCH2CCCH2OH 0.3 ± 0.1 0.5 ± 0.1 
4.17 O(CH2)3OH 0.6 ± 0.2 2.1 ± 0.8 
4.18 O(CH2)4OH 3 ± 1 23 ± 7 
4.20 O(CH2)2CO2H 1.5 ± 0.6 11 ± 4 
aMean  standard error of the mean; n  2 individual experiments run in triplicate. bKOR Emax = 100%.  




were more potent than any of the previous analogues, with the butyne and propane linkers being 
the most active (0.3 ± 0.1 nM for 4.16 and 0.6 ± 0.2 for 4.17).  
As the synthetic methodology for the addition of alcohols resulted in both  and derivatives, 
the activity of the epimers could be compared. However, no apparent trend in preference for either 
 orepimer was seen. Additionally, substitutions at the C17-position are potentially adding new 
points of interaction with the receptor, as different moieties have varying degrees of activities. 
Upon determining that three to four carbons was an optimal chain length for maintaining KOR 
activity, the carboxylic acid derivatives of the propane linkage were evaluated. These compounds, 
(4.20 and), were potent KOR agonists, with EC50 values of 1.5 ± 0.6 nM and 11 ± 4 nM, 
respectively. These compounds are the first salvinorin A derivatives with potent KOR activity to 
have an ionizable moiety, and they help to validate the lactone as a position through which the 
pharmacokinetic properties of salvinorin A could be modulated. Based upon these results, the 
lactone carbonyl of salvinorin A can be considered an auxophore of the scaffold, or an extraneous 
part of a molecule that is not essential for activity.7 
The physicochemical properties and the metrics of ligand efficiency (LE) and lipophilic-
adjusted ligand efficiency (LELP) of these lactone-modified analogues (4.1 - 4.20) were calculated 
in an effort to determine if the pharmaceutical properties of these analogues would differ from 
those of salvinorin A (Supplemental Table 2). Although none of these analogues were more 
efficient ligands at the KOR, several analogues are within the drug-like range (greater than 0.30 
for LE and less than 10 for LELP)8 and further highlight the need to explore strategies to improve 
the pharmacokinetic properties of the salvinorin A core. 
Study 3: Design, synthesis, and evaluation of analogues with C2 and C17 modifications 
With chemical methods to manipulate both the C2 and C17 positions, analogues containing 
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modifications to both positions were synthesized and evaluated. Although many modifications 
have been made to the C2 position, three were chosen for this dual-modification study: 
methoxymethyl salvinorin B (MOM-salvinorin B), methanesulfonyl salvinorin B (Mesyl-
salvinorin B), and herkinorin. These modifications were chosen because they have been evaluated 
in several different models and have different activity profiles. MOM-salvinorin B is more potent 
than salvinorin A in vitro, has a longer half-life in vivo, and has been shown to be effective in 
animal models of cocaine abuse.9 Similarly, Mesyl-salvinorin B is equipotent to salvinorin A in 
vitro, has a longer half-life in vivo, and has been shown to be effective in animal models of both 
cocaine and alcohol addiction.9d, 10 Additionally, the sulfonate derivatives such as Mesyl-salvinorin 
B have been suggested to adopt a different binding mode from salvinorin A based upon the fact 
that parallel changes in structure (methyl to phenyl) did not result in parallel changes in activity 
(KOR to MOR selectivity).11 Unlike the MOM- and Mesyl-salvinorin B, herkinorin acts at both 
KORs and MORs, being more potent at MORs. By modifying the lactone of herkinorin with 
modifications shown above to maintain KOR activity, the similarities of the binding poses between 
the MOR and the KOR can be directly compared.  
Synthesis of these dual-modified analogues was accomplished using the previously described 
methods for generating analogues 4.1 – 4.5 with the appropriately C2-substituted analogues as the 
starting material (MOM-salvinorin B, Mesyl-salvinorin B, herkinorin). The only analogue 
synthesized differently was 4.5a, which was synthesized from 17-deoxysalvinorin B following the 
previously published conditions for forming MOM-salvinorin B.9a Of note, the DIBALH reduction 
of the lactone was successfully accomplished without cleaving the C2-substituent, further 
highlighting the increased stability imparted by these moieties in comparison to the acetate.  
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These analogues were evaluated for their KOR activity using the previously described 
forskolin-induced cAMP accumulation assay (Table 4.3).12 C17 modifications to MOM-
salvinorin B (4.1a - 4.5a) resulted in the lowest overall fold-changes from the parent compound 
with all analogues being very potent KOR agonist with EC50 values in the picomolar range (from 






4.1a - 4.5a 
 
 
4.1b - 4.5b 
 




0.006 ± 0.001 0.12 ± 0.05 170 ± 20c 
4.1 
 
0.06 ± 0.02 4 ± 1 310 ± 50 
4.3 
 
0.016 ± 0.006 4 ± 1 200 ± 30 
4.4 
 
0.29 ± 0.01 10 ± 2 540 ± 60 
4.5 
 
0.021 ± 0.003 4.6 ± 0.2 130 ± 20 
aMean  standard error of the mean; n  2 individual experiments run in triplicate. b Emax = 100%, unless 




0.016 ± 0.006 nM for 4.3a to 0.29 ± 0.01 nM for 4.4a).  As the parent MOM-salvinorin B is one 
of the most potent KOR analogues known to date, the fact that modifying the lactone does not 
seem to dramatically affect activity indicates that these analogues are binding similarly to the 
parent and allowing the MOM group to maintain its strong interactions with the KOR. Based upon 
the previous indications that the sulfonates at C2 adopt a different binding mode than the esters 
and ethers, it is unsurprising that the C17 modified Mesyl-salvinorin B derivatives (4.1b – 4.5b) 
result in the largest activity changes from its parent, ranging from 4.1b, 4.3b, and 4.5b being 33-
fold less active to 4.4b being 80-fold less active.  
These C17 modifications to herkinorin (4.1c - 4.5c) only slightly affected activity at KORs 
(Table 4.3) or MORs (Table 4.4). 4.4c was the least active of the herkinorin analogues being 10-
fold less active than herkinorin at both KORs and MORs, while 4.5c was slightly more potent at 
KORs and 4.1c was twice as potent at MORs than herkinorin. While the modification of the 17-
position of herkinorin did not dramatically affect its activation of G-proteins associated with either 
MORs or KORs, it did affect its ability to recruit -arrestin-2 upon MOR activation. Analogues 
4.1c, 4.3c, and 4.5c are at least 5-fold more potent in recruiting -arrestin-2 than herkinorin, and, 
as such, are biased towards that pathway. The modifications found in these analogues do not affect 
the shape of the diterpene core in comparison to herkinorin, but the introduction of the double 
bond seen in 4.4c does. This analogue, 4.4c, is equipotent in recruiting -arrestin-2 with herkinorin, 
suggesting that the kink in the diterpene core and the lactone carbonyl of herkinorin both hold the 
receptor in a similar conformation and the increased activities of the reduced lactone derivatives 
4.1c, 4.3c, and 4.5c indicates that they are able to bind more potently to a receptor conformation 




Previously determined SAR of salvinorin A at KORs led to the exploration of the lactone 
carbonyl as an auxophore. Through the development of chemical methodology to selectively 
activate and transform the lactone, analogues at this position were designed and evaluated. These 
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(63) 
4.36 
aMean  standard error of the mean; n  2 individual experiments run in triplicate. b Emax = 100%. cMaximum 




analogues allowed for validation of the hypothesis that the lactone was not critical for KOR 
binding and that polar, ionizable groups could be added without compromising the KOR activity. 
Through the development of analogues with modifications to the lactone and the C2 position, both 
of which were confirmed to maintain KOR activity individually, the binding modes of the 
analogues at the KORs and MORs were explored.  
Using the chemistry described herein coupled with the SAR now understood at the C17 
position, salvinorin A analogues with water solubilizing moieties appended to this position can be 
designed and synthesized. The free alcohol of 4.17/ is not only a pharmacologically active 
moiety but it is also a useful chemical handle through which chemical transformations and prodrug 
linkers such as esters can be made.13 Substitutions of interest include various amines, polyethylene 
glycol units, and amino acid esters (Figure 4.3). It is expected that modification of the lactone of 
salvinorin A will be a viable handle through which the pharmacokinetic properties of the molecule 
can be modified while retaining significant KOR activity.  
 
Figure 4.3: Proposed modifications to increase solubility through the C17 position. Properties calculated 
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5. Understanding the Metabolism of Neoclerodane Diterpenes  
Results 
In an effort to understand how structural changes to neoclerodane diterpenes affects their 
metabolic profiles, we sought to develop a robust and straightforward method that allows us to 
evaluate and compare the metabolic stability of salvinorin A and related diterpenes. Using rat liver 
microsomes, we have developed such a method as well as identified structural modifications to 
salvinorin A that increase its metabolic stability. 
Study 1: Development of a robust system for determining the metabolic stability of 
neoclerodane diterpenes 
Initial attempts to evaluate the metabolic stability of salvinorin A and its derivatives followed 
a method that was previously described by Béguin, et. al.1 This method outlines 400 L 
incubations consisting of 0.25 mg/mL microsomal protein, 1 mM NADPH (omitted for control 
analyses), 2 mM MgCl2, and 50 mM potassium phosphate buffer at pH 7.4 run at 37 °C from 0 to 
40 minutes. Regarding the addition of the test compound, the only information specified is that 
“test compounds were added to the prewarmed (37 °C) incubation mixtures at the final 
concentration of 1 M.”1 Details regarding length of the prewarming time and the compound 
dilution were omitted from the original procedure, and as salvinorin A is not soluble in the buffer 
solution used, it was presumably diluted with an organic solvent. Upon evaluation of other 
microsomal stability methods, we chose to employ acetonitrile as the solvent of the stock solution 
and a 20 min pre-incubation time.2 At the specified time points after compound addition, 35 L of 
the incubation mixture was aliquoted into a quench tube containing 35 L of acetonitrile and 
tolbutamide (internal standard, 1 M). Samples were centrifuged and analyzed via LCMS.1  
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Upon following this method to the best of our abilities given the information at hand, several 
limitations led us to probe the development of a more robust and reproducible method. These 
limitations included the large volumes of protein required for the analysis of each compound, the 
high number of sample tubes and thus high chance for introduction of error, and, most importantly, 
our inability to reproduce their results due to limited information on their exact procedural method. 
Using the published method as a starting point, modifications to different steps were made to 
determine the optimal method for metabolic stability evaluation.  In the development of this new 
method, we identified several characteristics that our method must have to meet our needs: 1) The 
method should allow standardized evaluation of multiple compounds at a time with minimal 
intervention to limit the introduction of error; 2) The method should contain within-assay controls 
to quantitate the detection of the samples on each day of analysis; 3) The method should be general 
enough to accommodate quantitative screening of a variety of neoclerodane diterpenes without the 
need for radiolabeling in rat liver microsomes as well as other biological samples such as serum 
that may be needed in the future. 
Towards the development of a more standardized approach, we quickly identified the need to 
move away from individual tubes for each compound at each step of the assay, including the 
reaction mixture, quench solution, and LCMS analysis, towards a 96-well plate for each of these 
steps. Microsomal stability analysis in 96-well plates have been described previously,3 although 
none of these methods had evaluated salvinorin A and other related diterpenes. Adapting the 
Béguin, et. al. method1 to function in a 96-well protocol required reducing the total volume of the 
incubation sample to 250 L. With the 96-well format, the samples could all be dosed at the same 
time using a multi-channel pipette, and similarly, by having the quench solution ready in a separate 
96-well plate, all compounds at the same time point could be quenched at exactly the same time. 
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This method eliminated the error previously associated between duplicate samples due to their 
individual tubes. It also allowed for direct analysis from the quench solution, as the HPLC is 
equipped to read directly from 96-well plates but not from Eppindorf tubes, which also eliminates 
another transfer step and potential error.  
The HPLC instrument used can vary in detection limits from run to run because of its general 
use for not only this assay but also for other lab research. For this reason, we saw the importance 
of including a control within each plate to quantify the detection of each compound at the time of 
the run. Therefore, the first well of each row is left as a blank, with only assay buffer and the test 
compound added. This control allowed for the quantification of the amount of test compound 
added to each well, as the sample was added from the same sample plate that was used to dose the 
time point wells using a multi-channel pipette. Additionally, this well allowed for evaluation of 
the detector’s signal throughout the run, as it read this control well before reading the rest of the 
test wells. The signal readout throughout a single plate often declined, and these control wells gave 
indication as to when the detection loss began as well as how the detector was functioning for that 
particular compound.  
The most difficult characteristic to address was the ability to quantitatively measure 
compounds. Following the published procedure, the amount of salvinorin A was near the limit of 
detection of the instrument, and therefore the results were inconsistent at best. We evaluated 
several methods to increase the recovery of the material and therefore the quantity of compound 
seen by the LCMS detector. To confirm that the compounds were not adhering to the protein, the 
experiment was performed using the supernatant of the rat liver microsomes, but no differences 
were seen between these results and those using full microsomal solution. We then evaluated 
methods for concentrating the analysis sample, which included differing the ratio between reaction 
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mixture and quench solution, extractions with various organic solvents, and evaporating the 
buffer/quench solution followed by redissolving the residue.4 However, none of these methods 
yielded substantial improvements in detection, and as all introduced additional error and variability 
to the results, the LCMS sampling directly from the 1:1 assay buffer/quench solution method was 
continued. The analysis of the reconstituted samples did indicate that the presence of the buffer 
might be preventing reliable data by interfering with the internal standard’s chromatography. 
Therefore, we introduced 1% formic acid into the quench solution and saw an improvement in the 
detection of the test compounds and the internal standard. Lastly, we increased the concentration 
of test compound in the reaction mixture to 10 M, which resulted in higher concentrations in the 
analysis solution and therefore more reproducibility from run to run.  
After all of these optimizations, we were able to reproducibly generate metabolic data for 
neoclerodane diterpenes. However, contrary to our predicted outcomes, we did not see appreciable 
degradation of salvinorin A in either condition, with 80% and 100% remaining after 40 min in the 
presence and absence of NADPH, respectively. The high remaining values observed could 
potentially be attributed to the increased compound concentration that was required for optimal 
detection. To overcome this issue, we extended the incubation time from 40 min to 150 min in an 
effort to observe a differential effect between salvinorin A and its analogues while maintaining the 
compound amounts necessary for detection. Upon this extended incubation time, we were able to 
see substantial metabolism of salvinorin A in both conditions, with only 42% and 50% remaining 
at 150 min in the presence and absence of NADPH, respectively. Rat liver microsomes are 
composed of a variety of metabolizing enzymes, including CYPs, UGTs, and carboxylesterases,5 
all of which contribute to salvinorin A’s metabolism.4, 6 In the absence of NADPH, the metabolism 
of salvinorin A is presumably attributed to the activity of carboxylesterases.2 
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The optimized method for evaluating the metabolic stability of neoclerodane diterpenes has 
now been established. Incubations were carried out using a total volume of 250 µL per well in 96-
well plates as outlined in Figure 5.1 in a 50 mM potassium phosphate solution with 2 mM MgCl2 
buffered to pH 7.4. Rat liver microsomes were suspended in the buffered system for a final 
concentration of 0.25 mg/mL. The test plate was charged with 220 µL per well of either buffer 
(column 1) or protein solution (columns 2-12), and the plate was stored on ice until ready to begin 
the assay. The quench plate was charged with 150 µL per well of the quench solution, 1 µM 
tolbutamide in acetonitrile with 1% formic acid, and stored on ice throughout the entirety of the 
experiment. A third 96-well plate was used as the aliquot source for test compound and either 
NADPH solution or buffer solutions in a 2:1 mixture to be added directly to the test plate. Test 
compound solutions were made from 5 mM acetonitrile stocks and diluted in assay buffer to 125 
µM, and a 25 mM NAPDH in assay buffer solution was made. 
 
Figure 5.1: Layout of optimized method for microsomal stability analysis.  
Conditions (-)NADPH (+)NADPH Conditions
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To begin the assay, 30 µL of corresponding test compound and NADPH or buffer mixture was 
added to the appropriate wells (final compound concentration of 10 µM and less than 1% 
acetonitrile, final NADPH concentration of 1 mM). For columns 1-3 (no protein and 0-min time 
points), this addition was done with the test plate on ice. For the rest of the time points, this addition 
was done after a 20 min pre-incubation in a 37°C incubator. At the end of each time point (0, 10, 
30, 60, 90, 120, and 150 min), 150 µL of reaction mixture was removed and mixed in the 
corresponding wells of the quench plate. For the no protein and 0-min time points, this quench 
immediately followed the addition. At the end of the assay, the plates were centrifuged at 1500 
rpm for 10 min to precipitate any protein remaining in the solution, followed by LCMS analysis 
of each of the wells.  
Upon optimization of the method for determining metabolic stability of neoclerodane 
diterpenes, we required a straightforward analysis protocol to report our results. The published 
method reports their data as intrinsic clearance with the units 
µL
min× mg 
, and although a similar 
equation for intrinsic clearance is known,7 we viewed this analysis readout as an overextrapolation 
of the data. As the goal of our work is to develop a method that allows for direct comparison of 
neoclerodane diterepene metabolism, a more meaningful representation of the data was warranted. 
The most direct method for reporting our data is to report the percent remaining at the end of the 
analysis period (150 min). We first determined the in-well ratio between the target peak area to 
internal standard peak area to normalize the amount of sample in each well. This ratio at time 0 
was set to 100%, and the amount of sample present at the rest of the time points were analyzed as 
percent remaining. The natural log (ln) of the percent remaining was taken, and data were analyzed 
using linear regression analysis (GraphPad Prism 7.02; GraphPad, La Jolla, CA) to generate a 
linear equation. This equation was solved for y = 150 and the inverse ln of this value was taken to 
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give the percent remaining at 150 minutes. Comparison between the actual percent remaining at 
150 minutes and the calculated values from the natural log curve were not significantly different. 
The use of the linear equation of the natural log data ensures that the data reported throughout the 
analysis is evaluated and reduces the chance of reporting anomalous or erroneous data from a 
single data point. 
Statistical analysis of the percent remaining at 150 minutes was performed using a two-tailed, 
unpaired t-test, and p values are reported when applicable. All compounds were run in parallel 
assays in duplicate in > 2 individual experiments. Percent remaining values are reported as the 
means ± S.E.M. and represent the average of the individual experiments. 
Study 2: Evaluation of the metabolic stability of salvinorin A and selected analogues 
With a protocol in-hand to evaluate and report the metabolic stability of neoclerodane 
diterpenes, we first validated the method by evaluating dextromethorphan and verapamil, which 
are compounds known to be primarily metabolized by CYP450 enzymes.8 In our assay, we were 
able to distinguish significant differences between the compounds incubated in the presence and 
absence of NADPH (Figure 5.2). Both dextromethorphan and verapamil were extensively 
metabolized in the presence of NADPH (8.5 ± 0.9 and 26 ± 5% remaining at 150 min, respectively) 
 
Figure 5.2: Metabolic stability of control compounds at 150 minutes in the presence (stripes) or absence (no 




























and not in the absence of NADPH. These results confirmed that our assay is able to identify 
CYP450-mediated metabolism. 
Upon method validation, we began the evaluation and comparison of salvinorin A and selected 
analogues. We began by evaluating C2-analogues of salvinorin A that had previously been 
confirmed as KOR agonists, and their improved metabolic stability had been presumed but not 
confirmed. These compounds include EOM-salvinorin B, -tetrahydropyran salvinorin B, and 
Mesyl-salvinorin B (Figure 5.3).9 All three of these analogues have metabolic profiles similar to 
salvinorin A in the presence of NADPH, but in the absence of NADPH, they all have increased 
metabolic stabilities.10 Salvinorin A is extensively metabolized in the absence of NADPH (50 ± 
10% remaining at 150 min), in contrast to both EOM-salvinorin B and β-THP-salvinorin B which 
are not readily metabolized in the absence of NADPH (105 ± 6% and 104 ± 8% remaining at 150 
min, respectively) as well as Mesyl-salvinorin B which is only slightly metabolized in the absence 
of NADPH (84 ± 2% remaining). This method allowed us to confirm that these compounds are, in 
fact, more metabolically stable than salvinorin A in the absence of NADPH.  
We further evaluated the salvinorin A analogues that have activity at the MOR: herkinorin, 
herkamide, and kurkinorin (Figure 5.4A). Replacing salvinorin A’s acetate with a benzoate to 
form herkinorin significantly decreases herkinorin’s metabolic stability both in the presence and 
 
Figure 5.3: Metabolic stability of salvinorin A and known C2-analogues at 150 minutes in the presence 
(stripes) or absence (no shading) of NADPH; *p<0.05, **p<0.01, ***p<0.001 compared to salvinorin A in 



























in the absence of NADPH (**p<0.01 for both conditions, compared to salvinorin A under similar 
conditions, via two-tailed, unpaired t-test). Unsurprisingly with the modification of the ester to an 
amide linkage, herkamide is metabolically stable in the absence of NADPH, indicating an 
improved stability against esterases, and herkamide is also more stable than herkinorin and 
salvinorin A in the presence of NADPH (****p<0.0001 and **p<0.01, respectively, via two-
tailed, unpaired t-test). Introduction of the unsaturation between bonds C2 and C3 as seen in 
kurkinorin does significantly affect the metabolic stability. In both the presence and absence of 
NADPH, less than 1% of kurkinorin was present after 150 min of microsomal incubation. Upon 
further evaluation of the metabolism curve, the majority of kurkinorin is metabolized within the 
first 30 min of the incubation, regardless of the NADPH conditions (Figure 5.4B).  
Previous metabolic studies of salvinorin A that have identified metabolites indicate that the C2-
acetate and the lactone are two of the most metabolically labile positions of the molecule.4 With 
the development of analogues with modifications to both of these positions (4.1a-c – 4.5a-c), the 
role of each of these moieties could be assessed through the evaluation of the metabolic stability 
of these dual-modified compounds. The mesyl derivatives (4.1b – 4.5b) and the herkinorin 
derivatives (4.1c – 4.5c) were evaluated and the results were compared to Mesyl-salvinorin B or 
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Figure 5.4: A) Metabolic stability of MOR agonists herkinorin, herkamide, and kurkinorin at 150 minutes in the 
presence (stripes) or absence (no shading) of NADPH; *p<0.05, ****p<0.0001 compared to herkinrorin under 
the same NADPH conditions, n.s. = no significance, via two-tailed, unpaired t-test. (B) Metabolic stability curve 




herkinorin, respectively, in an effort to determine how modification of the lactone affects the 
metabolic profile of these compounds. These analogues were chosen for this evaluation because 
Mesyl-salvinorin B is more stable than salvinorin A in the absence of NADPH and has a similar 
profile in its presence (Figure 5.3), while herkinorin is less stable than salvinorin A under both 
conditions (Figure 5.4).  
Modifications to the lactone of Mesyl-salvinorin B have differing effects on its metabolism 
(Figure 5.5). The lactol derivative 4.1b is stable to CYP450-mediated metabolism (****p<0.0001 
compared to Mesyl-salvinorin B in the presence of NADPH, via two-tailed, unpaired t-test), with 
no significant difference in the metabolism of 4.1b in either the presence and absence of NADPH. 
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Figure 5.5: Metabolic stability of (A) Mesyl salvinorin B and its C17-modified analogues (4.1b - 4.5b) and (B) 
and herkinorin and its C17-modified analogues (4.1c - 4.5c) at 150 minutes in both the presence and absence of 
NADPH; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, n.s. = no significance compared to parent compound (A: 
Mesyl-salvinorin B or B: herkinorin) under the same NADPH conditions, via two-tailed, unpaired t-test. 
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significantly metabolized than the parent Mesyl-salvinorin B in both the presence and absence of 
NADPH. The introduction of the C8-C17 double bond in 4.4b did not significantly affect the 
metabolism in either the presence or absence of NADPH compared to Mesyl-salvinorin B, 
indicating that the pyran moiety is metabolized similarly to the lactone. By eliminating the unstable 
C17-oxygen bond to form 4.5b, the stability of the compound is increased, with a significant 
difference between Mesyl-salvinorin B and 4.5b in the presence of NADPH (**p<0.01, via two-
tailed, unpaired t-test). Modifying the lactone of herkinorin was not able to overcome its significant 
metabolism, with most of the analogues evaluated being less stable than herkinorin under similar 
NADPH conditions (Figure 5.5). 4.4c was the only analogue to be significantly more stable than 
herkinorin in the absence of NADPH (**p<0.01, via two-tailed, unpaired t-test) but did not 
statistically differ from salvinorin A under these conditions. These results confirm that the C2-
substituent is critical for metabolic stability, with the benzoate of herkinorin being readily cleaved 
while the mesylate of Mesyl-salvinorin B is relatively stable. Modifications to the 17-position can 
prevent CYP450-mediated metabolism, but these effects are not able to overcome rapid C2-
metabolism. 
Given that these C2-modifications have significantly improved the non-CYP450-mediated 
metabolic stability of salvinorin A, we set out to further explore modifications to the acetate that 
maintain KOR activity while improving the metabolic stability of the analogue. Through 
exploration of chemical modifications to the C1-C2 -hydroxy ketone functionality, access to the 
the spirobutyrolactone 5.1 was achieved.11 This analogue is synthesized in a single step from 
salvinorin B and has similar potency and selectivity to salvinorin A (EC50 = 0.6 ± 0.2 nM at KOR 
>10,000 nM at MOR and DOR).  
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The spirobutyrolactone moiety is a rigid, conformationally constrained analogue of salvinorin 
A’s acetate, and we hypothesized that it could provide increased metabolic liability. Using our 
optimized metabolic stability assay, we were able to directly compare the stability of salvinorin A 
to 5.1. The metabolic stability of 5.1 in both the presence and absence of NADPH is significantly 
improved in comparison to salvinorin A under the same conditions (75 ± 5% and 100 ± 10% 
remaining at 150 min, respectively, Figure 5.6). Not only does the spirobutyrolactone moiety 
impart resistance to non-CYP450-mediated metabolism, presumably esterases, but the CYP450-
mediated oxidation is also reduced. 
Conclusion 
In order for salvinorin A analogues to be further investigated as drug candidates, their metabolic 
stability profiles must be significantly improved from that of salvinorin A. Through the 
development of a robust method for determining the metabolic stability of neoclerodane 
diterpenes, we now have the ability to directly compare the metabolic profiles of salvinorin A and 
its analogues. This method has allowed us to characterize the stability profiles of previously 
identified salvinorin A analogues as well as novel analogues recently identified and under 
development in our lab.  
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Figure 5.6: Novel spirobutyrolactone is more metabolically stable than salvinorin A at 150 minutes in both the 
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6. Overall Conclusions 
Due to the current opioid epidemic in the United States, the development of therapeutics to 
combat both pain and addiction is a significant medical need. Existing therapies for these disease 
states are in need of improvement due to a variety of side effects that often lead to under-treatment 
and untoward suffering of patients. The  and  opioid receptors (MOR and KOR, respectively) 
are both targets of interest in the development of pain and addiction therapies. Activation of the 
MOR leads to pain relief, but many agonists also elicit side effects, including tolerance and 
dependence that ultimately can lead to addiction. Several of these MOR-associated side effects 
have been attributed to the recruitment of -arrestin-2, while the pain-relieving effects are the 
result of G-protein activation. Thus a compound biased towards G-protein activation over -
arrestin-2 recruitment has been pursued for the development of an analgesic therapy devoid of 
common side effects. Alternatively, activation of the KOR has analgesic effects without any 
addiction-related side effects and has been shown to reduce relapse and withdrawal symptoms in 
animal models of addiction, but its activation can elicit dysphoria and hallucinations. Therefore, 
targeting either of these receptors to elicit the beneficial effects without the associated side effects 
is a goal for combatting the opioid epidemic.  
The natural product salvinorin A is a potent KOR that can be semisynthetically modified into a 
MOR agonist. As it is structurally dissimilar from the other known MOR or KOR agonists, it is an 
ideal lead molecule for the identification of an opioid without the side effects of the current 
therapies. However, several properties must be addressed in order to further pursue salvinorin A-




Towards the development of a MOR agonist, the SAR about the recently-identified compound 
kurkinorin was undertaken, and more potent and biased analogues were identified. In particular, 
the 4’-benzylic alcohol derivative 3.46 (Figure 6.1) is the most potent salvinorin A-based MOR 
agonist identified to date, with a G-protein activation EC50 value of 0.03 ± 0.01 nM. It does recruit 
-arrestin-2 to a lesser extent, with an EC50 value of 14 ± 1 nM in this pathway. Through 
exploration of the SAR of activation of these two MOR-associated pathways, the 4’-
methoxymethoxy-3’-methyl derivative 3.39 was identified as a lead compound for a biased agonist 
as it moderately activates the G-protein pathway without any -arrestin-2 recruitment (EC50 values 
of 170 ± 20 nM and >25 000 nM, respectively). Based on the preliminary in vivo results with 
kurkinorin, indicating its antinociceptive activity with reduced abuse liability, and the 
identification of more potent and biased compounds, the kurkinorin scaffold appears to be a 
promising target towards the development of an analgesic therapy. 
Salvinorin A’s low water solubility and rapid metabolism limit its use in both animal and human 
studies, therefore its structure was probed in an effort towards both understanding and improving 
these pharmacokinetic properties. The lactone moiety was explored in the search for a point on the 
molecule through which the water solubility could be modulated, and the lactone carbonyl was 
determined to be an auxophore for both KOR and MOR binding. Analogues with polar substituents 
at the lactone position maintained KOR activity, and the carboxylic acid analogues 4.20and 
4.20 (Figure 6.1) were the first salvinorin A-based KOR agonists to have an ionizable 
functionality. The studies performed on the lactone of salvinorin A indicate that additional 
solubilizing moieties should be tolerated at this position while maintaining KOR activity. The 
metabolism of salvinorin A was explored through the development of a straightforward and robust 
method for determining the microsomal stability of salvinorin A and selected analogues. Through 
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this method, salvinorin A-based KOR and MOR agonists were evaluated for their metabolic 
stability. In comparison to salvinorin A, analogues with modifications to the C2-acetate such as 
EOM-salvinorin B, THP-salvinorin B, Mesyl-salvinorin B, and herkamide, were more stable to 
non-CYP450-dependent metabolic processes, while herkinorin and kurkinorin were not. With 
access to this method for evaluating metabolic stability in the laboratory, synthetic modifications 
can now be directly assessed for their effects on the metabolic stability of the analogues. 
This work is also the first to report a systematic study of dual-modified salvinorin A analogues. 
The methodology developed to modify the lactone was applied to selected C2-modified salvinorin 
A analogues known to have unique opioid receptor activity, MOM-salvinorin B (KOR agonist), 
Mesyl-salvinorin B (KOR agonist with a unique binding pose from salvinorin A or MOM-
salvinorin B), and herkinorin (MOR agonist). Through this systematic approach, the roles of both 
the lactone and the C2-derivatives were evaluated. The metabolic stability of several of these dual-
modified analogues was also explored, and the analogues with a C2-mesyl and either the C17-
lactol (4.1b) or the C17-H2 (4.5b) were more stable than Mesyl-salvinorin B under CYP450-
mediated metabolic conditions. These results indicate that the lactone is responsible for some of 
salvinorin A’s CYP450-mediated degradation.  
Because both of these projects compared results directly to herkinorin, the results can be 
extrapolated to hypothesize how kurkinorin analogues with modifications to their lactone might 
behave. Ultimately, as the lactone modifications to herkinorin resulted in increased -arrestin-2 
recruitment with decreased G-protein activation, the hypothesized kurkinorin lactone-modified 
analogue would be expected to be more biased towards -arrestin-2 than kurkinorin. While 
removing the lactone from kurkinorin may prevent the metabolism at that position, the C2-ester 
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linkage is still present and very rapidly metabolized, as shown in Figure 5.4. Therefore the lactone 
modifications are not envisioned to be able to compensate for this rapid metabolism, just as they 
are not able to compensate for the metabolism of herkinorin.  
Collectively, the studies and results described herein provide insight into the requirements of 
salvinorin A analogues for activation of MORs, both G-protein and -arrestin-2 pathways, and 
activation of KORs, as well as functionalities that enhance or reduce metabolic stability (Figure 
6.1). These results will help to further the exploration of salvinorin A-based compounds as 
potential pain and addiction therapies. 
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Herkinorin 109.1 3.7 36 0.28 13.12 
Herkamide 111.9 3.3 36 0.32 10.17 
Kurkinorin 109.1 3.8 36 0.34 11.19 
3.18 122 3.2 36 0.24 13.16 
3.19 122 3.2 36 0.32 9.90 
3.2 122 3.2 36 0.31 10.23 
3.21 134.9 2.6 36 0.31 8.31 
3.22 131.2 3.2 38 0.31 10.32 
3.23 122.2 3.9 39 0.26 14.76 
3.24 109.1 5 39 0.28 17.69 
3.25 109.1 3.8 35 0.35 10.96 
3.26 109.1 3.8 35 0.35 10.93 
3.27 135.1 2.2 35 0.29 7.47 
3.28 122 3.2 35 0.32 9.85 
3.29 135.1 2.2 35 N.A
d N.Ad 
3.30 122 3.2 35 N.A
d N.Ad 
3.31 109.1 3.7 37 0.25 14.51 
3.32 109.1 4.1 38 0.23 17.77 
3.33 109.1 4.1 38 0.27 15.12 
3.34 129.3 3.5 37 0.33 10.64 
3.35 129.3 3.5 37 0.34 10.39 
3.36 127.6 4.2 41 0.28 14.84 
3.38 127.6 4.6 41 0.23 20.34 
3.39 127.6 4.1 41 0.23 18.13 
3.40 129.3 3.9 38 0.33 11.73 
3.41 129.3 4.2 38 0.30 13.87 
3.42 129.3 4.3 38 0.28 15.35 
3.43 129.3 3.8 38 0.26 14.59 
3.44 122.3 3.9 39 0.31 12.58 
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3.45 122.3 3.9 39 0.28 13.80 
3.46 129.3 3.6 38 0.38 9.49 
3.47 129.3 3.6 38 0.31 11.58 
3.48 118.3 3.9 39 0.28 14.08 
3.49 152.2 2.9 39 0.35 8.26 
3.50 152.2 2.9 39 N.A
d N.Ad 
3.51 138.2 3 40 0.30 10.12 
3.52 138.2 3 40 0.29 10.31 
 
atPSA = total polar surface area (Å2); bsLogP = Wildman-Crippen calculated logP; cHAC = 
heavy atom count; dN.A.= not applicable. eProperties calculated using Forge 10.4.2 Revision: 
24876, Copyright 2006-2015, Cresset BioMolecular Discovery, Ltd. Efficiency metrics 
calculations for herkinorin, herkamide, kurkinorin, and kurkinorin derivatives based on activity in 
the G-protein cAMP assay. Ligand efficiency (LE) was calculated using the following equation: 
𝐿𝐸 = −1.37 𝑥 log (
𝑝𝑜𝑡𝑒𝑛𝑐𝑦,𝑀
𝐻𝑒𝑎𝑣𝑦 𝐴𝑡𝑜𝑚 𝐶𝑜𝑢𝑛𝑡
). Lipophilic-adjusted ligand efficiency (LELP) was 





















Salvinorin A 109 2.4 31 0.44 N.A. d 5.43 N.A. d 
4.1 112 2.6 31 0.39 N.A. d 6.59 N.A. d 
4.3 118 2.8 34 0.35 N.A. d 8.06 N.A. d 
4.4 92 3.1 30 0.40 N.A. d 7.80 N.A. d 
4.5 92 2.9 30 0.41 N.A. d 7.12 N.A. d 
4.6 115.8 2.8 32 0.38 N.A. d 7.36 N.A. d 
4.7 92 3.7 33 0.31 N.A. d 12.13 N.A. d 
4.8 109.1 3.2 34 0.29 N.A. d 11.03 N.A. d 
4.9 109.1 4.5 39 0.25 N.A. d 18.24 N.A. d 
4.10 101.3 4.4 38 0.24 0.25 17.99 17.32 
4.11 101.3 3.6 34 0.28 0.28 12.91 13.02 
4.12 101.3 3.3 34 0.31 0.32 10.64 10.43 
4.13 101.3 3 34 0.33 0.34 9.13 8.84 
4.14 125 3.2 35 0.35 0.32 9.13 9.85 
4.15 121.5 3 36 0.34 0.34 8.80 8.84 
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4.16 121.5 2.6 36 0.36 0.35 7.17 7.35 
4.17 122 3 35 0.36 0.34 8.31 8.83 
4.18 121.5 3.4 36 0.32 0.29 10.48 11.70 
4.20 141 2.7 36 0.34 0.30 8.04 8.91 
 
atPSA = total polar surface area (Å2); bsLogP = Wildman-Crippen calculated logP; cHAC = 
heavy atom count; dN.A.= not applicable. eProperties and efficiency metrics calculated as above 
in Supplemental Table 1.  
In vitro pharmacology 
Cell lines and cell culture. The HitHunterTM Chinese hamster ovary cells (CHO-K1) stably 
expressing the human µ-opioid receptor (OPRM1, catalog # 95-0107C2) the human κ-opioid 
receptor (OPRK1, catalog # 95-0088C2), or the human -opioid receptor, (OPRD1, catalog  # 95-
0108C2) and the PathHunterTM Chinese hamster ovary cells stably expressing the human µ-opioid 
receptor β-arrestin-2 EFC cell line (catalog # 93-0213C2) were purchased from DiscoverX Corp. 
(Fremont, CA) and maintained in F-12 media with 10% fetal bovine serum (Life Technologies, 
Grand Island, NY), 1% penicillin/streptomycin/ ʟ-glutamine (Life Technologies), and 800 µg/mL 
Geneticin (Mirus Bio, Madison, WI). The media of the PathHunterTM cells was additionally 
supplemented with an additional 250 µg/mL Hygromycin B (Mirus Bio). All cells were grown at 
37 °C and 5% CO2 in a humidified incubator. 
Forskolin-induced cAMP accumulation. Assays proceeded as previously described.1 Opioid 
receptor mediated G-protein activation was measured using the DiscoverX HitHunterTM 
technology. On day1, ~80% confluent CHO cells (OPRK1, OPRM1, or OPRD1) were detached 
from culture plates using non-enzymatic Cell Dissociation Buffer (Life Technologies) and counted 
using a hemocytometer.  Cells were plated at 10,000 cells/well in 20 µl Cell Plating Reagent 2 
(DiscoveRx) in 384-well tissue culture plates and incubated at 37 °C overnight.  On day 2, stock 
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solutions of all compounds were generated by dissolution in 100% DMSO to 5 mM.  Stock 
solutions were used to make 10 serial dilutions in 100% DMSO at 100X final compound 
concentrations.  100X compound concentrations were diluted in assay buffer (Hank’s Buffered 
Salt Solution (HBSS, Life Technologies) with 10 mM HEPES (Life Technologies)) containing 
forskolin (DiscoveRx) to yield 5X compound concentrations, 100 µM forskolin, and 5% DMSO 
in assay buffer.  The DiscoveRx HitHunter™ cAMP Assay was used according to manufacturer’s 
instructions.  Briefly, media was removed from cells, and cells were washed with 10 µl assay 
buffer.  Assay buffer containing antibody reagent (20 µl/well) was added to cells.  5 µl of 5X 
compound/forskolin solution were added to cells (final concentrations were 1X compound, 20 µM 
forskolin, and 1% DMSO).  Cells were incubated at 37 °C and 5% CO2 for 30 minutes, followed 
by incubation with detection reagents according to manufacturer’s instructions, and incubated at 
room temperature protected from light overnight.  On day 3, luminescence was quantified using a 
Synergy 2 plate reader with Gen5 software (BioTek, Winooski, VT).  Data were normalized to 
vehicle and forskolin only control values and analyzed using non-linear regression with GraphPad 
Prism 5.0.   
β-arrestin-2 EFC recruitment assay. Assays proceeded as previously described.2 The MOR 
agonist-mediated β-arrestin-2 recruitment was measured using the DiscoverX PathHunterTM 
technology. On day 1, ~80% confluent CHO-K1 OPRM1 β-arrestin-2 cells were detached from 
culture plates using nonenzymatic cell dissociation buffer (Life Technologies) and counted using 
a hemocytometer. Cells were plated at 5 000 cells/well in 20 μL of Cell Plating Reagent 2 
(DiscoveRx) in 384-well tissue culture plates and incubated at 37 °C overnight. On day 2, stock 
solutions of test compounds were generated in 100% DMSO to 5 mM. The stock solutions were 
used to make 11 serial dilutions and then diluted to yield 5x compound concentrations in assay 
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buffer (Hank’s Balanced Salt Solution [HBSS, Life Technologies] with 10 mM HEPES [Life 
Technologies]). The cells were treated with 5 µL of the test compound solutions, final 
concentration of 1X compound and 1% DMSO. Cells were incubated for 90 minutes at 37oC. Cells 
were then treated with detection reagents, 12.5 µL per well, according to manufacturer’s 
instructions and incubated at room temperature for at least 1 h protected from light. Luminescence 
was quantified using a Synergy 2 plate reader with Gen5 Software (BioTek, Winooski, VT). Data 
were normalized to vehicle (no compound, 1% DMSO final concentration) to remove any 
background luminescence. The highest dose(s) of DAMGO was used as 100% recruitment and all 
data was converted to percentages based upon the DAMGO response. 
Data analysis. Data were analyzed using nonlinear regression analysis in GraphPad Prism 5.0 
software (GraphPad, La Jolla, CA) to generate sigmoidal dose-response curves for both the cAMP 
accumulation assay and the β-arrestin-2 recruitment assay. cAMP accumulation data were 
normalized to vehicle and forskolin only control values, and β-arrestin-2 recruitment data were 
normalized to vehicle and DAMGO maximum response values. All compounds were run in 
parallel assays in triplicate in > 2 individual experiments. EC50 and Emax values are reported as the 
means ± S.E.M. and represent the average of each individual experiment following nonlinear 
regression analysis. Bias factors were calculated using relative activity values, as shown in 
Equation 2.1: 
 
Ligand-based alignment study 
Ligand-based alignment studies were performed using Forge (v 10.4.2, Cresset, Litlington, 
Cambridgeshire, UK; http://www.cresset-group.com/forge/) as used previously.3 All settings were 

















left as default, unless noted otherwise. All compounds were imported in “use input protonation 
state,” as none of the compounds contain ionizable moieties. Briefly, the 2-dimensional structure 
of salvinorin A was imported and the preferred conformation was found using the “very accurate 
and slow” method in the conformation hunt mode, with a maximum of 1000 conformations 
evaluated. The final conformation of salvinorin A used had a conformation energy of 65.56 
kcal/mol. Using the “alignment” tool, this conformation of salvinorin A was set to the “reference” 
role and the 2-dimensional structures of 4.4 was imported in the “prediction set.” The conformation 
hunt and alignment were set to “very accurate and slow” and “substructure,” respectively. The 
“substructure” setting weights shape similarity and alignment with the reference equally and holds 
the common core of the “prediction set” compounds in place while searching for the best 
conformation of the rest of the molecule that varies from the common core. The final conformation 
energies of 4.4 was 52.48 kcal/mol.  
Metabolic Stability Protocol 
Materials. Pooled IGS Sprague-Dawley rat liver microsomes (male, 20mg/mL) were purchased 
from Sekisui XenoTech, LLC (Kansas City, KS). Nicotinamide adenine dinucleotide phosphate 
tetrasodium salt hydrate (reduced form, NADPH, Fisher Scientific), Tolbutamide (Sigma Aldrich, 
St. Louis, MO), MeCN, (HPLC grade, Fisher Scientific)  
In Vitro Metabolic Stability in Rat Liver Microsomes. Incubations were carried out in 96-well 
plates with 250 µL per well. The reaction mixtures were in a 50 mM potassium phosphate buffer 
solution with 2 mM MgCl2 and buffered to pH 7.4. Rat liver microsomes solution, 220 µL, (protein 
suspended in buffered system for final concentration of 0.25 mg/mL) was added to all wells. The 
assay plate was pre-warmed to 37°C in an incubator (no CO2 injection or humidity) for 20 minutes. 
The 0-minute time points were performed on ice, with the exception of compound 5.1 t = 0 samples 
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which were prewarmed to prevent compound from crashing out of solution. To begin the assay, 
20 µL of test compound (5mM stock solution in MeCN [Fisher Scientific, HPLC grade] diluted in 
assay buffer to 125 µM, for final compound concentration of 10 µM and less than 1% MeCN in 
well) and 10 µL of NADPH in buffer (final concentration of 1mM) were added to the wells. At 
the end of each time point (0, 10, 30, 60, 90, 120, and 150 min), 150 µL of reaction mix was 
removed and mixed in a separate 96-well plate containing 150 µL of quench solution per well (1 
µM tolbutamide in MeCN with 1% formic acid). The quench plate was stored on ice until the end 
of the assay. For the test samples without NADPH, the same procedure as above was conducted 
with the addition of 10 uL buffer instead of the NADPH solution, and time points were collected 
at 0, 30, 90, and 150 min. At the end of all time points, the plate was centrifuged at 1500 rpm for 
10 min. to precipitate any protein remaining in the solution. The amount of compound remaining 
was quantified using LCMS. The plate wells were analyzed using liquid chromatography-high 
resolution mass spectrometry on a Waters Acquity UPLC coupled to a Waters LCT Premier TOF 
mass spectrometer.  The chromatography utilized a Waters Acquity HSS T3 C18 column (2.1 × 
50mm, 1.8um) with a guard column of the same stationary phase (2.1 × 5mm, 1.8um) and was run 
with gradient elution, using water and acetonitrile with 0.1% formic acid, from 40% to 80% 
acetonitrile over 3.4 minutes and held at 80% acetonitrile for 0.4 minutes. The flow rate was 
0.25ml/min and the injection volume was 15uL. Each well was sampled twice.  
Data analysis. The ratio between the target area peak to internal standard peak was used 
throughout the data to normalize the amount of sample in each well. This ratio at time 0 was set to 
100%, and the amount of sample present at the rest of the time points were analyzed as percent 
remaining. The ln of the % remaining was taken, and data were analyzed using linear regression 
analysis in GraphPad Prism 5.0 software (GraphPad, La Jolla, CA). The linear equation generated 
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in GraphPad was solved for y = 150 and the inverse ln of this value was taken to give the % 
remaining at 150 min. Statistical analysis of the % remaining at 150 min was performed using a 
two-tailed, unpaired t-test, and p values are reported when applicable. All compounds were run in 
parallel assays in duplicate in > 2 individual experiments. % remaining values are reported as the 
means ± S.E.M. and represent the average of each individual experiment. 
Chemistry 
General experimental procedures. Salvinorin A was isolated from the leaves of Salvia 
divinorum and converted to salvinorin B as previously described.4 All other chemical reagents 
were purchased from commercial suppliers and used without further purification. All solvents were 
obtained from a solvent purification system in which solvent was passed through two columns of 
activated alumina under argon. Reactions performed in standard glassware were performed under 
an atmosphere of argon using glassware dried overnight in an oven at 120 °C and cooled under a 
stream of argon. Reactions were monitored by thin-layer chromatography (TLC) on 0.25 mm 
Analtech GHLF silica gel plates and visualized using a UV Lamp (254 nm) and vanillin solution. 
Flash column chromatography was performed on silica gel (4-63 mm) from Sorbent Technologies. 
1H and 13C NMR were recorded a 500 MHz Bruker AVIII spectrometer equipped with a 
cryogenically-cooled carbon observe probe or a 400 MHz Bruker AVIIIHD spectrometer using 
tetramethyl silane as an internal standard. Chemical shifts (δ) are reported in ppm and coupling 
constants (J) are reported in Hz. High-resolution mass spectrum (HRMS) was performed on a LCT 
Premier (Micromass Ltd., Manchester UK) time of flight mass spectrometer with an electrospray 
ion source in either positive or negative mode. Melting points were measured with a Thomas 
Capillary Melting Point Apparatus and are uncorrected. HPLC was carried out on either an Agilent 
1100 series HPLC system with diode array detection at 209 nm on an Agilent Eclipse XDB-C18 
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column (250 × 10 mm, 5 mm) or a Waters Acquity UPLC with a photodiode array UV detector 
and an LCT Premiere TOF mass spectrometer on a Waters Acquity HSS T3 C-18 column (2.1 × 
50mm, 1.8 m). Compounds were identified as ≥90% pure by HPLC before all in vitro and  ≥95% 
before all in vivo analyses.  
Compounds from Chapter 3: 
General coupling procedure using standard benchtop glassware:  
An oven-dried flask was charged with 3.1 and 3.2 (mixture) (40 mg, 0.103 mmol), EDC·HCl 
(29.5 mg, 0.154 mmol), DMAP (18.8 mg, 0.154 mmol), and the appropriate benzoic acid (0.154 
mmol). To the flask was added CH2Cl2 (8 mL). After stirring overnight at r.t. the reaction was 
quenched with HCl (1 M, 8 mL) and the organic layer rinsed sequentially with saturated NaHCO3 
(8 mL) and brine (8 mL) then dried over Na2SO4. The solvent was evaporated and the resulting 
residue purified by FCC (30-35% EtOAc/Pentane). Compounds <95% pure as indicated by HPLC 
were further purified by reverse phase semi-preparatory HPLC. 
General procedure for deprotection of MOM-protected phenol coupling products: 
To a dry flask under Ar was added MOM-protected coupling product (0.07 mmol), carbon 
tetrabromide (CBr4) (0.035 mmol, 0.5 eq.), triphenylphosphine (PPh3) (0.035 mmol, 0.5 eq.), and 
dichloroethane (3mL).5 Reaction was heated to 40 °C overnight. If reaction was not complete as 
monitored by TLC the following day, a second addition of 0.5eq. of both CBr4 and PPh3 was added 
and the reaction was allowed to stir at 40 °C for a second night. Upon reaction completion as seen 




General procedure for deprotection of TBS-protected benzyl alcohol coupling products: 
To a flask containing crude TBS-protected coupling product (0.2 mmol) was added a 1:1 
mixture of MeOH and acetone (6 mL total) followed by a solution of KHSO4 (0.1 mmol, 0.5 eq.) 
in 3 mL of H2O.
6 Reaction is a white suspension after water addition. Reaction stirred overnight 
at r.t. Upon reaction completion, as monitored by TLC, the solvent was evaporated and the product 
was extracted from water (10 mL) into EtOAc (3x 10 mL). The combined organic layers were 
washed with brine, dried over Na2SO4, and solvent was removed. The compound was purified by 
FCC (50% EtOAc/Pentane). 
Methyl (2S,4aR,6aR,7R,10aR,10bR)-9-((benzo[b]thiophene-2-
carbonyl)oxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-1,4,4a,5,6,6a,7,10,10a,10b-
decahydro-2H-benzo[f]isochromene-7-carboxylate (3.24). 1H NMR (500 MHz, CDCl3) 8.20 (d, 
J = 0.7 Hz, 1H), 7.90 (td, J = 7.5, 1.0 Hz, 2H), 7.50 (ddd, J = 8.2, 7.0, 1.3 Hz, 1H), 7.47 – 7.43 (m, 
1H), 7.43 – 7.37 (m, 2H), 6.72 (d, J = 2.2 Hz, 1H), 6.39 (dd, J = 1.9, 0.9 Hz, 1H), 5.55 (dd, J = 
11.5, 5.2 Hz, 1H), 3.81 (s, 3H), 3.60 (d, J = 2.2 Hz, 1H), 3.08 (dd, J = 13.7, 5.3 Hz, 1H), 2.47 (s, 
1H), 2.24 – 2.17 (m, 2H), 2.15 – 2.10 (m, 1H), 1.77 – 1.72 (m, 1H), 1.71 – 1.64 (m, 2H), 1.39 (s, 
3H), 1.25 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 190.65, 171.36, 170.28, 160.54, 145.06, 143.67, 
142.79, 139.36, 138.53, 132.51, 131.11, 130.37, 127.54, 125.85, 125.40, 125.16, 122.81, 108.44, 
72.06, 63.47, 56.46, 52.51, 51.35, 44.22, 43.80, 38.44, 35.86, 17.94, 16.83, 14.85. HRMS 
calculated for C30H28O8S [M+Na]






1,4,4a,5,6,6a,7,10,10a,10b-decahydro-2H-benzo[f]isochromene-7-carboxylate (3.36). 1H 
NMR (500 MHz, CDCl3) 7.95 – 7.71 (m, 2H), 7.46 – 7.37 (m, 2H), 6.65 (d, J = 2.2 Hz, 1H), 6.39 
(dd, J = 2.0, 0.9 Hz, 1H), 5.54 (dt, J = 11.6, 5.8 Hz, 1H), 5.31 (s, 2H), 3.80 (s, 3H), 3.59 (d, J = 2.3 
Hz, 1H), 3.52 (d, J = 1.2 Hz, 3H), 3.06 (dd, J = 13.7, 5.4 Hz, 1H), 2.46 (s, 1H), 2.25 – 2.16 (m, 
2H), 2.16 – 2.08 (m, 1H), 1.79 – 1.63 (m, 3H), 1.57 – 1.48 (m, 1H), 1.37 (s, 3H), 1.23 (s, 3H). 13C 
NMR (126 MHz, CDCl3) δ 190.86, 171.37, 170.36, 163.34, 152.20 (d, J = 247.7 Hz), 149.99 (d, J 
= 10.7 Hz), 145.34, 143.68, 139.36, 130.05, 127.42, 125.41, 122.10, 118.22 (d, J = 20.5 Hz), 
116.44, 108.44, 95.08, 72.05, 63.46, 56.64, 56.48, 52.49, 51.37, 44.21, 43.80, 38.45, 35.85, 17.94, 
16.82, 14.86. HRMS calculated for C30H31O10F [M+Na]
+: 593.1788 (found); 593.1799 (calcd). 
Melting point: 88-90 °C. 
Methyl (2S,4aR,6aR,7R,10aR,10bR)-9-((3-chloro-4-
(methoxymethoxy)benzoyl)oxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-
1,4,4a,5,6,6a,7,10,10a,10b-decahydro-2H-benzo[f]isochromene-7-carboxylate (3.37). 1H 
NMR (500 MHz, CDCl3) 8.14 (dd, J = 3.4, 2.2 Hz, 1H), 7.97 (dd, J = 8.7, 2.1 Hz, 1H), 7.44 – 7.36 
(m, 2H), 7.24 (s, 1H), 6.65 (d, J = 2.2 Hz, 1H), 6.39 (dd, J = 1.9, 0.9 Hz, 1H), 5.54 (dd, J = 11.5, 
5.5 Hz, 1H), 5.34 (d, J = 1.5 Hz, 2H), 3.80 (s, 3H), 3.59 (d, J = 2.2 Hz, 1H), 3.52 (d, J = 1.2 Hz, 
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4H), 3.06 (dd, J = 13.7, 5.4 Hz, 1H), 2.46 (s, 1H), 2.24 – 2.15 (m, 1H), 2.16 – 2.09 (m, 1H), 1.78 
– 1.61 (m, 3H), 1.37 (s, 3H), 1.23 (s, 3H).z 13C NMR (126 MHz, CDCl3) δ 190.85, 171.37, 170.35, 
163.26, 157.28, 145.34, 143.68, 139.36, 132.45, 130.45, 130.03, 125.40, 123.62, 122.33, 115.04, 
108.44, 94.79, 72.05, 63.45, 56.63, 56.48, 52.49, 51.37, 44.21, 43.79, 38.46, 35.85, 17.94, 16.82, 
14.86. HRMS calculated for C30H31O10Cl [M+Na]
+: 587.1754 (found); 587.1679 (calcd). Melting 
point: 108-110 °C. 
Methyl (2S,4aR,6aR,7R,10aR,10bR)-9-((3-bromo-4-
(methoxymethoxy)benzoyl)oxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-
1,4,4a,5,6,6a,7,10,10a,10b-decahydro-2H-benzo[f]isochromene-7-carboxylate (3.38). 1H 
NMR (500 MHz, CDCl3) 8.31 (dd, J = 2.9, 2.1 Hz, 1H), 8.06 – 7.95 (m, 1H), 7.48 – 7.35 (m, 2H), 
7.21 (d, J = 8.7 Hz, 1H), 6.65 (d, J = 2.2 Hz, 1H), 6.39 (dd, J = 2.0, 0.9 Hz, 1H), 5.59 – 5.50 (m, 
1H), 5.33 (d, J = 1.6 Hz, 2H), 3.80 (s, 3H), 3.73 (dd, J = 5.3, 3.3 Hz, 1H), 3.59 (d, J = 2.3 Hz, 1H), 
3.52 (d, J = 1.3 Hz, 3H), 3.06 (dd, J = 13.7, 5.2 Hz, 1H), 2.47 (s, 1H), 2.24 – 2.16 (m, 2H), 1.82 – 
1.52 (m, 3H), 1.37 (s, 3H), 1.23 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 190.84, 171.37, 170.35, 
163.11, 158.15, 145.33, 143.67, 139.36, 135.57, 131.17, 130.02, 125.40, 122.72, 114.78, 112.54, 
108.44, 94.75, 72.05, 63.43, 56.63, 56.47, 52.48, 51.35, 44.21, 43.78, 38.45, 35.84, 17.94, 16.81, 
14.85. HRMS calculated for C30H31O10Br [M+Na]
+: 631.1156 (found); 631.1173 (calcd). Melting 





1,4,4a,5,6,6a,7,10,10a,10b-decahydro-2H-benzo[f]isochromene-7-carboxylate (3.39). 1H 
NMR (500 MHz, CDCl3) 8.01 – 7.84 (m, 2H), 7.43 – 7.35 (m, 2H), 7.15 – 7.04 (m, 1H), 6.62 (d, 
J = 2.2 Hz, 1H), 6.39 (dd, J = 1.9, 0.9 Hz, 1H), 5.54 (dd, J = 11.5, 5.2 Hz, 1H), 5.27 (s, 2H), 3.79 
(s, 3H), 3.59 (d, J = 2.2 Hz, 1H), 3.48 (s, 3H), 3.07 (dd, J = 13.7, 5.4 Hz, 1H), 2.47 (s, 1H), 2.27 
(s, 3H), 2.25 – 2.16 (m, 2H), 2.11 (dt, J = 13.0, 2.7 Hz, 1H), 1.76 – 1.60 (m, 3H), 1.37 (s, 3H), 1.23 
(s, 3H). 13C NMR (126 MHz, CDCl3) δ 191.05, 171.41, 170.45, 164.47, 159.93, 145.58, 143.64, 
139.37, 132.91, 130.05, 129.71, 127.53, 125.47, 121.00, 112.87, 108.47, 94.04, 72.07, 63.45, 
56.53, 56.21, 52.41, 51.38, 44.17, 43.81, 38.48, 35.85, 17.98, 16.81, 16.23, 14.86. HRMS 
calculated for C31H34O10 [M+H]
+: 567.2222  (found); 567.2225 (calcd). Melting point: 99-102 °C.  
 Methyl (2S,4aR,6aR,7R,10aR,10bR)-9-((3-fluoro-4-
hydroxybenzoyl)oxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-1,4,4a,5,6,6a,7,10,10a,10b-
decahydro-2H-benzo[f]isochromene-7-carboxylate (3.40). 1H NMR (500 MHz, CDCl3) 7.91 – 
7.76 (m, 2H), 7.47 – 7.32 (m, 2H), 7.07 (t, J = 8.5 Hz, 1H), 6.65 (d, J = 2.2 Hz, 1H), 6.39 (dd, J = 
1.9, 0.9 Hz, 1H), 5.54 (dd, J = 11.5, 5.3 Hz, 1H), 3.80 (s, 3H), 3.59 (d, J = 2.2 Hz, 1H), 3.06 (dd, 
J = 13.6, 5.3 Hz, 1H), 2.47 (s, 1H), 2.25 – 2.16 (m, 2H), 2.12 (dt, J = 12.9, 2.6 Hz, 1H), 1.80 – 1.56 
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(m, 3H), 1.37 (s, 3H), 1.23 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 190.96, 171.44, 170.37, 163.30, 
150.40 (d, J = 239.3 Hz), 148.91 (d, J = 14.2 Hz), 145.31, 143.68, 139.36, 130.09, 128.03, 125.37, 
120.96, 117.74 (d, J = 20.0 Hz), 117.28, 108.43, 72.07, 63.43, 56.47, 52.50, 51.36, 44.21, 43.78, 
38.45, 35.84, 17.93, 16.81, 14.86. HRMS calculated for C28H27O9F [M+H]
+: 527.173 (found); 
527.1711 (calcd). Melting point: 134-136 °C. 
 Methyl (2S,4aR,6aR,7R,10aR,10bR)-9-((3-chloro-4-
hydroxybenzoyl)oxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-1,4,4a,5,6,6a,7,10,10a,10b-
decahydro-2H-benzo[f]isochromene-7-carboxylate (3.41). 1H NMR (500 MHz, CDCl3) 8.12 (d, 
J = 2.0 Hz, 1H), 7.95 (dd, J = 8.4, 1.9 Hz, 1H), 7.45 – 7.33 (m, 2H), 7.09 (d, J = 8.6 Hz, 1H), 6.66 
(d, J = 2.1 Hz, 1H), 6.39 (s, 1H), 6.26 (s, 1H), 5.55 (dd, J = 11.6, 5.3 Hz, 1H), 3.80 (s, 3H), 3.60 
(d, J = 2.2 Hz, 1H), 3.49 (q, J = 7.0 Hz, 0H), 3.05 (dd, J = 13.7, 5.3 Hz, 1H), 2.48 (s, 1H), 2.24 – 
2.16 (m, 2H), 2.16 – 2.02 (m, 1H), 1.78 – 1.59 (m, 3H), 1.37 (s, 3H), 1.23 (s, 3H). 13C NMR (126 
MHz, CDCl3) δ 190.99, 171.50, 170.41, 163.21, 156.17, 145.28, 143.72, 139.40, 131.63, 131.14, 
130.16, 125.34, 121.60, 120.26, 116.32, 108.46, 72.10, 63.36, 56.46, 52.57, 51.36, 44.25, 43.73, 
38.45, 35.83, 17.94, 16.86, 14.87. HRMS calculated for C28H27ClO9 [M+H]
+: 543.1406 (found); 





decahydro-2H-benzo[f]isochromene-7-carboxylate (3.42). 1H NMR (500 MHz, CDCl3) 8.27 (d, 
J = 2.1 Hz, 1H), 7.99 (dd, J = 8.6, 2.1 Hz, 1H), 7.45 – 7.35 (m, 2H), 7.09 (d, J = 8.5 Hz, 1H), 6.65 
(d, J = 2.2 Hz, 1H), 6.39 (dd, J = 1.9, 0.9 Hz, 1H), 5.54 (dd, J = 11.5, 5.3 Hz, 1H), 3.80 (s, 3H), 
3.59 (d, J = 2.2 Hz, 1H), 3.06 (dd, J = 13.6, 5.3 Hz, 1H), 2.47 (s, 1H), 2.20 (td, J = 10.7, 9.6, 4.8 
Hz, 2H), 2.15 – 2.09 (m, 1H), 1.77 – 1.60 (m, 3H), 1.37 (s, 3H), 1.23 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ 190.91, 171.35, 170.33, 162.98, 157.00, 145.30, 143.67, 139.36, 134.63, 131.84, 130.06, 
125.39, 122.04, 116.06, 110.32, 108.43, 72.04, 63.43, 56.47, 52.49, 51.36, 44.22, 43.79, 38.46, 
35.84, 17.94, 16.81, 14.86. HRMS calculated for C28H27O9Br [M+H]
+: 587.0909 (found); 
587.0911 (calcd). Melting point: 144-147 °C. 
Methyl (2S,4aR,6aR,7R,10aR,10bR)-2-(furan-3-yl)-9-((4-
hydroxy-3-methylbenzoyl)oxy)-6a,10b-dimethyl-4,10-dioxo-1,4,4a,5,6,6a,7,10,10a,10b-
decahydro-2H-benzo[f]isochromene-7-carboxylate (3.43). 1H NMR (500 MHz, CDCl3) 7.90 
(dd, J = 2.2, 0.9 Hz, 1H), 7.85 (dd, J = 8.4, 2.2 Hz, 1H), 7.45 – 7.33 (m, 2H), 6.82 (d, J = 8.4 Hz, 
1H), 6.62 (d, J = 2.2 Hz, 1H), 6.38 (dd, J = 2.0, 0.9 Hz, 1H), 5.54 (dd, J = 11.5, 5.3 Hz, 1H), 3.80 
(s, 3H), 3.59 (d, J = 2.3 Hz, 1H), 3.07 (dd, J = 13.7, 5.4 Hz, 1H), 2.47 (s, 1H), 2.28 (s, 3H), 2.25 – 
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2.15 (m, 2H), 2.11 (dt, J = 12.9, 2.5 Hz, 1H), 1.76 – 1.63 (m, 3H), 1.38 (s, 3H), 1.23 (s, 3H). 13C 
NMR (126 MHz, CDCl3) δ  191.16, 171.46, 170.47, 164.43, 158.90, 145.55, 143.66, 139.37, 
133.59, 130.30, 129.78, 125.45, 124.18, 120.55, 114.93, 108.46, 72.10, 63.47, 56.54, 52.43, 51.41, 
44.20, 43.82, 38.50, 35.85, 17.97, 16.82, 15.61, 14.88. HRMS calculated for C29H30O9 [M+H]
+: 
523.1963 (found); 593.1938 (calcd). Melting point: 124-127 °C (decomp). 
Methyl (2S,4aR,6aR,7R,10aR,10bR)-9-((benzofuran-6-
carbonyl)oxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-1,4,4a,5,6,6a,7,10,10a,10b-
decahydro-2H-benzo[f]isochromene-7-carboxylate (3.44). 1H NMR (500 MHz, CDCl3) 8.28 (p, 
J = 0.8 Hz, 1H), 8.01 (dd, J = 8.2, 1.5 Hz, 1H), 7.80 (d, J = 2.2 Hz, 1H), 7.68 (dd, J = 8.2, 0.6 Hz, 
1H), 7.49 – 7.36 (m, 2H), 6.85 (dd, J = 2.2, 1.0 Hz, 1H), 6.68 (d, J = 2.2 Hz, 1H), 6.39 (dd, J = 1.9, 
0.9 Hz, 1H), 5.60 – 5.46 (m, 1H), 3.81 (s, 3H), 3.61 (d, J = 2.2 Hz, 1H), 3.08 (dd, J = 13.7, 5.3 Hz, 
1H), 2.49 (s, 1H), 2.26 – 2.17 (m, 1H), 2.13 (dt, J = 13.2, 2.7 Hz, 1H), 1.79 – 1.58 (m, 2H), 1.39 
(s, 3H), 1.26 (d, J = 2.2 Hz, 5H). 13C NMR (126 MHz, CDCl3) δ 190.96, 171.39, 170.40, 164.78, 
154.30, 148.44, 145.52, 143.65, 139.36, 132.69, 129.94, 125.42, 124.74, 124.25, 121.15, 113.87, 
108.45, 106.92, 72.07, 63.46, 56.51, 52.47, 51.38, 44.20, 43.80, 38.46, 35.85, 17.96, 16.84, 14.86. 
HRMS calculated for C30H28O9 [M+H]
+: 533.1819 (found); 533.1806 (calcd). Melting point: 156-





decahydro-2H-benzo[f]isochromene-7-carboxylate (3.45). 1H NMR (500 MHz, CDCl3) 8.46 – 
8.40 (m, 1H), 8.08 (dd, J = 8.7, 1.8 Hz, 1H), 7.71 (d, J = 2.2 Hz, 1H), 7.57 (dt, J = 8.7, 0.8 Hz, 
1H), 7.48 – 7.34 (m, 2H), 6.86 (dd, J = 2.2, 1.0 Hz, 1H), 6.68 (d, J = 2.2 Hz, 1H), 6.39 (dd, J = 2.0, 
0.9 Hz, 1H), 5.62 – 5.47 (m, 1H), 3.80 (s, 3H), 3.61 (d, J = 2.2 Hz, 1H), 3.08 (dd, J = 13.7, 5.3 Hz, 
1H), 2.49 (s, 1H), 2.20 (ddt, J = 12.6, 6.9, 3.5 Hz, 2H), 2.12 (dt, J = 13.1, 2.7 Hz, 1H), 1.79 – 1.63 
(m, 3H), 1.39 (s, 3H), 1.25 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 191.04, 171.39, 170.42, 164.76, 
157.96, 146.54, 145.52, 143.65, 139.36, 129.92, 127.66, 126.67, 125.41, 124.67, 123.18, 111.63, 
108.45, 107.13, 72.06, 63.45, 56.51, 52.47, 51.38, 44.20, 43.80, 38.47, 35.85, 17.96, 16.84, 14.86. 
HRMS calculated for C30H28O9 [M+H]




decahydro-2H-benzo[f]isochromene-7-carboxylate (3.46). 1H NMR (500 MHz, CDCl3) 8.14 – 
8.02 (m, 2H), 7.48 (d, J = 8.3 Hz, 2H), 7.45 – 7.36 (m, 2H), 6.66 (d, J = 2.2 Hz, 1H), 6.39 (dd, J = 
1.9, 0.9 Hz, 1H), 5.54 (dd, J = 11.5, 5.3 Hz, 1H), 4.80 (d, J = 2.6 Hz, 2H), 3.80 (s, 3H), 3.60 (d, J 
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= 2.3 Hz, 1H), 3.06 (dd, J = 13.7, 5.3 Hz, 1H), 2.47 (s, 1H), 2.24 – 2.16 (m, 2H), 2.12 (dt, J = 13.4, 
2.7 Hz, 1H), 1.90 (s, 1H), 1.77 – 1.64 (m, 3H), 1.37 (s, 3H), 1.24 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ 190.90, 171.40, 170.39, 164.40, 147.14, 145.42, 143.66, 139.37, 130.53, 129.99, 127.37, 
126.55, 125.40, 108.44, 72.06, 64.57, 63.44, 56.49, 52.48, 51.36, 44.19, 43.79, 38.45, 35.84, 17.94, 
16.82, 14.85. HRMS calculated for C29H30O9 [M+H]
+: 523.1964 (found); 523.1963 (calcd). 
Melting point: 115-118°C. 
 Methyl (2S,4aR,6aR,7R,10aR,10bR)-2-(furan-3-yl)-9-((3-
(hydroxymethyl)benzoyl)oxy)-6a,10b-dimethyl-4,10-dioxo-1,4,4a,5,6,6a,7,10,10a,10b-
decahydro-2H-benzo[f]isochromene-7-carboxylate (3.47). 1H NMR (500 MHz, CDCl3) 8.11 (d, 
J = 1.7 Hz, 1H), 8.03 (d, J = 7.8 Hz, 1H), 7.64 (d, J = 7.6 Hz, 1H), 7.48 (t, J = 7.7 Hz, 1H), 7.43 – 
7.37 (m, 2H), 6.66 (d, J = 2.1 Hz, 1H), 6.39 (d, J = 1.8 Hz, 1H), 5.54 (dd, J = 11.5, 5.3 Hz, 1H), 
4.77 (s, 2H), 3.80 (s, 3H), 3.60 (d, J = 2.1 Hz, 1H), 3.06 (dd, J = 13.7, 5.4 Hz, 1H), 2.47 (s, 1H), 
2.24 – 2.07 (m, 3H), 1.85 (s, 1H), 1.77 – 1.63 (m, 3H), 1.37 (s, 3H), zj1.24 (s, 3H). 13C NMR (126 
MHz, CDCl3) δ 190.87, 171.38, 170.37, 164.47, 145.45, 143.67, 141.56, 139.38, 132.31, 129.98, 
129.49, 128.90, 128.56, 128.52, 125.44, 108.45, 72.06, 64.63, 63.49, 56.51, 52.46, 51.38, 44.22, 
43.82, 38.48, 35.86, 17.97, 16.82, 14.86.HRMS calculated for C29H30O9 [M+H]
+: 523.1959 





decahydro-2H-benzo[f]isochromene-7-carboxylate (3.48). 1H NMR (500 MHz, CDCl3) 8.17 – 
8.00 (m, 2H), 7.47 – 7.43 (m, 2H), 7.41 (dd, J = 1.6, 0.9 Hz, 1H), 7.39 (t, J = 1.7 Hz, 1H), 6.66 (d, 
J = 2.1 Hz, 1H), 6.39 (dd, J = 1.9, 0.9 Hz, 1H), 5.60 – 5.48 (m, 1H), 4.54 (s, 2H), 3.80 (s, 3H), 3.60 
(d, J = 2.3 Hz, 1H), 3.42 (s, 3H), 3.07 (dd, J = 13.7, 5.3 Hz, 1H), 2.47 (s, 1H), 2.20 (ddd, J = 12.2, 
6.4, 3.1 Hz, 2H), 2.12 (dt, J = 13.1, 2.7 Hz, 1H), 1.80 – 1.62 (m, 3H), 1.38 (s, 3H), 1.24 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 190.90, 171.38, 170.38, 164.42, 145.43, 144.74, 143.66, 139.36, 
130.42, 129.97, 127.42, 127.28, 125.41, 108.44, 73.90, 72.05, 63.45, 58.45, 56.49, 52.47, 51.37, 
44.19, 43.80, 38.45, 35.84, 17.95, 16.82, 14.85. HRMS calculated for C30H32O9 [M+Na]
+: 
559.1922 (found); 559.1944 (calcd). Melting point: 135-140 °C. 
Methyl (2S,4aR,6aR,7R,10aR,10bR)-9-((4-
carbamoylbenzoyl)oxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-
1,4,4a,5,6,6a,7,10,10a,10b-decahydro-2H-benzo[f]isochromene-7-carboxylate (3.49). 1H 
NMR (500 MHz, CDCl3) 8.26 – 8.09 (m, 2H), 7.96 – 7.84 (m, 2H), 7.47 – 7.30 (m, 2H), 6.70 (d, 
J = 2.2 Hz, 1H), 6.39 (dd, J = 1.9, 0.9 Hz, 1H), 6.11 (d, J = 21.1 Hz, 1H), 5.67 (s, 1H), 5.55 (dd, J 
= 11.6, 5.5 Hz, 1H), 3.81 (s, 3H), 3.80 (s, 1H), 3.61 (d, J = 2.2 Hz, 1H), 3.06 (dd, J = 13.7, 5.3 Hz, 
1H), 2.48 (s, 1H), 2.26 – 2.14 (m, 2H), 2.16 – 2.09 (m, 1H), 1.46 (s, 1H), 1.38 (s, 3H), 1.35 (s, 
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1H), 1.25 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 190.73, 171.45, 170.31, 167.89, 163.67, 145.28, 
143.70, 139.37, 137.95, 131.36, 130.58, 130.26, 127.60, 125.38, 108.43, 72.02, 63.48, 56.47, 
52.53, 51.36, 44.25, 43.81, 38.45, 35.86, 17.94, 16.83, 14.86. HRMS calculated for C29H30NO9 
[M+Na]+: 558.1728 (found); 558.1740 (calcd). Melting point: 201-203 °C. 
Methyl (2S,4aR,6aR,7R,10aR,10bR)-9-((3-
carbamoylbenzoyl)oxy)-2-(furan-3-yl)-6a,10b-dimethyl-4,10-dioxo-
1,4,4a,5,6,6a,7,10,10a,10b-decahydro-2H-benzo[f]isochromene-7-carboxylate (3.50). 1H 
NMR (500 MHz, CDCl3) 8.51 (dt, J = 4.1, 1.7 Hz, 1H), 8.25 (ddt, J = 7.8, 3.2, 1.4 Hz, 1H), 8.14 
(dq, J = 7.8, 1.4 Hz, 1H), 7.59 (td, J = 7.8, 1.5 Hz, 1H), 7.44 – 7.36 (m, 2H), 6.68 (d, J = 2.2 Hz, 
1H), 6.54 – 6.40 (m, 1H), 6.38 (dt, J = 1.8, 0.9 Hz, 1H), 6.19 – 5.99 (m, 1H), 5.53 (ddd, J = 13.2, 
8.3, 5.4 Hz, 1H), 3.80 (d, J = 4.1 Hz, 3H), 3.62 (d, J = 2.2 Hz, 1H), 3.04 (td, J = 13.5, 12.9, 5.3 Hz, 
1H), 2.50 (s, 1H), 2.20 (ddd, J = 16.0, 9.1, 3.2 Hz, 2H), 2.12 (dd, J = 13.3, 3.6 Hz, 1H), 1.81 – 1.62 
(m, 2H), 1.44 (s, 1H), 1.36 (s, 3H), 1.23 (s, 3H). 13C NMR (126 MHz, CDCl3) δ  190.82, 171.43, 
170.35, 168.05, 163.77, 145.24, 143.68, 139.40, 133.96, 133.46, 133.07, 130.31, 129.21, 128.84, 
128.70, 125.35, 108.44, 72.02, 63.34, 56.40, 52.52, 51.26, 44.24, 43.71, 38.40, 35.82, 17.93, 16.82, 
14.84. HRMS calculated for C29H30NO9 [M+Na]
+: 558.1754 (found); 558.1740 (calcd). Melting 





benzo[f]isochromen-9-yl 3-oxoisoindoline-5-carboxylate (3.51). 1H NMR (500 MHz, CDCl3) 
8.69 – 8.56 (m, 1H), 8.31 (ddd, J = 7.9, 2.8, 1.6 Hz, 1H), 7.61 (dd, J = 7.9, 0.9 Hz, 1H), 7.55 (s, 
1H), 7.42 (ddt, J = 2.6, 1.8, 0.8 Hz, 1H), 7.39 (t, J = 1.7 Hz, 1H), 6.70 (d, J = 2.2 Hz, 1H), 6.39 
(dd, J = 1.9, 0.9 Hz, 1H), 5.58 – 5.51 (m, 1H), 4.56 (d, J = 2.7 Hz, 2H), 3.81 (s, 2H), 3.62 (d, J = 
2.2 Hz, 1H), 3.06 (dd, J = 13.8, 5.5 Hz, 1H), 2.49 (s, 1H), 2.25 – 2.17 (m, 2H), 2.16 – 2.08 (m, 
1H), 2.01 (s, 1H), 1.84 – 1.61 (m, 3H), 1.38 (s, 3H), 1.25 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 
190.72, 171.39, 170.54, 170.30, 163.77, 148.90, 145.30, 143.67, 139.36, 133.48, 132.80, 130.23, 
128.75, 126.06, 125.40, 123.69, 108.44, 72.04, 63.41, 56.43, 52.50, 51.32, 45.89, 44.22, 43.75, 
38.40, 35.85, 17.94, 16.81, 14.84. HRMS calculated for C30H29O9N [M+H]
+: 548.1910 (found); 
548.19151 (calcd). Melting point: 189-194 °C. 
(2S,4aR,6aR,7R,10aR,10bR)-2-(furan-3-yl)-7-
(methoxycarbonyl)-6a,10b-dimethyl-4,10-dioxo-1,4,4a,5,6,6a,7,10,10a,10b-decahydro-2H-
benzo[f]isochromen-9-yl 1-oxoisoindoline-5-carboxylate (3.52). 1H NMR (500 MHz, CDCl3) 
8.26 – 8.19 (m, 2H), 7.97 (d, J = 8.3 Hz, 1H), 7.60 (s, 1H), 7.45 – 7.25 (m, 3H), 6.71 (d, J = 2.1 
Hz, 1H), 6.39 (dd, J = 2.0, 0.9 Hz, 1H), 5.54 (dd, J = 11.5, 5.4 Hz, 1H), 4.54 (s, 2H), 3.81 (s, 3H), 
3.62 (d, J = 2.2 Hz, 1H), 3.07 (td, J = 13.5, 6.8 Hz, 1H), 2.50 (s, 1H), 2.20 (td, J = 11.5, 10.0, 4.7 
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Hz, 2H), 2.14 – 2.09 (m, 1H), 2.01 (s, 0H), 1.76 (ddd, J = 14.3, 10.7, 5.4 Hz, 2H), 1.69 (d, J = 13.1 
Hz, 1H), 1.38 (s, 3H), 1.25 (s, 3H).z 13C NMR (126 MHz, CDCl3) δ 190.79, 171.32, 170.48, 
170.32, 163.90, 145.27, 143.69, 143.57, 139.37, 136.85, 131.43, 130.30, 130.20, 125.37, 125.31, 
124.05, 108.43, 72.00, 63.42, 56.43, 52.53, 51.31, 45.65, 44.26, 43.76, 38.42, 35.85, 17.93, 16.82, 
14.84. HRMS calculated for C30H29O9N [M+NH4]
+: 565.2198 (found); 565.2186 (calcd). Melting 
point: 229-232 °C. 
General procedure for MOM-protection of benzoic acids: Protection of the phenolic acids 
were accomplished following the published protection method.7 To a solution of 3’X-
4’hydroxybenzoic acid (1.6 mmol) in DCM (5 mL) stirring under Ar at 0 °C was added N,N-
diisopropylethylamine (DIPEA) (1.5 mL, 5.5 eq.) followed by the dropwise addition of 
methoxymethylchloride (0.7 mL, 5.5 eq.). This reaction was allowed to stir at r.t. for 48 h before 
being quenched with sat. aq. NH4Cl solution (20 mL) and extracted into DCM (3x). The combined 
organic layers were dried over Na2SO4 and the solvent was removed under reduced pressure to 
afford the crude ether ester. To a solution of the crude ester in MeOH (20mL), a 15% aq. NaOH 
solution was added and the mixture was heated for 70 °C for 3 h. After cooling the reaction to 0 
°C, the pH was adjusted to 5 with 6M HCl to precipitate a white solid. This solid was filtered to 
give the desired MOM-protected phenolic acid. 
3-Fluoro-4-(methoxymethoxy)benzoic acid. 1H NMR (400 MHz, CDCl3) 
7.90 – 7.80 (m, 2H), 7.26 (d, J = 16.5 Hz, 1H), 5.31 (s, 2H), 3.53 (s, 3H). 13C NMR (101 MHz, 
DMSO) δ 165.99, 151.48 (d, J = 245.0 Hz), 148.21 (d, J = 10.7 Hz), 126.44 (d, J = 3.1 Hz), 124.69 
(d, J = 6.2 Hz), 116.85 (d, J = 19.6 Hz), 116.67, 94.67, 56.09. HRMS calculated for C9H9O4F [M-
H]-: 199.0457 (found); 199.0412 (calcd). Melting point: 163-164 °C.  
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3-Chloro-4-(methoxymethoxy)benzoic acid. 1H NMR (400 MHz, CDCl3) δ 
8.14 (d, J = 2.1 Hz, 1H), 7.97 (dd, J = 8.8, 2.1 Hz, 1H), 7.24 (d, J = 8.7 Hz, 1H), 5.34 (s, 2H), 3.53 
(s, 3H).  13C NMR (101 MHz, CDCl3) δ 169.80, 157.22, 132.43, 130.36, 123.56, 123.29, 114.98, 
94.85, 56.63. HRMS calculated for C9H9O4Cl [M-H]
-
: 215.0154 (found); 215.0117 (calcd). 
Melting point: 169-170 °C. 
3-Bromo-4-(methoxymethoxy)benzoic acid. 1H NMR (400 MHz, CDCl3) 
8.30 (d, J = 2.1 Hz, 1H), 8.00 (dd, J = 8.7, 2.1 Hz, 1H), 7.20 (d, J = 8.7 Hz, 1H), 5.33 (s, 2H), 3.53 
(s, 3H). 13C NMR (101 MHz, CDCl3) δ 169.88, 158.11, 135.58, 131.09, 123.70, 114.70, 112.51, 
94.81, 56.64. HRMS calculated for C9H9O4Br [M-H]
-
: 258.9652 (found); 258.9611 (calcd). 
Melting point: 167-168 °C. 
4-(methoxymethoxy)-3-methylbenzoic acid. 1H NMR NMR (400 MHz, 
DMSO-d6) δ 7.80 – 7.70 (m, 2H), 7.10 (d, J = 9.2 Hz, 1H), 5.30 (s, 2H), 3.39 (s, 3H), 2.51 (p, J = 
1.9 Hz, 3H). 13C NMR (101 MHz, DMSO) δ 167.07, 158.32, 131.75, 128.80, 126.44, 123.36, 
112.92, 93.72, 55.78, 15.89. HRMS calculated for C10H12O4 [M-H]
-
: 195.0708 (found); 195.0657 
(calcd). Melting point: 136-138 °C. 
3-(((tert-butyldimethylsilyl)oxy)methyl)benzoic acid.  To a mixture of 3-
hydroxymethyl benzoic acid (304 mg, 2.0 mmol) in DMF (4mL) was added tert-
Butyldimethylsilyl chloride (724 mg, 4.8 mmol), and imidazaole (300 mg, 4.4 mmol). The reaction 
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mixture was stirred at r.t. overnight before being quenched with acetone (20mL). The reaction 
mixture was chilled in the refrigerator for 20 minutes and then the white precipitate was filtered. 
The solvent was evaporated, and the crude product was dissolved in THF (10mL) and sat. aq. 
NaHCO3 solution (10mL) to hydrolyze the formed silyl ester. The reaction was allowed to stir at 
r.t. overnight followed by evaporation of the THF. The resulting mixture was acidified with 1N 
HCl (30 mL) and extracted with Et2O (3x 20mL). The combined organic extracts were washed 
with brine (50 mL), dried (Na2SO4) and concentrated. The resulting clear, pale yellow oil was used 
without further purification. 1H NMR (400 MHz, CDCl3) δ  8.06 (dp, J = 1.5, 0.8 Hz, 1H), 8.00 
(ddt, J = 7.9, 1.9, 1.0 Hz, 1H), 7.61 (ddq, J = 7.6, 2.0, 0.9 Hz, 1H), 7.45 (t, J = 7.7 Hz, 1H), 4.80 
(t, J = 0.8 Hz, 2H), 0.96 (d, J = 0.8 Hz, 9H), 0.12 (d, J = 0.6 Hz, 6H). 13C NMR (101 MHz, CDCl3) 
δ 171.94, 142.04, 131.46, 129.22, 128.80, 128.46, 127.74, 64.46, 25.94, 18.47, -5.25. HRMS 
calculated for C14H22O3Si [M-H]
-
: 265.1302 (found); 265.1265 (calcd). Melting point: 40-42 °C. 
Compounds from Chapter 4: 
Methyl (2S,4aR,6aR,7R,9S,10aR,10bS)-9-acetoxy-2-(furan-3-yl)-4-
hydroxy-6a,10b-dimethyl-10-oxododecahydro-2H-benzo[f]isochromene-7-carboxylate (4.1). 
To a dry flask flushed with Ar salvinorin A (1g, 2.31 mmol) was added and dissolved in THF 
(100mL). The reaction mixture was cooled with a dry ice/acetone bath to -78°C. Upon cooling 
completely, a 1M solution of DIBALH in hexanes was added dropwise (18.5 mmol, 18.5 mL). 
The reaction mixture was kept stirring and maintained at -78°C until TLC indicated complete 
consumption of starting material, usually 4 hours. Reaction flask was moved to an ice/water bath 
and was quenched at 0 °C with sat. aq. NH4Cl solution (100mL). The resulting mixture stirred for 
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20 minutes and was allowed to reach room temperature. The mixture was then extracted with 
EtOAc (3 x 150 mL). The combined organic extracts were washed with brine (200 mL), dried 
(Na2SO4) and concentrated. The crude mixture of lactols (4.1 and 4.2, 0.830g) was carried into the 
next acetylation reaction without further purification. Compound previously described; 
characterization matches literature. 4.1 was purified via FCC (40% EtOAC in DCM) for 
pharmacological assays. HRMS calculated for C23H30O8 [M+Na]
+: 457.1825 (found); 457.1838 
(calcd). Melting point: 170-171 °C. 
Methyl (2S,4aR,6aR,7R,9S,10aR,10bS)-2-(furan-3-yl)-4,9-dihydroxy-
6a,10b-dimethyl-10-oxododecahydro-2H-benzo[f]isochromene-7-carboxylate (4.2). 1H NMR 
(400 MHz, CDCl3) 7.40 – 7.35 (m, 2H), 6.52 – 6.27 (m, 1H), 5.34 – 5.07 (m, 1H), 4.91 (dd, J = 
11.6, 2.4 Hz, 1H), 4.83 (dd, J = 8.7, 6.1 Hz, 1H), 4.26 – 3.95 (m, 1H), 3.70 (s, 3H), 3.67 (dd, J = 
13.4, 3.4 Hz, 1H), 3.05 (d, J = 6.2 Hz, 1H), 2.70 (dt, J = 13.8, 3.0 Hz, 1H), 2.43 (dtd, J = 13.4, 7.9, 
3.2 Hz, 1H), 2.20 (ddd, J = 33.5, 13.0, 2.4 Hz, 1H), 2.08 (s, 1H), 2.05 (s, 1H), 2.04 – 1.96 (m, 1H), 
1.83 (dq, J = 13.6, 3.5 Hz, 1H), 1.72 (dt, J = 13.3, 3.4 Hz, 1H), 1.65 (s, 1H), 1.57 (dd, J = 13.4, 4.2 





diacetate (4.3). To a flask containing the crude mix of 4.1 and 4.2 (0.83g, 2.1 mmol) in DCM 
(100mL) was added DMAP (0.516 g, 4.2 mmol) and Ac2O (0.4mL, 4.2mmol). The reaction 
mixture was stirred at r.t. overnight and was then quenched with MeOH (25mL). The quenched 
reaction was allowed to stir for 20 min. and followed by solvent evaporation. The crude residue 
was dissolved in DCM (100mL) and sat. aq. NaHCO3 solution (100mL) and organic layers 
separated. Following further extraction with DCM (2 x 50 mL) the organic layers were combined 
and washed with H2O (90 mL) and 1M HCl (10 mL). The combined organic extracts were washed 
with brine (100 mL), dried (Na2SO4) and concentrated to afford 4.3 (0.933 g, 93% yield).  
1H NMR 
(400 MHz, CDCl3) δ 7.38 – 7.31 (m, 2H), 6.37 (s, 1H), 5.83 (d, J = 8.0 Hz, 1H), 5.22 – 5.06 (m, 
1H), 4.95 (dd, J = 11.2, 2.1 Hz, 1H), 3.71 (d, J = 1.1 Hz, 3H), 2.76 (dd, J = 11.1, 5.9 Hz, 1H), 2.27 
(dd, J = 13.6, 8.7 Hz, 2H), 2.15 (d, J = 1.2 Hz, 3H), 2.10 (d, J = 1.2 Hz, 3H), 2.08 (s, 1H), 1.72 (d, 
J = 13.2 Hz, 1H), 1.62 (d, J = 12.1 Hz, 0H), 1.55 (d, J = 5.1 Hz, 3H), 1.46 (s, 3H), 1.37 (d, J = 8.6 
Hz, 2H), 1.30 – 1.16 (m, 2H), 1.09 (s, 2H). 13C NMR (126 MHz, CDCl3) δ 202.24, 171.84, 169.97, 
169.67, 143.05, 139.39, 125.62, 108.94, 92.46, 75.06, 66.98, 65.40, 53.76, 51.90, 49.62, 44.34, 
42.44, 38.70, 35.96, 30.89, 21.17, 20.68, 17.58, 16.81, 14.89. HRMS calculated for C25H32O9 
[M+Na]+: 499.1937 (found); 499.1944 (calcd). Melting point: 184-185 °C. 
Methyl (2S,6aR,7R,9S,10aS,10bR)-9-acetoxy-2-(furan-3-yl)-6a,10b-
dimethyl-10-oxo-1,5,6,6a,7,8,9,10,10a,10b-decahydro-2H-benzo[f]isochromene-7-
carboxylate (4.4). Compound previously described; characterization matches literature. 1H NMR 
(400 MHz, CDCl3) δ  7.46 – 7.33 (m, 2H), 6.37 (dd, J = 1.9, 0.9 Hz, 1H), 6.27 (d, J = 1.7 Hz, 1H), 
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5.12 (ddd, J = 10.6, 8.6, 1.0 Hz, 1H), 4.78 (dd, J = 11.6, 1.9 Hz, 1H), 3.70 (s, 3H), 2.79 – 2.66 (m, 
1H), 2.39 – 2.22 (m, 4H), 2.16 (s, 3H), 2.13 (s, 1H), 1.94 (ddd, J = 14.6, 4.6, 2.6 Hz, 1H), 1.70 
(ddd, J = 13.0, 4.3, 2.5 Hz, 1H), 1.53 (d, J = 0.7 Hz, 3H), 1.49 (dd, J = 13.4, 4.6 Hz, 1H), 1.44 – 
1.34 (m, 1H), 1.15 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 202.97, 172.01, 169.91, 143.20, 139.31, 
137.05, 125.80, 117.01, 108.66, 75.17, 66.59, 65.44, 53.45, 51.80, 44.34, 42.76, 40.01, 34.06, 
30.59, 22.74, 22.59, 20.66, 15.39. HRMS calculated for C23H28O7 [M+Na]
+: 439.1727 (found); 
439.1733 (calcd). Melting point: 77-79 °C. 
Methyl (2S,6aR,7R,9S,10aR,10bS)-9-acetoxy-2-(furan-3-yl)-6a,10b-
dimethyl-10-oxododecahydro-2H-benzo[f]isochromene-7-carboxylate (4.5). Synthesized as 
previously described, following General Method A (below) using triethylsilane. Alternate reaction 
conditions: To a flask containing 4.3 (0.105 mmol, 0.05 g) under Ar was added CH3CN (3 mL) 
and triethylsilane (0.315 mmol, 3 equiv.). The reaction flask was cooled to 0°C with an ice bath 
and trimethylsilyl trifluoromethanesulfonate (0.21 mmol, 2 equiv.) was added dropwise. Reaction 
was monitored by TLC for consumption of starting material, generally within an hour, at which 
time it was quenched with sat. aq. NaHCO3 solution (3 mL) and extracted with EtOAc (3x 5 mL). 
The combined organic extracts were washed with brine (50 mL), dried (Na2SO4) and concentrated. 
Purification by FCC (30% EtOAc in Pentane) afforded 4.5 as a white solid (49% yield). Compound 
previously described; characterization matches literature. 1H NMR (400 MHz, CDCl3) δ 7.33 (d, 
J = 1.4 Hz, 2H), 6.35 (t, J = 1.5 Hz, 1H), 5.22 – 5.07 (m, 1H), 4.71 (dd, J = 11.5, 2.4 Hz, 1H), 3.71 
(s, 3H), 3.58 (d, J = 7.6 Hz, 2H), 2.83 – 2.70 (m, 1H), 2.36 – 2.21 (m, 2H), 2.16 (s, 3H), 2.13 (dd, 
J = 13.1, 2.5 Hz, 1H), 2.10 (d, J = 2.3 Hz, 1H), 1.73 – 1.59 (m, 2H), 1.54 – 1.41 (m, 1H), 1.39 (s, 
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3H), 1.38 – 1.24 (m, 2H), 1.24 – 1.16 (m, 1H), 1.09 (s, 3H). HRMS calculated for C23H30O7 
[M+Na]+: 441.1873 (found); 441.1889 (calcd). Melting point: 126-128 °C. 
General Methods of Substituting at 17: 
General Method A: A solution of 4.3 (40 mg) and the appropriate nucleophile (5 equiv.)  in 
DCM (3mL) was cooled to -78 °C with a dry ice/acetone bath. BF3•Et2O (0.02 mL, 1.2 equiv.) 
was added dropwise to the stirring reaction. Reaction was kept at -78 °C and monitored for 
consumption of 4.3 by TLC, usually 1h, and was then transferred to ice water bath for another 
hour. Reaction was quenched at 0 °C with sat. aq. NaHCO3 solution. The resulting mixture stirred 
for 30 minutes and was then extracted with DCM (3 x 25 mL). The combined organic extracts 
were washed with brine (50 mL), dried (Na2SO4) and concentrated.  The resulting solid was 
purified by flash column chromatography.  
General Method B: A solution of 4.3 (40 mg) in the appropriate alcohol (neat, 3mL) was cooled 
to 0-5°C with an ice/water bath. HCl in dioxane (4M solution, 20 equiv.) was added dropwise to 
the stirring reaction. Reaction was kept between 0-5 °C (to prevent dioxane freezing) and 
monitored for consumption of 4.3 by TLC, usually 20-40 min. Reaction was quenched at 0 °C with 
solid K2CO3 (0.150 g)  and stirred for 20 min. The resulting mixture was filtered through a short 
pad of celite, washed with DCM, and concentrated. The K2CO3 cleaved the C2 acetate, so the 
resulting crude mixture was acetylated with Ac2O and DMAP (1.1 equiv. each, 0.01 mL and 0.12 
g, respectively) in DCM (4 mL) overnight. MeOH (5mL) was added to quench Ac2O, the reaction 
mixture stirred for 20 min, and the solvent was evaporated. The reaction mixture was purified by 
flash column chromatography. 
General Method C: A solution of 4.3 (40 mg) and the appropriate alcohol (10 equiv.)  in THF 
(1mL) was cooled to 0 °C with an ice bath. HCl in Dioxane (4M solution, 10 equiv.) was added 
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dropwise to the stirring reaction. Reaction was kept at 0°C until 4.3 and monitored for consumption 
of 4.3 by TLC, usually 20-40 min. Reaction was quenched at 0 °C with sat. aq. NaHCO3 solution. 
The resulting mixture stirred for 10 minutes and was then extracted with EtOAc (3 x 25 mL). The 
combined organic extracts were washed with brine (50 mL), dried (Na2SO4) and concentrated.  
The resulting mixture was purified by flash column chromatography. 
Methyl (2S,4S,4aR,6aR,7R,9S,10aR,10bS)-9-acetoxy-4-cyano-2-
(furan-3-yl)-6a,10b-dimethyl-10-oxododecahydro-2H-benzo[f]isochromene-7-carboxylate 
(4.6). Compound 4.6 was prepared using General Method A, described above, with 
Trimethylsilyl cyanide as the nucleophile. FCC (30% EtOAc in Pentane) to afford 4.6 as a white 
solid (38% yield). 1H NMR (500 MHz, CDCl3) δ 7.42 – 7.32 (m, 2H), 6.36 (dd, J = 1.9, 0.9 Hz, 
1H), 5.12 (ddd, J = 10.7, 9.0, 1.0 Hz, 1H), 5.08 (dd, J = 11.6, 2.2 Hz, 1H), 4.62 (d, J = 4.9 Hz, 1H), 
3.72 (s, 3H), 3.49 (d, J = 5.1 Hz, 1H), 2.80 – 2.71 (m, 1H), 2.32 – 2.30 (m, 1H), 2.29 – 2.26 (m, 
2H), 2.16 (s, 3H), 2.03 (s, 1H), 1.83 – 1.66 (m, 2H), 1.66 – 1.65 (m, 3H), 1.47 – 1.43 (m, 1H), 1.32 
– 1.19 (m, 2H), 1.14 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 201.54, 171.58, 169.91, 143.29, 
139.52, 125.28, 117.67, 108.63, 74.89, 65.70, 65.60, 65.57, 53.68, 51.96, 46.46, 43.85, 42.61, 
38.77, 34.91, 30.69, 20.60, 19.64, 16.90, 14.85. IR: peak at 1730.03. HRMS calculated for 
C24H29NO7 [M+NH4]





(4.7). Compound 4.7 was prepared using General Method A, described above, with 
allyltrimethylsilane as the nucleophile. FCC (10% 20% EtOAc in Pentane) to afford 4.7 as a 
white solid (37% yield). 1H NMR (500 MHz, CDCl3) δ 7.33 (d, J = 2.0 Hz, 2H), 6.39 – 6.29 (m, 
1H), 5.86 (ddt, J = 17.0, 10.1, 6.8 Hz, 1H), 5.12 (dd, J = 10.9, 9.6 Hz, 1H), 5.08 (dd, J = 17.1, 1.8 
Hz, 1H), 5.04 (dd, J = 10.1, 1.7 Hz, 1H), 4.80 (dd, J = 11.4, 2.2 Hz, 1H), 3.84 (ddd, J = 11.5, 5.6, 
3.0 Hz, 1H), 3.71 (s, 3H), 2.80 – 2.71 (m, 1H), 2.71 – 2.60 (m, 1H), 2.29 – 2.25 (m, 2H), 2.24 (d, 
J = 5.1 Hz, 0H), 2.21 (dd, J = 13.1, 2.2 Hz, 1H), 2.15 (s, 3H), 2.08 (s, 1H), 1.74 – 1.61 (m, 4H), 
1.52 (qd, J = 12.7, 4.0 Hz, 1H), 1.45 (s, 3H), 1.38 – 1.30 (m, 1H), 1.19 (t, J = 12.2 Hz, 1H), 1.09 
(s, 3H).13C NMR (126 MHz, CDCl3) δ 202.32, 171.95, 169.86, 142.86, 139.05, 136.59, 127.04, 
116.13, 109.06, 77.61, 75.04, 66.59, 60.68, 53.68, 51.78, 48.30, 44.60, 42.81, 39.63, 35.03, 32.87, 
30.80, 20.82, 20.63, 17.15, 16.71. HRMS calculated for C26H34O7 [M+H]
+: 459.2381 (found); 
459.2377 (calcd). Melting point: 66-68 °C. 
Methyl (2S,4R,4aR,6aR,7R,9S,10aR,10bS)-9-acetoxy-2-(furan-3-
yl)-6a,10b-dimethyl-10-oxo-4-(2-oxopropyl)dodecahydro-2H-benzo[f]isochromene-7-
carboxylate (4.8). Compound 4.8 was prepared using General Method A, described above, 
with 2-(Trimethylsiloxy)propene as the nucleophile. FCC (40% EtOAc in Pentane) to afford 4.8 
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as a white solid (57% yield). 1H NMR (500 MHz, CDCl3) δ 7.33 (dq, J = 4.7, 1.6 Hz, 2H), 6.34 – 
6.30 (m, 1H), 5.14 – 5.06 (m, 1H), 4.79 (ddd, J = 33.7, 11.5, 2.2 Hz, 1H), 4.07 (s, 1H), 3.87 (dd, J 
= 10.8, 5.7 Hz, 1H), 3.71 (d, J = 1.6 Hz, 3H), 2.83 (d, J = 17.6 Hz, 1H), 2.79 – 2.71 (m, 1H), 2.64 
– 2.48 (m, 1H), 2.30 – 2.20 (m, 2H), 2.14 (s, 3H), 2.06 (d, J = 27.0 Hz, 1H), 1.95 (s, 2H), 1.78 – 
1.55 (m, 3H), 1.53 – 1.43 (m, 1H), 1.40 (s, 2H), 1.29 (s, 0H), 1.18 (s, 3H), 1.13 (t, J = 12.4 Hz, 
1H), 1.07 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 210.54, 202.17, 171.88, 169.90, 142.97, 139.25, 
126.76, 108.81, 74.88, 71.59, 66.38, 61.03, 53.73, 51.76, 48.43, 45.37, 42.77, 39.46, 37.97, 34.93, 
31.28, 30.74, 27.27, 20.61, 16.65, 16.42. HRMS calculated for C26H34O8 [M+H]
+: 475.2325, 
(found); 475.2327 (calcd). Melting point: 109-111 °C. 
Methyl (2S,4R,4aR,6aR,7R,9S,10aR,10bS)-9-acetoxy-2-(furan-3-
yl)-6a,10b-dimethyl-10-oxo-4-(2-oxo-2-phenylethyl)dodecahydro-2H-benzo[f]isochromene-
7-carboxylate (4.9). Compound 4.9 was prepared using General Method A, described above, 
with 1-Phenyl-1-trimethylsiloxyethylene as the nucleophile. FCC (30% EtOAc in Pentane) to 
afford 4.9 as a white solid (24% yield). 1H NMR (500 MHz, CDCl3) 8.01 – 7.88 (m, 2H), 7.61 – 
7.53 (m, 1H), 7.52 – 7.43 (m, 2H), 7.28 (t, J = 1.7 Hz, 1H), 7.23 (dd, J = 1.6, 0.8 Hz, 1H), 6.21 
(dd, J = 1.8, 0.9 Hz, 1H), 5.20 – 5.07 (m, 1H), 4.88 (dd, J = 11.5, 2.1 Hz, 1H), 4.60 (ddd, J = 9.4, 
5.6, 3.4 Hz, 1H), 3.71 (s, 3H), 3.64 (dd, J = 15.3, 9.6 Hz, 1H), 2.91 (dd, J = 15.4, 3.4 Hz, 1H), 2.84 
– 2.69 (m, 1H), 2.35 – 2.20 (m, 3H), 2.16 (s, 3H), 2.10 (s, 1H), 1.81 – 1.73 (m, 1H), 1.73 – 1.66 
(m, 1H), 1.55 (s, 3H), 1.50 – 1.40 (m, 2H), 1.25 (s, 1H), 1.25 – 1.18 (m, 1H), 1.10 (s, 3H).13C 
NMR (126 MHz, CDCl3) δ 202.33, 198.75, 171.90, 169.87, 142.81, 139.10, 137.16, 133.15, 
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128.67, 128.20, 126.59, 108.91, 75.03, 73.72, 66.34, 61.41, 53.60, 51.84, 47.96, 44.30, 42.75, 
39.39, 37.82, 34.91, 30.79, 20.64, 20.59, 16.83, 16.73. HRMS calculated for C31H36O8 [M+Na]
+: 
559.2274  (found); 559.2307(calcd). Melting point: 185-186 °C. 
Methyl (2S,4S,4aR,6aR,7R,9S,10aR,10bS)-9-acetoxy-4-
(benzyloxy)-2-(furan-3-yl)-6a,10b-dimethyl-10-oxododecahydro-2H-benzo[f]isochromene-
7-carboxylate (4.10). Compound 4.10 was prepared using General Method A, described above, 
with Benzyl alcohol as the nucleophile. FCC (18% 20% EtOAc in Pentane) to afford 4.10 as 
a white solid (28% yield). 1H NMR (500 MHz, CDCl3) δ 7.37 – 7.31 (m, 6H), 7.28 (ddd, J = 6.8, 
3.4, 2.1 Hz, 1H), 6.35 (dd, J = 1.8, 0.9 Hz, 1H), 5.12 (ddd, J = 10.7, 9.1, 0.9 Hz, 1H), 5.00 (dd, J = 
11.7, 2.2 Hz, 1H), 4.79 (dd, J = 7.9, 4.6 Hz, 2H), 4.47 (d, J = 12.4 Hz, 1H), 3.70 (s, 3H), 2.74 (dd, 
J = 9.3, 7.5 Hz, 1H), 2.26 (td, J = 9.5, 2.1 Hz, 2H), 2.21 (dd, J = 13.1, 2.3 Hz, 1H), 2.15 (s, 3H), 
2.04 (s, 1H), 1.82 – 1.72 (m, 1H), 1.69 (dt, J = 13.3, 3.2 Hz, 1H), 1.65 – 1.58 (m, 2H), 1.45 (ddd, 
J = 12.6, 3.5, 1.9 Hz, 1H), 1.39 (dq, J = 13.7, 2.7 Hz, 1H), 1.29 – 1.21 (m, 2H), 1.12 (s, 3H). 13C 
NMR (126 MHz, CDCl3) δ 202.19, 171.98, 169.93, 143.02, 139.19, 138.51, 128.29, 127.33, 
127.18, 126.65, 108.89, 100.66, 75.03, 69.59, 66.15, 60.99, 53.85, 51.79, 48.63, 44.61, 42.76, 
39.46, 34.67, 30.76, 20.65, 20.14, 16.93, 16.72.HRMS calculated for C30H36O8 [M+Na]
+: 





7-carboxylate (4.10). Compound 4.10 was prepared using General Method A, described above, 
with Benzyl alcohol as the nucleophile. FCC (25% EtOAc in Pentane) to afford 4.10 as a white 
solid (23% yield).  1H NMR (500 MHz, CDCl3) δ 7.39 – 7.31 (m, 6H), 7.29 (ddd, J = 7.9, 6.0, 3.2 
Hz, 1H), 6.39 (dd, J = 1.9, 0.9 Hz, 1H), 5.13 (ddd, J = 10.5, 8.8, 0.9 Hz, 1H), 4.91 (d, J = 12.1 Hz, 
1H), 4.82 (dd, J = 11.5, 2.4 Hz, 1H), 4.59 (d, J = 2.2 Hz, 1H), 4.57 (d, J = 6.1 Hz, 1H), 3.70 (s, 
3H), 2.79 – 2.70 (m, 1H), 2.30 – 2.21 (m, 2H), 2.15 (s, 3H), 2.12 (d, J = 2.4 Hz, 1H), 2.08 (s, 1H), 
1.95 – 1.86 (m, 1H), 1.74 – 1.64 (m, 1H), 1.37 (s, 3H), 1.36 – 1.33 (m, 0H), 1.31 (dd, J = 8.9, 2.4 
Hz, 2H), 1.25 (s, 1H), 1.24 – 1.17 (m, 1H), 1.07 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 202.58, 
171.96, 169.88, 142.87, 138.91, 138.02, 128.31, 127.62, 127.55, 126.59, 108.88, 99.03, 75.06, 
70.19, 66.18, 65.56, 53.67, 51.77, 50.70, 45.01, 42.40, 38.87, 35.74, 30.90, 20.63, 17.54, 16.75, 
15.13. HRMS calculated for C30H36O8 [M+Na]
+: 547.2318 (found); 547.2308 (calcd). Melting 
point: 71-73 °C. 
Methyl (2S,4S,4aR,6aR,7R,9S,10aR,10bS)-9-acetoxy-2-(furan-3-yl)-
4-isopropoxy-6a,10b-dimethyl-10-oxododecahydro-2H-benzo[f]isochromene-7-carboxylate 
(4.11). Compound 4.11 was prepared using General Method B, described above, with isopropyl 
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alcohol. FCC (20% EtOAc in Pentane) followed by preparative HPLC (75% MeCN in H2O; tR = 
9.12 min) to afford 4.11 as a white solid (37 % single epimer, 82% both epimers).   1H NMR (500 
MHz, CDCl3) δ 7.35 (d, J = 1.4 Hz, 2H), 6.36 (t, J = 1.4 Hz, 1H), 5.16 – 5.08 (m, 1H), 5.01 (dd, J 
= 11.6, 2.3 Hz, 1H), 4.76 (d, J = 3.3 Hz, 1H), 3.83 (p, J = 6.2 Hz, 1H), 3.71 (s, 3H), 2.78 – 2.70 
(m, 1H), 2.25 (td, J = 9.6, 2.2 Hz, 2H), 2.21 – 2.17 (m, 1H), 2.15 (s, 3H), 2.03 – 2.00 (m, 1H), 1.71 
– 1.59 (m, 3H), 1.52 (d, J = 0.7 Hz, 3H), 1.41 – 1.30 (m, 2H), 1.26 (t, J = 1.8 Hz, 1H), 1.21 (d, J = 
6.2 Hz, 3H), 1.11 (s, 3H), 1.08 (d, J = 6.1 Hz, 3H). 13C NMR (126 MHz, CDCl3) δ 202.27, 172.04, 
169.93, 142.98, 139.06, 126.96, 108.95, 99.36, 75.04, 69.46, 66.27, 60.67, 53.88, 51.76, 48.59, 
44.72, 42.76, 39.43, 34.75, 30.78, 23.64, 21.62, 20.66, 20.13, 16.92, 16.58. HRMS calculated for 
C26H36O8 [M+Na]
+: 499.2314 (found); 499.2308 (calcd). Melting point: 69-70 °C. 
Methyl (2S,4R,4aR,6aR,7R,9S,10aR,10bS)-9-acetoxy-2-(furan-3-
yl)-4-isopropoxy-6a,10b-dimethyl-10-oxododecahydro-2H-benzo[f]isochromene-7-
carboxylate (4.11). Compound 4.11 was prepared using General Method B, described above, 
with isopropyl alcohol. FCC (20% EtOAc in Pentane) followed by preparative HPLC (75% MeCN 
in H2O; tR = 12.65 min) to afford 4.11 as a white solid (45 % single epimer, 82% both epimers). 
1H NMR (500 MHz, CDCl3) δ 7.37 – 7.29 (m, 2H), 6.36 (dd, J = 1.9, 0.9 Hz, 1H), 5.18 – 5.05 (m, 
1H), 4.80 (ddd, J = 11.5, 2.5, 1.0 Hz, 1H), 4.55 (d, J = 8.6 Hz, 1H), 3.94 (p, J = 6.2 Hz, 1H), 3.70 
(s, 3H), 2.79 – 2.68 (m, 1H), 2.31 – 2.20 (m, 2H), 2.15 (s, 3H), 2.14 – 2.09 (m, 1H), 2.06 – 2.03 
(m, 1H), 1.82 (ddt, J = 13.4, 5.1, 2.8 Hz, 1H), 1.68 (dt, J = 13.5, 3.4 Hz, 1H), 1.58 (td, J = 13.0, 
4.1 Hz, 1H), 1.43 (s, 1H), 1.42 – 1.39 (m, 3H), 1.33 – 1.27 (m, 1H), 1.24 (d, J = 6.2 Hz, 3H), 1.18 
(ddd, J = 12.2, 2.7, 1.5 Hz, 1H), 1.13 (d, J = 6.1 Hz, 3H), 1.08 (s, 3H).13C NMR (126 MHz, CDCl3) 
158 
 
δ 202.65, 172.01, 169.87, 142.73, 138.79, 126.83, 108.90, 98.48, 75.07, 71.18, 66.02, 65.69, 53.70, 
51.75, 50.65, 44.92, 42.44, 38.94, 35.79, 30.93, 23.73, 22.13, 20.65, 17.50, 16.77, 15.16. HRMS 
calculated for C26H36O8 [M+Na]
+: 499.2308 (found); 499.2308 (calcd). Melting point: 66-67 °C.  
Methyl (2S,4S,4aR,6aR,7R,9S,10aR,10bS)-9-acetoxy-4-(allyloxy)-
2-(furan-3-yl)-6a,10b-dimethyl-10-oxododecahydro-2H-benzo[f]isochromene-7-carboxylate 
(4.12). Compound 4.12was prepared using General Method B, described above, with allyl 
alcohol. FCC (20% EtOAc in Pentane) followed by preparative HPLC (60% MeCN in H2O; tR = 
26.31 min) to afford 4.12as a white solid (31 % single epimer, 92.4% both epimers).   1H NMR 
(400 MHz, CDCl3) δ 7.35 (s, 2H), 6.37 (s, 1H), 5.90 (ddt, J = 16.1, 10.5, 5.2 Hz, 1H), 5.28 (d, J = 
17.1 Hz, 1H), 5.22 – 5.09 (m, 2H), 4.98 (d, J = 11.6 Hz, 1H), 4.73 (d, J = 3.0 Hz, 1H), 4.22 (dd, J 
= 13.2, 4.3 Hz, 1H), 3.92 (dd, J = 13.5, 5.6 Hz, 1H), 3.71 (s, 3H), 2.74 (t, J = 8.5 Hz, 1H), 2.32 – 
2.17 (m, 3H), 2.15 (s, 3H), 2.03 (s, 1H), 1.70 (d, J = 11.0 Hz, 1H), 1.42 (q, J = 11.9, 8.7 Hz, 2H), 
1.26 (s, 5H), 1.22 (d, J = 11.7 Hz, 1H), 1.12 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 202.21, 172.00, 
169.94, 143.03, 139.12, 134.68, 126.74, 116.00, 108.89, 100.49, 75.03, 68.39, 66.17, 60.88, 53.87, 
51.80, 48.62, 44.64, 42.75, 39.46, 34.68, 30.77, 20.65, 20.12, 16.91, 16.63. HRMS calculated for 
C26H34O8 [M+Na]





carboxylate (4.12). Compound 4.12was prepared using General Method B, described above, 
with allyl alcohol. FCC (20% EtOAc in Pentane) followed by preparative HPLC (60% MeCN in 
H2O; tR = 21.57 min) to afford 4.12as a white solid (61.2% single epimer, 92.4% both epimers).  
1H NMR (400 MHz, CDCl3) δ 7.36 – 7.30 (m, 2H), 6.37 (s, 1H), 5.91 (ddt, J = 16.4, 10.7, 5.5 Hz, 
1H), 5.27 (d, J = 17.3 Hz, 1H), 5.21 – 5.03 (m, 2H), 4.80 (d, J = 11.2 Hz, 1H), 4.53 (d, J = 8.3 Hz, 
1H), 4.36 (dd, J = 13.1, 5.0 Hz, 1H), 4.04 (dd, J = 13.1, 6.0 Hz, 1H), 3.70 (s, 3H), 2.75 (dd, J = 
10.7, 6.3 Hz, 1H), 2.26 (t, J = 10.9 Hz, 2H), 2.15 (s, 3H), 2.11 (s, 1H), 2.07 (s, 1H), 1.86 (d, J = 
13.5 Hz, 1H), 1.74 – 1.63 (m, 1H), 1.58 (td, J = 13.0, 4.0 Hz, 1H), 1.40 (s, 3H), 1.26 (s, 2H), 1.18 
(t, J = 12.4 Hz, 1H), 1.09 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 202.59, 171.96, 169.88, 142.85, 
138.90, 134.48, 126.57, 116.81, 108.88, 99.07, 75.07, 69.41, 66.11, 65.58, 53.68, 51.78, 50.69, 
44.95, 42.41, 38.87, 35.75, 30.92, 20.64, 17.49, 16.76, 15.13. HRMS calculated for C26H34O8 
[M+Na]+: 497.2162 (found); 497.2151 (calcd). Melting point: 74-76°C. 
Methyl (2S,4S,4aR,6aR,7R,9S,10aR,10bS)-9-acetoxy-2-(furan-3-
yl)-6a,10b-dimethyl-10-oxo-4-(prop-2-yn-1-yloxy)dodecahydro-2H-benzo[f]isochromene-7-
carboxylate (4.13). Compound 4.13was prepared using General Method B, described above, 
with propargyl alcohol. FCC (20% EtOAc in Pentane) followed by preparative HPLC (60% MeCN 
in H2O; tR = 14-16 min) to afford 4.13as a white solid (22.2 % single epimer, 35.3% both 
epimers).  1H NMR (500 MHz, CDCl3) δ 7.37 – 7.30 (m, 2H), 6.38 (dd, J = 1.9, 0.9 Hz, 1H), 5.16 
– 5.06 (m, 1H), 4.99 (dd, J = 11.6, 2.3 Hz, 1H), 4.87 (d, J = 3.1 Hz, 1H), 4.23 (dd, J = 3.4, 2.4 Hz, 
2H), 3.71 (s, 3H), 2.74 (dd, J = 9.2, 7.7 Hz, 1H), 2.37 (t, J = 2.4 Hz, 1H), 2.26 (dd, J = 9.2, 1.6 Hz, 
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2H), 2.23 (dd, J = 6.0, 2.4 Hz, 1H), 2.20 (d, J = 2.3 Hz, 1H), 2.15 (s, 3H), 2.02 (s, 1H), 1.75 – 1.66 
(m, 2H), 1.54 – 1.51 (m, 3H), 1.44 (tdd, J = 15.9, 4.3, 2.8 Hz, 2H), 1.24 – 1.19 (m, 1H), 1.11 (s, 
3H). 13C NMR (126 MHz, CDCl3) δ  202.14, 171.96, 169.94, 143.04, 139.17, 126.54, 108.86, 
99.74, 79.85, 75.02, 73.88, 66.10, 61.25, 54.67, 53.86, 51.80, 48.34, 44.55, 42.75, 39.43, 34.62, 
30.75, 20.64, 19.91, 16.90, 16.49. HRMS calculated for C26H32O8 [M+Na]
+:495.2008 (found); 
495.1995 (calcd). Melting point: 74-76 °C.  
Methyl (2S,4R,4aR,6aR,7R,9S,10aR,10bS)-9-acetoxy-2-(furan-
3-yl)-6a,10b-dimethyl-10-oxo-4-(prop-2-yn-1-yloxy)dodecahydro-2H-benzo[f]isochromene-
7-carboxylate (4.13). Compound 4.13 was prepared using General Method B, described above, 
with propargyl alcohol. FCC (20% EtOAc in Pentane) followed by preparative HPLC (60% MeCN 
in H2O; tR = 12.5-14 min) to afford 4.13 as a white solid (13.1% single epimer, 35.3% both 
epimers).  1H NMR (500 MHz, CDCl3) δ 7.38 – 7.31 (m, 2H), 6.37 (dd, J = 1.9, 0.9 Hz, 1H), 5.17 
– 5.07 (m, 1H), 4.83 (dd, J = 11.5, 1.8 Hz, 1H), 4.70 (d, J = 8.7 Hz, 1H), 4.35 (d, J = 5.1 Hz, 1H), 
3.71 (s, 3H), 2.79 – 2.70 (m, 1H), 2.41 (t, J = 2.4 Hz, 1H), 2.31 – 2.23 (m, 2H), 2.15 (s, 3H), 2.13 
(d, J = 2.5 Hz, 1H), 2.08 (d, J = 1.0 Hz, 1H), 1.89 – 1.81 (m, 1H), 1.73 – 1.66 (m, 1H), 1.59 (d, J 
= 9.1 Hz, 2H), 1.42 (d, J = 0.8 Hz, 3H), 1.36 (dd, J = 13.2, 3.7 Hz, 1H), 1.27 – 1.24 (m, 2H), 1.09 
(s, 3H). 13C NMR (126 MHz, CDCl3) δ 202.53, 171.93, 169.88, 142.91, 138.95, 126.38, 108.83, 
97.84, 79.58, 75.07, 74.21, 66.28, 65.53, 55.24, 53.69, 51.80, 50.46, 44.88, 42.42, 38.78, 35.80, 
30.92, 20.63, 17.32, 16.77, 15.13. HRMS calculated for C26H32O8 [M+Na]
+:495.2008 (found); 





7-carboxylate (4.14). Compound 4.14was prepared using General Method B, described above, 
with 3-hydroxypropionitrile. FCC (30% EtOAc in Pentane) to afford 4.14as a white solid (33 % 
single epimer, 79% both epimers). 1H NMR (500 MHz, CDCl3) δ 7.40 – 7.31 (m, 2H), 6.37 (dd, J 
= 1.9, 0.9 Hz, 1H), 5.11 (ddd, J = 10.9, 9.1, 0.9 Hz, 1H), 5.03 (dd, J = 11.7, 2.3 Hz, 1H), 4.74 (d, 
J = 3.3 Hz, 1H), 3.92 (ddd, J = 10.1, 6.4, 5.5 Hz, 1H), 3.71 (s, 3H), 3.60 (ddd, J = 10.0, 6.9, 5.5 
Hz, 1H), 2.74 (dd, J = 9.3, 7.5 Hz, 1H), 2.63 (ddd, J = 6.3, 5.4, 3.7 Hz, 2H), 2.31 – 2.23 (m, 2H), 
2.20 (d, J = 2.4 Hz, 1H), 2.15 (s, 3H), 2.02 (s, 1H), 1.80 – 1.69 (m, 2H), 1.63 (dd, J = 13.5, 4.3 Hz, 
1H), 1.55 (s, 3H), 1.50 – 1.39 (m, 2H), 1.24 – 1.18 (m, 1H), 1.12 (s, 3H). 13C NMR (126 MHz, 
CDCl3) δ 202.01, 171.91, 169.95, 143.15, 139.26, 126.37, 117.93, 108.74, 101.71, 75.00, 66.02, 
63.01, 61.43, 53.85, 51.82, 48.40, 44.57, 42.73, 39.36, 34.53, 30.73, 20.64, 19.97, 19.16, 16.92, 
16.42.HRMS calculated for C26H33NO8 [M+Na]
+: 510.2101 (found); 510.2104 (calcd). Melting 
point: 76-78 °C. 
Methyl (2S,4R,4aR,6aR,7R,9S,10aR,10bS)-9-acetoxy-4-(2-
cyanoethoxy)-2-(furan-3-yl)-6a,10b-dimethyl-10-oxododecahydro-2H-benzo[f]isochromene-
7-carboxylate (4.14). Compound 4.14 was prepared using General Method B, described above, 
with 3-hydroxypropionitrile. FCC (30% EtOAc in Pentane) followed by preparative HPLC (60% 
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MeCN in H2O; tR = 10.6 min) to afford 4.14 as a white solid (46 % single epimer, 79% both 
epimers). 1H NMR (500 MHz, CDCl3) δ 7.35 (d, J = 1.9 Hz, 2H), 6.36 (dd, J = 1.7, 1.0 Hz, 1H), 
5.13 (ddd, J = 10.9, 8.4, 0.9 Hz, 1H), 4.82 (dd, J = 11.5, 2.5 Hz, 1H), 4.55 (d, J = 8.7 Hz, 1H), 4.05 
(ddd, J = 10.0, 6.0, 5.0 Hz, 1H), 3.71 (s, 3H), 2.79 – 2.72 (m, 1H), 2.71 – 2.55 (m, 2H), 2.31 – 2.23 
(m, 2H), 2.15 (s, 3H), 2.08 (s, 1H), 1.87 (dt, J = 10.9, 3.2 Hz, 1H), 1.71 (dt, J = 13.5, 3.4 Hz, 1H), 
1.65 – 1.53 (m, 4H), 1.42 – 1.38 (m, 3H), 1.39 – 1.33 (m, 0H), 1.25 (s, 1H), 1.23 – 1.13 (m, 1H), 
1.08 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 202.48, 171.90, 169.90, 143.01, 138.94, 126.26, 
117.83, 108.78, 100.31, 75.06, 66.27, 65.47, 63.56, 53.67, 51.81, 50.54, 44.79, 42.39, 38.80, 35.63, 
30.87, 20.63, 19.20, 17.32, 16.75, 15.02. HRMS calculated for C26H33NO8 [M+Na]
+: 510.2091 
(found); 510.2104 (calcd). Melting point: 95-97 °C.  
Methyl (2S,4S,4aR,6aR,7R,9S,10aR,10bS)-9-acetoxy-2-(furan-3-
yl)-4-(((Z)-4-hydroxybut-2-en-1-yl)oxy)-6a,10b-dimethyl-10-oxododecahydro-2H-
benzo[f]isochromene-7-carboxylate (4.15). Compound 4.15 was prepared using General 
Method C, described above, with cis-2-butene-diol. FCC (1040% EtOAc in CH2Cl2) followed 
by preparative HPLC (60% MeCN in H2O; tR = 8.4 min) to afford 4.15 as a white solid (32% 
single epimer, 49% both epimers). 1H NMR (500 MHz, CDCl3) δ 7.39 – 7.24 (m, 3H), 6.37 (dd, J 
= 1.9, 0.9 Hz, 1H), 5.82 (dddd, J = 12.7, 8.0, 4.6, 1.4 Hz, 1H), 5.74 – 5.61 (m, 1H), 5.11 (ddd, J = 
10.0, 9.2, 0.9 Hz, 1H), 4.97 (dd, J = 11.7, 2.2 Hz, 1H), 4.74 (d, J = 3.3 Hz, 1H), 4.24 – 4.17 (m, 
2H), 4.17 – 4.09 (m, 2H), 3.71 (s, 3H), 2.79 – 2.70 (m, 1H), 2.30 – 2.16 (m, 3H), 2.15 (s, 3H), 2.03 
– 2.00 (m, 1H), 1.78 (q, J = 13.1, 9.9 Hz, 1H), 1.75 – 1.63 (m, 2H), 1.52 (s, 3H), 1.47 – 1.32 (m, 
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2H), 1.25 (s, 1H), 1.24 – 1.19 (m, 1H), 1.11 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 202.17, 171.96, 
169.94, 143.13, 139.11, 132.31, 128.16, 126.52, 108.81, 100.06, 75.02, 66.09, 62.82, 61.09, 58.50, 
53.84, 51.81, 48.47, 44.71, 42.74, 39.43, 34.66, 30.75, 20.64, 20.02, 16.91, 16.55. HRMS 
calculated for C27H36O9 [M+Na]
+: 527.2255 (found); 525.2257 (calcd). Melting point: 62-64 °C.  
Methyl (2S,4R,4aR,6aR,7R,9S,10aR,10bS)-9-acetoxy-2-
(furan-3-yl)-4-(((Z)-4-hydroxybut-2-en-1-yl)oxy)-6a,10b-dimethyl-10-oxododecahydro-2H-
benzo[f]isochromene-7-carboxylate (4.15). Compound 4.15 was prepared using General 
Method C, described above, with cis-2-butene-diol. FCC (1040% EtOAc in CH2Cl2) followed 
by preparative HPLC (60% MeCN in H2O; tR = 7.4 min) to afford 4.15 as a white solid (17 % 
single epimer, 49% both epimers).  1H NMR (500 MHz, CDCl3) δ 7.38 – 7.31 (m, 2H), 6.37 (dd, 
J = 1.8, 0.9 Hz, 1H), 5.81 (dtt, J = 11.2, 6.6, 1.4 Hz, 1H), 5.73 – 5.65 (m, 1H), 5.15 – 5.08 (m, 1H), 
4.86 – 4.77 (m, 1H), 4.53 (d, J = 8.6 Hz, 1H), 4.45 – 4.37 (m, 1H), 4.23 – 4.18 (m, 2H), 4.18 – 
4.14 (m, 1H), 3.70 (s, 3H), 2.78 – 2.70 (m, 1H), 2.31 – 2.22 (m, 2H), 2.15 (s, 3H), 2.12 (d, J = 2.4 
Hz, 1H), 2.07 (d, J = 1.9 Hz, 1H), 1.81 (dq, J = 13.5, 3.1 Hz, 1H), 1.69 (dt, J = 13.5, 3.4 Hz, 1H), 
1.43 – 1.37 (m, 3H), 1.34 (qd, J = 12.9, 3.7 Hz, 1H), 1.25 (s, 3H), 1.22 – 1.14 (m, 1H), 1.08 (s, 
3H). 13C NMR (126 MHz, CDCl3) δ 202.54, 171.94, 169.89, 142.94, 138.92, 132.16, 128.16, 
126.43, 108.82, 99.15, 75.06, 66.21, 65.52, 64.10, 58.70, 53.67, 51.80, 50.64, 44.96, 42.39, 38.82, 
35.74, 30.91, 20.64, 17.44, 16.76, 15.11. HRMS calculated for C27H36O9 [M+Na]
+: 527.2275 





benzo[f]isochromene-7-carboxylate (4.16). Compound 4.16 was prepared using General 
Method C, described above, with 1,4-butyndiol. FCC (25% EtOAc in CH2Cl2) to afford 4.16 as 
a white solid (32% single epimer, 66% both epimers). 1H NMR (500 MHz, Chloroform-d) 7.40 – 
7.32 (m, 2H), 6.37 (dd, J = 1.8, 0.9 Hz, 1H), 5.11 (ddd, J = 10.1, 9.2, 0.9 Hz, 1H), 4.99 (dd, J = 
11.6, 2.3 Hz, 1H), 4.85 (d, J = 3.2 Hz, 1H), 4.31 – 4.22 (m, 4H), 3.71 (s, 3H), 2.74 (dd, J = 9.2, 7.7 
Hz, 1H), 2.26 (dd, J = 9.2, 1.6 Hz, 1H), 2.23 (dd, J = 6.9, 2.5 Hz, 1H), 2.20 (d, J = 2.3 Hz, 0H), 
2.18 (s, 1H), 2.15 (s, 3H), 2.02 (s, 1H), 1.73 – 1.67 (m, 2H), 1.65 – 1.59 (m, 1H), 1.54 – 1.52 (m, 
3H), 1.47 – 1.39 (m, 2H), 1.27 – 1.25 (m, 1H), 1.24 – 1.20 (m, 1H), 1.11 (s, 3H).13C NMR (126 
MHz, CDCl3) δ 202.15, 171.96, 169.94, 143.09, 139.13, 126.60, 108.81, 99.91, 83.96, 82.03, 
75.02, 66.08, 61.28, 55.05, 53.85, 51.82, 51.19, 48.39, 44.62, 42.74, 39.43, 34.64, 30.75, 20.65, 
19.97, 16.91, 16.53. HRMS calculated for C27H34O9 [M+Na]
+: 525.2108 (found); 525.2101 
(calcd). Melting point: 99-101 °C 
Methyl (2S,4R,4aR,6aR,7R,9S,10aR,10bS)-9-acetoxy-2-(furan-3-
yl)-4-((4-hydroxybut-2-yn-1-yl)oxy)-6a,10b-dimethyl-10-oxododecahydro-2H-
benzo[f]isochromene-7-carboxylate (4.16). Compound 4.16 was prepared using General 
Method C, described above, with 1,4-butyndiol. FCC (25% EtOAc in CH2Cl2) to afford 4.16 as 
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a white solid (34% single epimer, 66% both epimers).  1H NMR (500 MHz, CDCl3) δ  7.36 (dt, J 
= 1.7, 0.8 Hz, 1H), 7.34 (t, J = 1.7 Hz, 1H), 6.37 (dd, J = 1.9, 0.9 Hz, 1H), 5.17 – 5.05 (m, 1H), 
4.83 (dd, J = 11.7, 2.4 Hz, 1H), 4.65 (d, J = 8.7 Hz, 1H), 4.46 – 4.33 (m, 2H), 4.31 (t, J = 1.8 Hz, 
2H), 3.71 (s, 3H), 2.78 – 2.69 (m, 1H), 2.32 – 2.22 (m, 2H), 2.15 (s, 3H), 2.15 – 2.09 (m, 1H), 2.08 
(d, J = 1.1 Hz, 1H), 1.84 (dq, J = 13.7, 3.3 Hz, 1H), 1.72 – 1.67 (m, 1H), 1.42 – 1.40 (m, 3H), 1.35 
(dd, J = 13.3, 3.6 Hz, 1H), 1.25 (d, J = 1.4 Hz, 3H), 1.22 – 1.17 (m, 1H), 1.09 (s, 3H).  13C NMR 
(126 MHz, CDCl3) δ 202.53, 171.92, 169.90, 142.92, 138.95, 126.37, 108.83, 98.12, 84.28, 81.75, 
75.07, 66.25, 65.51, 55.60, 53.68, 51.81, 51.20, 50.48, 44.88, 42.41, 38.77, 35.78, 30.91, 20.63, 
17.36, 16.78, 15.14.HRMS calculated for C27H34O9 [M+Na]
+: 525.2130 (found); 525.2101 (calcd). 
Melting point: 92-94 °C.  
Methyl (2S,4S,4aR,6aR,7R,9S,10aR,10bS)-9-acetoxy-2-(furan-
3-yl)-4-(3-hydroxypropoxy)-6a,10b-dimethyl-10-oxododecahydro-2H-benzo[f]isochromene-
7-carboxylate (4.17). Compound 4.17 was prepared using General Method C, described above, 
with 1,3-propanediol. FCC (2040% EtOAc in CH2Cl2) to afford 4.17 as a white solid (38% 
single epimer, 66% both epimers).  1H NMR (500 MHz, CDCl3) δ 7.45 – 7.30 (m, 2H), 6.37 (dd, 
J = 1.8, 0.9 Hz, 1H), 5.11 (dd, J = 10.6, 9.3 Hz, 1H), 4.96 (dd, J = 11.6, 2.3 Hz, 1H), 4.70 (d, J = 
3.1 Hz, 1H), 3.94 (ddd, J = 9.8, 6.3, 4.9 Hz, 1H), 3.83 – 3.76 (m, 2H), 3.71 (s, 3H), 3.46 (ddd, J = 
9.8, 6.8, 5.0 Hz, 1H), 2.78 – 2.69 (m, 1H), 2.29 – 2.24 (m, 1H), 2.24 – 2.18 (m, 1H), 2.15 (s, 3H), 
2.05 (d, J = 25.1 Hz, 1H), 1.97 (s, 1H), 1.90 – 1.82 (m, 2H), 1.76 – 1.66 (m, 2H), 1.66 – 1.57 (m, 
1H), 1.52 (s, 3H), 1.43 (ddt, J = 11.6, 8.3, 2.7 Hz, 2H), 1.28 – 1.19 (m, 2H), 1.10 (s, 3H). 13C NMR 
(126 MHz, CDCl3) δ 202.15, 171.93, 169.95, 143.08, 139.14, 126.60, 108.84, 101.42, 75.01, 
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66.80, 66.09, 61.63, 60.92, 53.84, 51.82, 48.45, 44.49, 42.72, 39.38, 34.62, 32.16, 30.75, 20.64, 
20.05, 16.90, 16.57.HRMS calculated for C26H36O9 [M+Na]
+: 515.2255 (found); 515.2257 (calcd). 
Melting point: 69-72 °C (dec).  
Methyl (2S,4R,4aR,6aR,7R,9S,10aR,10bS)-9-acetoxy-2-
(furan-3-yl)-4-(3-hydroxypropoxy)-6a,10b-dimethyl-10-oxododecahydro-2H-
benzo[f]isochromene-7-carboxylate (4.17). Compound 4.17 was prepared using General 
Method C, described above, with 1,3-propanediol. FCC (2040% EtOAc in CH2Cl2) to afford 
4.17 as a white solid (28% single epimer, 66% both epimers).  1H NMR (500 MHz, CDCl3) δ 
7.40 – 7.31 (m, 2H), 6.36 (dd, J = 1.9, 0.9 Hz, 1H), 5.25 – 5.04 (m, 1H), 4.82 (dd, J = 11.3, 2.3 Hz, 
1H), 4.50 (d, J = 8.7 Hz, 1H), 4.01 (ddd, J = 9.8, 6.8, 5.4 Hz, 1H), 3.76 (dd, J = 11.1, 5.2 Hz, 1H), 
3.70 (s, 3H), 3.71 – 3.63 (m, 1H), 2.81 – 2.67 (m, 1H), 2.32 – 2.21 (m, 3H), 2.15 (s, 4H), 2.08 (d, 
J = 1.3 Hz, 1H), 1.82 (tdd, J = 9.0, 7.9, 4.5, 1.9 Hz, 2H), 1.69 (dt, J = 13.5, 3.3 Hz, 1H), 1.63 (d, J 
= 5.0 Hz, 2H), 1.55 (d, J = 15.0 Hz, 0H), 1.40 (s, 3H), 1.35 (td, J = 13.2, 3.8 Hz, 1H), 1.25 – 1.16 
(m, 2H), 1.08 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 202.53, 171.93, 169.88, 142.99, 138.90, 
126.35, 108.76, 100.09, 75.06, 67.06, 66.22, 65.50, 60.74, 53.67, 51.79, 50.61, 44.88, 42.38, 38.82, 
35.70, 32.14, 30.89, 20.64, 17.50, 16.75, 15.07. HRMS calculated for C26H36O9 [M+Na]
+: 





benzo[f]isochromene-7-carboxylate (4.18). Compound 4.18 was prepared using General 
Method C, described above, with 1,4-butanediol. FCC (2040% EtOAc in CH2Cl2) to afford 
4.18 as a white solid (26% single epimer, 47% both epimers). 1H NMR (500 MHz, CDCl3) δ 
7.42 – 7.31 (m, 2H), 6.37 (dd, J = 1.8, 0.9 Hz, 1H), 5.16 – 5.07 (m, 1H), 4.95 (dd, J = 11.6, 2.3 Hz, 
1H), 4.68 (d, J = 3.2 Hz, 1H), 4.11 (t, J = 6.5 Hz, 2H), 3.71 (s, 3H), 3.69 (d, J = 10.8 Hz, 2H), 3.39 
– 3.30 (m, 1H), 2.79 – 2.68 (m, 2H), 2.29 – 2.21 (m, 2H), 2.22 – 2.18 (m, 1H), 2.17 (d, J = 2.4 Hz, 
1H), 2.15 (s, 3H), 2.06 (s, 3H), 1.76 – 1.70 (m, 3H), 1.52 (s, 3H), 1.49 – 1.38 (m, 2H), 1.11 (s, 
3H). 13C NMR (126 MHz, CDCl3) δ 202.20, 171.98, 169.94, 143.05, 139.10, 126.74, 108.87, 
101.22, 75.03, 67.99, 64.27, 62.41, 53.86, 51.80, 48.62, 44.64, 42.75, 39.45, 34.70, 30.77, 29.93, 
29.11, 26.24, 25.06, 20.65, 16.93, 16.58. HRMS calculated for C27H38O9 [M+Na]
+: 529.2405 
(found); 529.2414 (calcd). Melting point: 110-113 °C. 
Methyl (2S,4R,4aR,6aR,7R,9S,10aR,10bS)-9-acetoxy-2-
(furan-3-yl)-4-(4-hydroxybutoxy)-6a,10b-dimethyl-10-ojxododecahydro-2H-
benzo[f]isochromene-7-carboxylate (4.18). Compound 4.18 was prepared using General 
Method C, described above, with 1,4-butanediol. FCC (2040% EtOAc in CH2Cl2) to afford 
4.18 as a white solid (21% single epimer, 47% both epimers). 1H NMR (500 MHz, CDCl3) δ 7.37 
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– 7.30 (m, 2H), 6.36 (dd, J = 1.8, 0.9 Hz, 1H), 5.16 – 5.08 (m, 1H), 4.81 (dd, J = 11.5, 2.3 Hz, 1H), 
4.48 (d, J = 8.6 Hz, 1H), 4.00 – 3.92 (m, 1H), 3.92 – 3.82 (m, 2H), 3.70 (s, 3H), 3.67 – 3.64 (m, 
2H), 3.51 – 3.38 (m, 2H), 2.77 – 2.69 (m, 1H), 2.31 – 2.21 (m, 2H), 2.17 – 2.16 (m, 2H), 2.12 (dd, 
J = 13.2, 2.4 Hz, 1H), 2.11 – 2.04 (m, 1H), 1.91 – 1.77 (m, 3H), 1.73 – 1.65 (m, 2H), 1.40 (s, 3H), 
1.08 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 202.57, 171.97, 169.88, 142.87, 138.88, 126.55, 
108.84, 99.99, 75.07, 67.21, 65.55, 62.66, 53.67, 51.78, 50.70, 44.98, 42.39, 38.87, 35.71, 32.35, 
30.90, 30.17, 26.39, 23.46, 20.64, 16.76, 15.09. HRMS calculated for C27H38O9 [M+Na]
+: 
529.2422 (found); 529.2414 (calcd). Melting point: 101-105 °C. 
Methyl (2S,4S,4aR,6aR,7R,9S,10aR,10bS)-9-acetoxy-2-(furan-
3-yl)-6a,10b-dimethyl-10-oxo-4-(3-oxopropoxy)dodecahydro-2H-benzo[f]isochromene-7-
carboxylate (4.19). To a dry flask under Ar, 4.17 (34.6 mg, 0.07 mmol) and Dess-Martin 
periodinane (41.5mg, 0.098 mmol) in DCM (1mL) was added and the reaction stirred overnight at 
r.t. Upon reaction completion as monitored by TLC, the reaction was quenched with sat. aq. 
NaHCO3 (2mL) and sat. aq. Na2S2O3 (2mL). The reaction mixture allowed to stir for 20 min. 
before being extracted into DCM (3x 10mL). The combined organic extracts were washed with 
brine (30 mL), dried (Na2SO4) and concentrated to yield crude aldehyde which was purified by 
FCC (8% EtOAc in DCM) to afford 4.19 as a white solid (44% yield). 1H NMR (500 MHz, 
CDCl3) δ 9.81 (q, J = 1.8 Hz, 1H), 7.46 – 7.32 (m, 2H), 6.38 (dd, J = 1.8, 0.9 Hz, 1H), 5.21 – 5.05 
(m, 1H), 4.96 (dd, J = 11.6, 2.3 Hz, 1H), 4.70 (d, J = 3.2 Hz, 1H), 4.09 (dt, J = 10.2, 5.8 Hz, 1H), 
3.71 (s, 3H), 3.67 (dt, J = 10.2, 5.7 Hz, 1H), 2.79 – 2.71 (m, 1H), 2.67 (td, J = 5.9, 1.9 Hz, 2H), 
2.25 (td, J = 10.2, 9.5, 2.2 Hz, 2H), 2.22 – 2.16 (m, 1H), 2.15 (s, 3H), 2.01 (s, 1H), 1.71 – 1.62 (m, 
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1H), 1.60 (t, J = 4.9 Hz, 3H), 1.45 (s, 3H), 1.42 – 1.34 (m, 1H), 1.23 – 1.19 (m, 1H), 1.09 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 202.10, 200.96, 171.94, 169.93, 143.09, 139.19, 126.57, 108.82, 
101.49, 75.00, 66.07, 61.95, 61.04, 53.84, 51.80, 48.44, 44.56, 43.76, 42.72, 39.37, 34.61, 30.74, 
20.64, 19.99, 16.89, 16.44. HRMS calculated for C26H34O9 [M+H]
+: 491.2235 (found); 491.2276 
(calcd). Melting point: 221-223 °C. 
Methyl (2S,4R,4aR,6aR,7R,9S,10aR,10bS)-9-acetoxy-2-(furan-3-
yl)-6a,10b-dimethyl-10-oxo-4-(3-oxopropoxy)dodecahydro-2H-benzo[f]isochromene-7-
carboxylate (4.19). To a dry flask under Ar, 4.17 (30 mg, 0.061 mmol) and Dess-Martin 
periodinane (36.2 mg, 0.085 mmol) in DCM (1mL) was added and the reaction stirred overnight 
at r.t. Upon reaction completion as monitored by TLC, the reaction was quenched with sat. aq. 
NaHCO3 (2mL) and sat. aq. Na2S2O3 (2mL). The reaction mixture allowed to stir for 20 min. 
before being extracted into DCM (3x 10mL). The combined organic extracts were washed with 
brine (30 mL), dried (Na2SO4) and concentrated to yield crude aldehyde which was purified by 
FCC (8% EtOAc in DCM) to afford 4.19 as a white solid (32% yield). 1H NMR (500 MHz, 
CDCl3) δ 9.78 (d, J = 3.3 Hz, 1H), 7.34 (dt, J = 6.3, 1.8 Hz, 2H), 6.36 (dd, J = 1.8, 0.9 Hz, 1H), 
5.19 – 5.06 (m, 1H), 4.81 (dd, J = 11.5, 2.4 Hz, 1H), 4.51 (d, J = 8.7 Hz, 1H), 4.18 (ddd, J = 10.3, 
6.2, 5.0 Hz, 1H), 3.84 (ddd, J = 10.2, 7.8, 4.8 Hz, 1H), 3.70 (s, 3H), 2.74 (dt, J = 17.2, 10.1, 7.3 
Hz, 1H), 2.78 – 2.68 (m, 1H), 2.64 (dddd, J = 17.3, 6.4, 4.8, 1.8 Hz, 1H), 2.29 – 2.22 (m, 2H), 2.15 
(s, 3H), 2.16 – 2.09 (m, 1H), 2.08 – 2.03 (m, 1H), 1.70 (ddt, J = 26.5, 13.5, 3.5 Hz, 2H), 1.56 (td, 
J = 13.1, 4.2 Hz, 1H), 1.40 (s, 3H), 1.38 – 1.25 (m, 1H), 1.22 – 1.14 (m, 2H), 1.08 (s, 3H). 13C 
NMR (126 MHz, CDCl3) δ  202.52, 201.08, 171.92, 169.89, 142.92, 138.91, 126.42, 108.84, 
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100.17, 75.05, 66.12, 65.52, 62.72, 53.67, 51.78, 50.56, 44.84, 43.87, 42.38, 38.81, 35.65, 30.88, 
20.63, 17.34, 16.75, 15.06. HRMS calculated for C26H34O9 [M+H]
+: 491.2165 (found); 491.2276 
(calcd). Melting point: 114-118 °C. 
3-(((2S,4S,4aR,6aR,7R,9S,10aR,10bS)-9-acetoxy-2-(furan-3-yl)-
7-(methoxycarbonyl)-6a,10b-dimethyl-10-oxododecahydro-2H-benzo[f]isochromen-4-
yl)oxy)propanoic acid (4.20). To a solution of 4.19 (19.6 mg, 0.04 mmol) in DMF (1mL) was 
added OXONE (24.6 mg, 0.04 mmol). The reaction mixture was stirred at r.t. for 3h. Upon 
consumption of the starting material, as monitored by TLC, 1M HCl (3mL) was added and the 
mixture was extracted into EtOAc (3x 10mL). The combined organic extracts were washed with 
brine (30 mL), dried (Na2SO4) and concentrated. The resulting mixture was purified by preparative 
HPLC to afford 4.20 as a white solid (7.0 mg, 35 % yield).  1H NMR (500 MHz, CDCl3) δ 7.41 
– 7.32 (m, 2H), 6.38 (dd, J = 1.8, 0.9 Hz, 1H), 5.13 – 5.08 (m, 1H), 5.00 (dd, J = 11.7, 2.2 Hz, 1H), 
4.70 (d, J = 3.2 Hz, 1H), 4.03 (dt, J = 9.9, 6.3 Hz, 1H), 3.70 (s, 3H), 3.59 (dt, J = 9.9, 5.8 Hz, 1H), 
2.80 – 2.69 (m, 1H), 2.62 (d, J = 6.0 Hz, 1H), 2.25 (td, J = 10.0, 9.5, 2.2 Hz, 2H), 2.18 (dd, J = 
13.1, 2.3 Hz, 1H), 2.15 (s, 3H), 2.02 (d, J = 8.5 Hz, 2H), 1.70 – 1.58 (m, 3H), 1.47 (s, 3H), 1.38 
(tt, J = 12.2, 2.6 Hz, 2H), 1.26 – 1.19 (m, 1H), 1.10 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 202.15, 
175.85, 171.98, 169.95, 143.03, 139.28, 126.57, 108.90, 101.37, 75.03, 66.12, 63.47, 60.91, 53.84, 
51.80, 48.47, 44.47, 42.74, 39.42, 34.85, 34.62, 30.75, 20.64, 19.94, 16.90, 16.38. HRMS 
calculated for C26H34O10 [M+NH4]





yl)oxy)propanoic acid (4.20). To a solution of 4.19 (16.2 mg, 0.033 mmol) in DMF (1mL) was 
added OXONE (16.2 mg, 0.033 mmol). The reaction mixture was stirred at r.t. for 3h. Upon 
consumption of the starting material, as monitored by TLC, 1M HCl (3mL) was added and the 
mixture was extracted into EtOAc (3x 10mL). The combined organic extracts were washed with 
brine (30 mL), dried (Na2SO4) and concentrated. The resulting mixture was purified by preparative 
HPLC to afford 4.20 as a white solid (4.3 mg, 26 % yield).  1H NMR (500 MHz, CDCl3) δ 7.41 
– 7.31 (m, 2H), 6.36 (dd, J = 1.9, 0.9 Hz, 1H), 5.22 – 5.06 (m, 1H), 4.82 (dd, J = 11.5, 2.3 Hz, 1H), 
4.53 (d, J = 8.6 Hz, 1H), 4.11 (dt, J = 10.2, 5.8 Hz, 1H), 3.79 (ddd, J = 10.2, 7.5, 5.5 Hz, 1H), 3.70 
(s, 3H), 2.75 (dd, J = 9.3, 7.6 Hz, 1H), 2.68 – 2.56 (m, 1H), 2.24 (td, J = 9.5, 2.1 Hz, 2H), 2.15 (s, 
3H), 2.12 (dd, J = 13.2, 2.5 Hz, 1H), 2.08 (d, J = 7.2 Hz, 1H), 2.03 (s, 1H), 1.76 (dt, J = 13.4, 3.5 
Hz, 1H), 1.67 (dt, J = 13.5, 3.3 Hz, 1H), 1.56 (td, J = 13.1, 4.2 Hz, 1H), 1.39 (s, 3H), 1.32 (qd, J = 
12.8, 3.7 Hz, 1H), 1.25 – 1.15 (m, 2H), 1.07 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 202.60, 
175.20, 171.96, 169.90, 142.93, 138.94, 126.36, 108.81, 100.38, 75.09, 66.23, 65.36, 64.53, 53.60, 
51.78, 50.44, 44.72, 42.38, 38.78, 35.65, 34.94, 30.88, 20.64, 17.29, 16.76, 15.04. HRMS 
calculated for C26H34O10 [M+NH4]





carboxylate (4.1a). Synthesized following procedure for 4.1 using methoxymethyl-salvinorin B 
(0.188 mmol, synthesized as previously described8) as the starting material, yielding 4.1a (51.4 
mg, 63% yield, mixture of lactol epimers). 1H NMR (500 MHz, CDCl3) δ 7.43 – 7.33 (m, 2H), 
6.40 (dd, J = 1.9, 0.9 Hz, 1H), 5.23 – 5.14 (m, 0H), 4.90 (dd, J = 11.6, 2.4 Hz, 1H), 4.83 (dd, J = 
8.7, 5.2 Hz, 1H), 4.75 – 4.62 (m, 2H), 4.14 – 4.06 (m, 1H), 3.70 (d, J = 1.1 Hz, 3H), 3.37 (d, J = 
1.1 Hz, 3H), 2.94 (d, J = 6.1 Hz, 1H), 2.69 (dt, J = 13.4, 3.5 Hz, 1H), 2.61 – 2.56 (m, 0H), 2.32 
(dddd, J = 14.8, 11.3, 7.3, 3.4 Hz, 1H), 2.26 (dd, J = 13.0, 2.4 Hz, 0H), 2.22 – 2.11 (m, 2H), 1.98 
(s, 1H), 1.92 (s, 0H), 1.82 (dp, J = 13.8, 3.0 Hz, 1H), 1.71 (dt, J = 13.3, 3.4 Hz, 1H), 1.60 (s, 1H), 
1.42 (s, 2H), 1.25 (s, 1H), 1.23 – 1.13 (m, 1H), 1.12 (s, 1H), 1.09 (s, 2H). 13C NMR (126 MHz, 
CDCl3) δ 206.32, 172.21, 143.10, 139.12, 126.35, 108.75, 95.71, 94.24, 77.93, 66.28, 65.61, 55.78, 
54.02, 52.24, 51.74, 44.97, 42.33, 38.87, 35.72, 32.73, 17.70, 16.75, 15.02. HRMS calculated for 
C23H32O8 [M+H]
+: 437.2264 (found); 437.2170 (calcd). Melting point: 87-91 °C.  
Methyl (2S,4aR,6aR,7R,9S,10aR,10bS)-2-(furan-3-yl)-4-hydroxy-
6a,10b-dimethyl-9-((methylsulfonyl)oxy)-10-oxododecahydro-2H-benzo[f]isochromene-7-
carboxylate (4.1b). Synthesized following procedure for 4.1 using methanesulfonyl-salvinorin B 
(0.271 mmol, synthesized as previously described9) as the starting material, yielding 4.1b as a 
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mixture of lactol epimers which was carried through without further purification. 1H NMR (500 
MHz, CDCl3) δ 7.43 – 7.32 (m, 2H), 6.42 – 6.38 (m, 1H), 5.26 – 5.11 (m, 1H), 5.02 (ddd, J = 14.8, 
12.3, 7.5 Hz, 1H), 4.87 (ddd, J = 29.4, 10.1, 4.2 Hz, 1H), 3.72 (d, J = 1.1 Hz, 3H), 3.22 (d, J = 3.0 
Hz, 3H), 2.82 – 2.67 (m, 2H), 2.46 (ddq, J = 14.4, 7.0, 3.6 Hz, 1H), 2.38 (dd, J = 14.3, 12.1 Hz, 
1H), 2.25 – 2.10 (m, 1H), 2.04 (s, 1H), 1.86 (dd, J = 14.0, 3.4 Hz, 1H), 1.73 (dt, J = 13.5, 3.4 Hz, 
1H), 1.59 (s, 1H), 1.41 (s, 2H), 1.25 (s, 2H), 1.24 – 1.19 (m, 1H), 1.13 (s, 1H), 1.10 (s, 2H). 13C 
NMR (126 MHz, CDCl3) δ 201.88, 171.37, 143.25, 139.24, 126.10, 108.80, 94.14, 80.69, 66.16, 
65.59, 53.52, 52.02, 44.74, 42.26, 39.56, 38.66, 35.82, 32.24, 29.74, 17.62, 16.86, 15.03. HRMS 
calculated for C22H30O9S [M+H]




(4.1c). Synthesized following procedure for 4.1 using herkinorin (0.404 mmol, synthesized as 
previously described9) as the starting material, yielding 4.1c as a mixture of lactol epimers (190 
mg, 94% yield) Mixture of epimers: 1H NMR (500 MHz, CDCl3) δ 8.08 (dd, J = 8.4, 1.3 Hz, 2H), 
7.57 (tt, J = 7.2, 1.4 Hz, 1H), 7.45 (ddt, J = 8.8, 7.6, 1.5 Hz, 2H), 7.40 – 7.30 (m, 2H), 6.38 (ddd, 
J = 8.7, 1.9, 0.9 Hz, 1H), 5.42 – 5.35 (m, 1H), 5.22 – 5.16 (m, 0H), 4.87 (ddd, J = 21.4, 10.1, 4.1 
Hz, 2H), 3.73 (d, J = 1.3 Hz, 3H), 2.89 – 2.77 (m, 1H), 2.68 (d, J = 6.2 Hz, 1H), 2.48 – 2.38 (m, 
2H), 2.26 (dd, J = 13.2, 2.4 Hz, 0H), 2.20 – 2.14 (m, 2H), 2.05 (s, 0H), 1.90 – 1.85 (m, 1H), 1.79 
– 1.73 (m, 1H), 1.62 (s, 2H), 1.61 (s, 1H), 1.45 – 1.37 (m, 3H), 1.26 (t, J = 7.1 Hz, 1H), 1.15 (s, 
2H). 13C NMR (126 MHz, CDCl3) δ 202.27, 201.91, 172.01, 171.95, 165.44, 143.08, 139.12, 
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133.36, 133.32, 129.88, 129.24, 128.41, 126.21, 108.81, 95.81, 94.20, 77.21, 75.48, 75.44, 66.33, 
66.09, 65.50, 60.99, 53.92, 53.78, 52.27, 51.87, 51.84, 48.45, 44.92, 44.81, 42.52, 39.52, 38.91, 
35.76, 34.61, 31.07, 30.94, 20.23, 17.72, 17.01, 16.85, 16.57, 15.03. HRMS calculated for 
C28H32O8 [M+NH4]
+: 514.2458 (found); 514.2435 (calcd). Melting point: 119-121 °C.  
Methyl (2S,4aR,6aR,7R,9S,10aR,10bS)-4-acetoxy-2-(furan-3-yl)-
9-(methoxymethoxy)-6a,10b-dimethyl-10-oxododecahydro-2H-benzo[f]isochromene-7-
carboxylate (4.3a). Synthesized following procedure for 4.3 using 4.1a (0.03 mmol) as starting 
material, yielding 4.3a (11.1 mg, 77% yield).  1H NMR (500 MHz, CDCl3) δ 7.46 – 7.34 (m, 2H), 
6.40 (dd, J = 1.9, 0.9 Hz, 1H), 5.85 (d, J = 8.8 Hz, 1H), 4.99 (dd, J = 11.4, 2.4 Hz, 1H), 4.75 – 4.68 
(m, 3H), 4.15 (dd, J = 12.0, 7.6 Hz, 1H), 3.72 (s, 3H), 3.39 (s, 3H), 2.73 (dd, J = 13.5, 3.4 Hz, 1H), 
2.42 – 2.28 (m, 1H), 2.26 – 2.16 (m, 2H), 2.12 (s, 3H), 2.03 (s, 1H), 1.77 – 1.67 (m, 2H), 1.65 – 
1.52 (m, 1H), 1.49 (s, 3H), 1.38 (d, J = 7.7 Hz, 1H), 1.23 (t, J = 12.3 Hz, 1H), 1.11 (s, 3H). 13C 
NMR (126 MHz, CDCl3) δ 205.99, 172.09, 169.60, 143.06, 139.35, 125.81, 108.83, 95.75, 92.48, 
77.93, 66.93, 65.56, 55.81, 54.05, 51.73, 49.67, 44.56, 42.32, 38.71, 35.97, 32.70, 21.11, 17.57, 
16.76, 14.87. HRMS calculated for C25H34O9 [M+Na]
+: 501.2094 (found); 501.2101 (calcd). 





carboxylate (4.3b). Synthesized following procedure for 4.3 using 4.1b (crude, 0.271 mmol) as 
starting material, yielding 4.3b (102 mg, 73% yield over two steps).  1H NMR (500 MHz, CDCl3) 
δ 7.40 – 7.30 (m, 2H), 6.39 (dd, J = 1.9, 0.9 Hz, 1H), 5.83 (d, J = 8.7 Hz, 1H), 5.04 (ddd, J = 12.4, 
7.5, 0.9 Hz, 1H), 4.97 (dd, J = 11.6, 2.4 Hz, 1H), 3.71 (s, 3H), 3.22 (s, 3H), 2.74 (dd, J = 13.5, 3.5 
Hz, 1H), 2.48 (ddd, J = 13.3, 7.6, 3.5 Hz, 1H), 2.37 (td, J = 13.4, 12.3 Hz, 1H), 2.18 (dd, J = 13.1, 
2.5 Hz, 1H), 2.10 (s, 3H), 2.05 (d, J = 5.6 Hz, 1H), 1.73 (dt, J = 14.8, 3.5 Hz, 1H), 1.64 – 1.57 (m, 
1H), 1.49 – 1.42 (m, 3H), 1.41 – 1.33 (m, 2H), 1.30 – 1.21 (m, 1H), 1.21 (t, J = 7.0 Hz, 1H), 1.10 
(s, 3H). 13C NMR (126 MHz, CDCl3) δ 201.56, 171.20, 169.58, 143.15, 139.45, 125.53, 108.86, 
92.29, 80.49, 76.75, 66.80, 65.50, 53.53, 51.98, 49.51, 44.35, 42.22, 39.55, 38.48, 36.02, 32.19, 
21.10, 17.46, 16.82, 14.83. HRMS calculated for C24H32O10S [M+NH4]
+: 530.2053 (found); 
530.5054 (calcd). Melting point: 140-141 °C. 
Methyl (2S,4aR,6aR,7R,9S,10aR,10bS)-4-acetoxy-9-(benzoyloxy)-
2-(furan-3-yl)-6a,10b-dimethyl-10-oxododecahydro-2H-benzo[f]isochromene-7-carboxylate 
(4.3c). Synthesized following procedure for 4.3 using 4.1c (0.20 mmol) as starting material, 
yielding 4.3c (75.6 mg, 70% yield). 1H NMR (500 MHz, CDCl3) δ 8.11 – 8.06 (m, 2H), 7.61 – 
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7.55 (m, 1H), 7.48 – 7.42 (m, 2H), 7.37 (dt, J = 1.6, 0.8 Hz, 1H), 7.33 (t, J = 1.7 Hz, 1H), 6.38 (dd, 
J = 1.9, 0.8 Hz, 1H), 5.86 – 5.82 (m, 1H), 5.43 – 5.37 (m, 1H), 4.96 (dd, J = 11.7, 2.3 Hz, 1H), 
3.73 (s, 3H), 2.88 – 2.82 (m, 1H), 2.48 – 2.41 (m, 2H), 2.23 – 2.19 (m, 2H), 2.11 (s, 3H), 1.78 – 
1.73 (m, 1H), 1.47 (s, 3H), 1.41 (td, J = 9.3, 3.3 Hz, 2H), 1.33 – 1.24 (m, 2H), 1.15 (s, 3H). 13C 
NMR (126 MHz, CDCl3) δ 201.97, 171.84, 169.61, 165.44, 143.03, 139.36, 133.39, 129.89, 
129.20, 128.42, 125.62, 108.90, 92.43, 75.41, 66.96, 65.40, 53.77, 51.87, 49.61, 44.36, 42.48, 
38.72, 35.96, 31.03, 21.13, 17.57, 16.85, 14.85. HRMS calculated for C30H34O9 [M+NH4]
+: 
556.2549 (found); 556.2541 (calcd). Melting point: 171-172 °C. 
Methyl (2S,6aR,7R,9S,10aS,10bR)-2-(furan-3-yl)-9-
(methoxymethoxy)-6a,10b-dimethyl-10-oxo-1,5,6,6a,7,8,9,10,10a,10b-decahydro-2H-
benzo[f]isochromene-7-carboxylate (4.4a). Synthesized following procedure previously 
described for 4.4 using 4.1a (0.046 mmol) as starting material, yielding 4.4a (5.0 mg, 26.3% yield).  
1H NMR (500 MHz, CDCl3) δ 7.43 – 7.34 (m, 2H), 6.38 (d, J = 1.9 Hz, 1H), 6.28 (d, J = 1.8 Hz, 
1H), 4.85 – 4.78 (m, 2H), 4.78 – 4.66 (m, 1H), 4.03 (ddd, J = 12.2, 7.6, 1.3 Hz, 1H), 3.70 (s, 3H), 
3.38 (s, 1H), 2.68 (dd, J = 13.5, 3.2 Hz, 1H), 2.44 (ddd, J = 13.3, 7.6, 3.1 Hz, 1H), 2.39 – 2.24 (m, 
3H), 2.14 (s, 1H), 2.11 – 2.00 (m, 1H), 2.00 – 1.90 (m, 1H), 1.70 (ddd, J = 12.9, 4.4, 2.6 Hz, 1H), 
1.63 (q, J = 8.8, 8.1 Hz, 2H), 1.55 (d, J = 3.3 Hz, 3H), 1.53 – 1.34 (m, 1H), 1.13 (s, 3H). 13C NMR 
(126 MHz, CDCl3) δ 206.70, 172.31, 143.21, 139.28, 136.88, 126.00, 117.38, 108.60, 95.80, 
78.14, 66.59, 65.65, 55.78, 53.78, 51.67, 44.67, 42.66, 40.09, 34.13, 32.41, 22.75, 22.63, 15.38. 
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HRMS calculated for C23H30O7 [M+H]




7-carboxylate (4.4b). 1H NMR (500 MHz, CDCl3) δ 7.39 (d, J = 1.9 Hz, 1H), 6.38 (d, J = 1.8 Hz, 
1H), 6.28 (d, J = 1.7 Hz, 1H), 5.01 (dd, J = 12.3, 7.5 Hz, 1H), 4.85 – 4.71 (m, 1H), 3.71 (s, 3H), 
3.22 (s, 3H), 2.70 (dd, J = 13.2, 3.7 Hz, 1H), 2.50 – 2.42 (m, 1H), 2.42 – 2.32 (m, 2H), 2.27 (dt, J 
= 13.9, 3.2 Hz, 1H), 2.07 (s, 1H), 1.96 (ddd, J = 14.7, 4.9, 2.8 Hz, 1H), 1.71 (dt, J = 13.2, 3.7 Hz, 
1H), 1.53 (s, 3H), 1.48 (dd, J = 13.4, 4.6 Hz, 1H), 1.39 (t, J = 12.6 Hz, 1H), 1.16 (s, 3H). 13C NMR 
(126 MHz, CDCl3) δ 202.29, 171.44, 143.31, 139.39, 137.31, 125.78, 116.66, 108.63, 80.74, 
66.55, 65.70, 53.31, 51.93, 44.48, 42.59, 39.84, 39.55, 34.19, 31.98, 22.73, 22.51, 15.46. HRMS 
calculated for C22H28O8S [M+H]
+:453.1602 (found); 453.1578 (calcd). Melting point: 108-109 °C.   
Methyl (2S,6aR,7R,9S,10aS,10bR)-9-(benzoyloxy)-2-(furan-3-yl)-
6a,10b-dimethyl-10-oxo-1,5,6,6a,7,8,9,10,10a,10b-decahydro-2H-benzo[f]isochromene-7-
carboxylate (4.4c). 1H NMR (500 MHz, CDCl3) δ 8.09 (dd, J = 7.9, 1.4 Hz, 2H), 7.63 – 7.52 (m, 
1H), 7.45 (t, J = 7.7 Hz, 2H), 7.41 – 7.34 (m, 2H), 6.41 – 6.33 (m, 1H), 6.28 (d, J = 1.6 Hz, 1H), 
5.38 (dd, J = 12.3, 7.6 Hz, 1H), 4.84 – 4.73 (m, 1H), 3.72 (s, 3H), 2.81 (dd, J = 12.8, 4.0 Hz, 1H), 
2.52 – 2.34 (m, 3H), 2.34 – 2.26 (m, 1H), 2.21 (s, 1H), 1.97 (ddd, J = 14.6, 4.7, 2.6 Hz, 1H), 1.73 
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(ddd, J = 13.1, 4.3, 2.6 Hz, 1H), 1.58 (s, 1H), 1.54 (s, 3H), 1.21 (s, 3H), 1.18 (d, J = 7.2 Hz, 1H). 
13C NMR (126 MHz, CDCl3) δ 202.73, 172.06, 165.44, 143.18, 139.30, 137.08, 133.34, 129.90, 
129.32, 128.42, 125.85, 117.09, 108.70, 75.60, 66.67, 65.50, 53.54, 51.81, 44.43, 42.87, 40.10, 
34.13, 30.81, 22.78, 22.64, 15.49. HRMS calculated for C28H30O7 [M+H]
+: 479.2044 (found); 
479.2065 (calcd). Melting point: 74-76 °C.  
Methyl (2S,4aR,6aR,7R,9S,10aR,10bS)-2-(furan-3-yl)-9-hydroxy-6a,10b-
dimethyl-10-oxododecahydro-2H-benzo[f]isochromene-7-carboxylate. To a flask containing 
4.5 (0.05 mmol) in MeOH (2mL) was added Na2CO3 (0.20 mmol, 4 equiv.). Reaction stirred at r.t. 
until starting material consumed as seen by TLC. Upon reaction completion, solvent was 
evaporated. The crude residue was dissolved in CH2Cl2 (10 mL) and HCl (1 M, 8 mL), and the 
organic layer separated. Following further extraction with DCM (2 x 10 mL), the organic layers 
were combined and washed with brine (8 mL) then dried over Na2SO4, and concentrated to afford 
17-deoxysalvinorin B (0.016 g, 83% yield). 1H NMR (500 MHz, CDCl3) δ 7.35 (t, J = 1.5 Hz, 2H), 
6.35 (dd, J = 1.8, 1.0 Hz, 1H), 4.74 (dd, J = 11.5, 2.4 Hz, 1H), 4.06 (dd, J = 11.8, 7.8 Hz, 1H), 3.70 
(s, 3H), 3.59 (d, J = 7.6 Hz, 2H), 2.74 (dd, J = 13.5, 3.2 Hz, 1H), 2.45 (ddd, J = 13.4, 7.7, 3.3 Hz, 
1H), 2.16 (dd, J = 12.9, 2.4 Hz, 1H), 2.10 (d, J = 1.1 Hz, 1H), 2.00 (td, J = 13.5, 11.9 Hz, 1H), 1.72 
– 1.55 (m, 2H), 1.49 (dtt, J = 12.0, 8.0, 4.2 Hz, 1H), 1.42 (d, J = 0.8 Hz, 3H), 1.38 – 1.28 (m, 3H), 
1.19 – 1.12 (m, 1H), 1.06 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 209.44, 172.20, 143.04, 138.91, 
127.07, 108.61, 77.27, 74.21, 67.46, 67.09, 65.22, 53.35, 51.73, 46.45, 45.58, 43.30, 38.96, 34.60, 
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34.42, 19.57, 16.92, 13.81. HRMS calculated for C21H28O6 [M+Na]
+: 399.1774 (found); 399.1784 
(calcd). Melting point: 57-59 °C. 
Methyl (2S,4aR,6aR,7R,9S,10aR,10bS)-2-(furan-3-yl)-9-
(methoxymethoxy)-6a,10b-dimethyl-10-oxododecahydro-2H-benzo[f]isochromene-7-
carboxylate (4.5a). To a flask containing 17-deoxysalvinorin B (0.02 g, 0.053 mmol) under Ar 
was added CH2Cl2 (2 mL), diisopropylethylamine (0.372 mmol, 7 equiv.) and chloromethyl 
methyl ether (0.372 mmol, 7 equiv.). Reaction stirred at r.t. for 48 h, until starting material had 
been consumed as monitored by TLC, and was quenched with saturated NaHCO3 (4 mL) and 
extracted with CH2Cl2 (3x 5 mL). The combined organic extracts were washed with brine (50 mL), 
dried (Na2SO4) and concentrated. Purification by FCC (40% EtOAc in Pentane) afforded 4.5a as 
a white solid (32% yield). 1H NMR (500 MHz, CDCl3) δ 7.35 (dd, J = 2.7, 1.3 Hz, 2H), 6.36 (dd, 
J = 1.9, 0.9 Hz, 1H), 4.73 (dd, J = 8.5, 3.0 Hz, 1H), 4.70 (d, J = 3.6 Hz, 2H), 4.12 (ddd, J = 12.2, 
7.3, 0.9 Hz, 1H), 3.70 (s, 3H), 3.60 – 3.57 (m, 2H), 3.37 (s, 3H), 2.72 (dd, J = 13.5, 3.4 Hz, 1H), 
2.33 (ddd, J = 13.4, 7.3, 3.5 Hz, 1H), 2.24 – 2.11 (m, 2H), 1.99 (s, 1H), 1.73 – 1.60 (m, 2H), 1.46 
(tdt, J = 12.5, 6.2, 3.4 Hz, 1H), 1.42 – 1.39 (m, 3H), 1.38 – 1.27 (m, 2H), 1.19 – 1.11 (m, 1H), 1.08 
(s, 3H). 13C NMR (126 MHz, CDCl3) δ 206.28, 172.26, 142.99, 138.91, 127.16, 108.66, 95.73, 
77.93, 67.54, 67.13, 65.76, 55.77, 54.13, 51.70, 46.49, 45.64, 42.64, 39.04, 34.61, 32.68, 19.60, 
16.83, 13.71. HRMS calculated for C23H32O7 [M+H]
+: 421.2236 (found); 421.2221 (calcd). 





Synthesized following procedure for 4.5 using 4.3b (0.082 mmol) as starting material, yielding 
4.5b (18.6 mg, 50% yield). 1H NMR (500 MHz, CDCl3) δ  7.36 (d, J = 1.4 Hz, 2H), 6.37 (t, J = 
1.4 Hz, 1H), 5.03 (ddd, J = 12.4, 7.6, 0.9 Hz, 1H), 4.72 (dd, J = 11.5, 2.4 Hz, 1H), 3.71 (s, 3H), 
3.62 (d, J = 25.1 Hz, 1H), 3.58 (d, J = 1.8 Hz, 1H), 3.21 (s, 3H), 2.76 (dd, J = 13.4, 3.5 Hz, 1H), 
2.47 (ddd, J = 13.3, 7.6, 3.5 Hz, 1H), 2.37 (td, J = 13.4, 12.3 Hz, 1H), 2.13 (dd, J = 13.0, 2.4 Hz, 
1H), 2.05 (d, J = 1.0 Hz, 1H), 1.73 – 1.58 (m, 3H), 1.54 – 1.44 (m, 1H), 1.39 (s, 3H), 1.36 – 1.28 
(m, 1H), 1.24 – 1.15 (m, 1H), 1.09 (s, 3H). 13C NMR (126 MHz, CDCl3) δ 201.81, 171.37, 143.07, 
139.02, 126.92, 108.70, 80.64, 67.44, 67.05, 65.72, 53.62, 51.94, 46.34, 45.44, 42.52, 39.53, 38.82, 
34.73, 32.23, 19.48, 16.91, 13.70. HRMS calculated for C22H30O8S [M+H]
+: 455.1740 (found); 
455.1734 (calcd). Melting point: 90-91 °C. 
Methyl (2S,4aR,6aR,7R,9S,10aR,10bS)-9-(benzoyloxy)-2-(furan-3-yl)-
6a,10b-dimethyl-10-oxododecahydro-2H-benzo[f]isochromene-7-carboxylate (4.5c). 
Synthesized following procedure for 4.5 using 4.3c (0.080 mmol) as starting material, yielding 
4.5c (21.2 mg, 55% yield).  1H NMR (500 MHz, CDCl3) δ 8.15 – 8.02 (m, 2H), 7.57 (ddt, J = 8.7, 
7.1, 1.3 Hz, 1H), 7.47 – 7.41 (m, 2H), 7.34 (d, J = 1.5 Hz, 2H), 6.35 (t, J = 1.4 Hz, 1H), 5.46 – 5.35 
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(m, 1H), 4.71 (dd, J = 11.5, 2.4 Hz, 1H), 3.73 (s, 3H), 3.63 – 3.51 (m, 2H), 2.90 – 2.82 (m, 1H), 
2.48 – 2.37 (m, 2H), 2.18 (s, 1H), 2.18 – 2.14 (m, 1H), 1.74 – 1.68 (m, 2H), 1.52 (qd, J = 7.6, 3.8 
Hz, 1H), 1.40 (s, 3H), 1.34 – 1.29 (m, 1H), 1.26 (d, J = 3.1 Hz, 2H), 1.14 (s, 3H). 13C NMR (126 
MHz, CDCl3) δ 202.26, 172.00, 165.44, 142.95, 138.93, 133.33, 129.89, 129.29, 128.40, 127.00, 
108.75, 75.47, 67.57, 67.10, 65.63, 53.86, 51.83, 46.44, 45.48, 42.80, 39.06, 34.64, 31.04, 19.62, 
16.94, 13.72. HRMS calculated for C28H32O7 [M+NH4]
+: 498.2492 (found); 498.2486 (calcd). 
Melting point: 120-121 °C. 
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